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Population Pharmacokinetics of Therapeutic Monoclonal Antibodies: Examples
and Estimation Method Performance Differences
Abstract
Over the past two decades, there has been an increase in the research and development and therapeutic
application of monoclonal antibodies (mAbs). An application of pharmacokinetic (PK) and
pharmacodynamic concepts that has likely contributed to the success of the pre-clinical and clinical drug
development of therapeutic mAbs is population PK, which attempts to quantify the typical disposition
characteristics and sources of PK variability (such as between-subject, within-subject, and inter-occasion
variability) within study populations. Population PK also attempts to identify and quantify the impact of
covariates on systemic drug exposure and assess their potential implications for clinical dosing. The
general theme of my dissertation research was population PK modeling of therapeutic mAbs, which
focused on the population PK modeling of cetuximab, and the evaluation of different estimation methods
for population PK modeling of therapeutic mAbs with nonlinear PK characteristics.
Cetuximab is a therapeutic mAb directed against the epidermal growth factor receptor and is indicated in
the treatment of squamous cell carcinoma of the head and neck (SCCHN). I performed a population PK
analysis of cetuximab using nonlinear mixed effects modeling and the software NONMEM. A total of 912
cetuximab concentrations were available from 143 patients with recurrent and/or metastatic SCCHN
enrolled in two phase I/II studies. The PK of cetuximab was best described by a two-compartment model
with Michaelis-Menten type saturable elimination. Mean population estimates (between-subject
variability, %CV) of the PK parameters were: Vmax 4.38 mg/hr (15.4%), Km 74 μg/ml, V1 2.83 L (18.6%), V2
2.43 L (56.4%), and Q 0.103 L/hr (97.2%). Ideal body weight and white blood cell count were identified as
predictors of Vmax, and total body weight as a predictor of V1. My findings suggested that clinical dose
adjustments beyond the approved body surface area-based dosing of cetuximab may be warranted in
patients with extreme deviations of their actual body weight from ideal body weight. Agreement between
simulated and measured concentrations for up to 43 weeks of therapy indicated that the final population
PK model was able to adequately describe the nonlinear PK of cetuximab in patients with SCCHN at the
currently approved dosage regimen, and that the cetuximab PK parameters remained constant during
prolonged therapy.
Nonlinear eliminaton is a common characteristic of the PK of therapeutic mAbs. Accordingly, PK models
with nonlinear elimination are commonly used in population PK analyses of mAbs, but difficulties
detecting and characterizing this nonlinear PK have been reported in a number of studies. The challenge
with detecting and characterizing the nonlinear elimination of therapeutic mAbs may not only be
dependent on the clinical study design, but also on the estimation method used for the population PK
analysis. However, little work has been done so far evaluating population estimation methods using PK
models that are representative of the typical disposition characteristics of therapeutic mAbs. In order to
address this question, I conducted a simulation study to compare the parameter estimation performance
of the first-order (FO), first-order conditional estimation with interaction (FOCE-I), and Laplacian
estimation with interaction (LAP-I) methods in NONMEM and a Bayesian Markov Chain Monte Carlo
(MCMC) method in WinBUGS when applied to population PK modeling of therapeutic mAbs with nonlinear
PK. The Bayesian MCMC method was evaluated with both vague and informative priors. Published
findings of population PK analyses of therapeutic mAbs were used to define the informative priors.
Simulations were performed with uncertainty included simultaneously on all parameters in the population
PK model in order to evaluate the sensitivity of estimation performance to uncertainty in the simulation
model parameters. The impact of study design on estimation performance was explored by evaluating
the methods under a dose-ranging design (‘informative design’) and four different single dose level
designs at different dose levels (‘uninformative designs’).

Under all study designs, the FO method generally produced larger bias and lower precision for all model
parameters compared to the other estimation methods. Comparison between the methods in NONMEM
and WinBUGS was limited to the informative and uninformative 600 mg dose level study designs due to
prolonged run times with WinBUGS. Under the informative study design, bias and precision for all model
parameters was less than ±25% and 52%, respectively, for FOCE-I, LAP-I, and Bayesian MCMC with both
sets of priors. Under the uninformative 600 mg dose level design, the estimation performance of FOCE-I
and LAP-I decreased as bias and precision for many of the model parameters, in particular those related
to nonlinear elimination, significantly increased to ±40-173% and 53-173%, respectively, while Bayesian
MCMC with informative priors provided a clear performance advantage producing results that were
comparable to those under the informative design. Under both informative and uninformative 600 mg
dose level designs, the estimation performance of FOCE-I, LAP-I, and Bayesian MCMC showed sensitivity
to uncertainty in the simulation parameter values for one or more parameters. This was especially evident
when informative Bayesian priors were used under the uninformative 600 mg dose level design, which
was expected given the relative uninformativeness of the data under this particular design.
The findings from this work should be of value to pharmacometricians involved in population PK
modeling of therapeutic mAbs. When sufficient concentration-time data are available to characterize the
nonlinear elimination of the mAb, then FOCE-I, LAP-I, or Bayesian MCMC would likely be suitable for the
populatin PK analysis. In situations where insufficient data are available to characterize the nonlinear
elimination of the mAb, and relevant prior information is readily available, the use of a Bayesian MCMC
method with informative priors should be considered.
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ABSTRACT
Over the past two decades, there has been an increase in the research and
development and therapeutic application of monoclonal antibodies (mAbs). An
application of pharmacokinetic (PK) and pharmacodynamic concepts that has likely
contributed to the success of the pre-clinical and clinical drug development of therapeutic
mAbs is population PK, which attempts to quantify the typical disposition characteristics
and sources of PK variability (such as between-subject, within-subject, and inter-occasion
variability) within study populations. Population PK also attempts to identify and
quantify the impact of covariates on systemic drug exposure and assess their potential
implications for clinical dosing. The general theme of my dissertation research was
population PK modeling of therapeutic mAbs, which focused on the population PK
modeling of cetuximab, and the evaluation of different estimation methods for population
PK modeling of therapeutic mAbs with nonlinear PK characteristics.
Cetuximab is a therapeutic mAb directed against the epidermal growth factor
receptor and is indicated in the treatment of squamous cell carcinoma of the head and
neck (SCCHN). I performed a population PK analysis of cetuximab using nonlinear
mixed effects modeling and the software NONMEM. A total of 912 cetuximab
concentrations were available from 143 patients with recurrent and/or metastatic SCCHN
enrolled in two phase I/II studies. The PK of cetuximab was best described by a twocompartment model with Michaelis-Menten type saturable elimination. Mean population
estimates (between-subject variability, %CV) of the PK parameters were: Vmax 4.38
mg/hr (15.4%), Km 74 μg/ml, V1 2.83 L (18.6%), V2 2.43 L (56.4%), and Q 0.103 L/hr
(97.2%). Ideal body weight and white blood cell count were identified as predictors of
Vmax, and total body weight as a predictor of V1. My findings suggested that clinical dose
adjustments beyond the approved body surface area-based dosing of cetuximab may be
warranted in patients with extreme deviations of their actual body weight from ideal body
weight. Agreement between simulated and measured concentrations for up to 43 weeks
of therapy indicated that the final population PK model was able to adequately describe
the nonlinear PK of cetuximab in patients with SCCHN at the currently approved dosage
regimen, and that the cetuximab PK parameters remained constant during prolonged
therapy.
Nonlinear eliminaton is a common characteristic of the PK of therapeutic mAbs.
Accordingly, PK models with nonlinear elimination are commonly used in population PK
analyses of mAbs, but difficulties detecting and characterizing this nonlinear PK have
been reported in a number of studies. The challenge with detecting and characterizing
the nonlinear elimination of therapeutic mAbs may not only be dependent on the clinical
study design, but also on the estimation method used for the population PK analysis.
However, little work has been done so far evaluating population estimation methods
using PK models that are representative of the typical disposition characteristics of
therapeutic mAbs. In order to address this question, I conducted a simulation study to
compare the parameter estimation performance of the first-order (FO), first-order
conditional estimation with interaction (FOCE-I), and Laplacian estimation with
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interaction (LAP-I) methods in NONMEM and a Bayesian Markov Chain Monte Carlo
(MCMC) method in WinBUGS when applied to population PK modeling of therapeutic
mAbs with nonlinear PK. The Bayesian MCMC method was evaluated with both vague
and informative priors. Published findings of population PK analyses of therapeutic
mAbs were used to define the informative priors. Simulations were performed with
uncertainty included simultaneously on all parameters in the population PK model in
order to evaluate the sensitivity of estimation performance to uncertainty in the
simulation model parameters. The impact of study design on estimation performance
was explored by evaluating the methods under a dose-ranging design (‘informative
design’) and four different single dose level designs at different dose levels
(‘uninformative designs’).
Under all study designs, the FO method generally produced larger bias and lower
precision for all model parameters compared to the other estimation methods.
Comparison between the methods in NONMEM and WinBUGS was limited to the
informative and uninformative 600 mg dose level study designs due to prolonged run
times with WinBUGS. Under the informative study design, bias and precision for all
model parameters was less than ±25% and 52%, respectively, for FOCE-I, LAP-I, and
Bayesian MCMC with both sets of priors. Under the uninformative 600 mg dose level
design, the estimation performance of FOCE-I and LAP-I decreased as bias and precision
for many of the model parameters, in particular those related to nonlinear elimination,
significantly increased to ±40-173% and 53-173%, respectively, while Bayesian MCMC
with informative priors provided a clear performance advantage producing results that
were comparable to those under the informative design. Under both informative and
uninformative 600 mg dose level designs, the estimation performance of FOCE-I, LAP-I,
and Bayesian MCMC showed sensitivity to uncertainty in the simulation parameter
values for one or more parameters. This was especially evident when informative
Bayesian priors were used under the uninformative 600 mg dose level design, which was
expected given the relative uninformativeness of the data under this particular design.
The findings from this work should be of value to pharmacometricians involved
in population PK modeling of therapeutic mAbs. When sufficient concentration-time
data are available to characterize the nonlinear elimination of the mAb, then FOCE-I,
LAP-I, or Bayesian MCMC would likely be suitable for the populatin PK analysis. In
situations where insufficient data are available to characterize the nonlinear elimination
of the mAb, and relevant prior information is readily available, the use of a Bayesian
MCMC method with informative priors should be considered.
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CHAPTER 1. POPULATION PHARMACOKINETICS OF THERAPEUTIC
MONOCLONAL ANTIBODIES*
Introduction
Over the past two decades there has been an increase in the research and
development and therapeutic application of monoclonal antibodies (mAbs). Currently,
there are over 20 mAb products (i.e. antibodies, antibody fragments, or antibodyconjugates) approved by the U.S. Food and Drug Administration (FDA) for therapeutic
use in areas such as oncology, immunology, ophthalmology, cardiovascular disease, and
infectious disease. As most approved therapeutic mAb products are intact and
unconjugated, this review will focus on this class.
It is estimated that half of all current projects in new drug development are
biologics, with mAbs being the predominant class of biologics under clinical study (1).
In 2008, it was reported that there were over 200 mAbs undergoing clinical study (2).
One likely reason for the continued success of the clinical development of mAbs is the
application and integration of pharmacokinetic (PK) and pharmacodynamic (PD)
concepts in all stages of pre-clinical and clinical drug development (3, 4). Such
implementation of PK/PD modeling and simulation in drug product development
provides a rational, scientifically based framework for efficient decision making
regarding the selection of potential drug candidates, for maximum information gain from
the performed experiments and studies, and for conducting fewer, more focused clinical
trials with improved efficiency and cost effectiveness (5). One application of PK/PD
concepts in drug development is population PK, which attempts to quantify the typical
disposition characteristics and sources of PK variability (such as between-subject, withinsubject, and inter-occasion) within study populations. Population PK also attempts to
identify and quantify the impact of covariates on systemic drug exposure, and assess their
potential implications for clinical dosing. Findings from population PK analyses are
included in the drug labeling of over half of the approved therapeutic mAb products, and
several mAb population PK studies have also been published in the scientific literature.
The aim of this report is to review the population PK of therapeutic intact mAbs, while
highlighting important similarities/dissimilarities across different mAbs with respect to
their drug disposition characteristics. The report will be supplemented with discussions
on the general PK behavior of mAbs and their structural properties, which have partially
been reviewed elsewhere in different context (6-9).
Antibody Structure
The basic structure of human antibodies or immunoglobulins (Ig) consists of two
*This chapter adapted with permission. Dirks NL, Meibohm B. Population
pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet
2010;49(10) In press.
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identical heavy chains and two identical light chains joined together by a number of
disulfide bridges. There are five classes (isotypes) of antibodies termed IgG, IgA, IgM,
IgE, and IgD, which share the same basic structure, but differ with regards to their heavy
chains γ, α, μ, ε, δ, respectively (10). In addition to the different heavy chain structures,
there are also two types of light chains (κ and λ). IgG is the most predominant of the
five isotypes with a serum concentration of approximately 12 mg/ml, representing about
70-80% of total serum Ig (10). The IgG class can be further subdivided into four
subclasses (or subisotypes), IgG1, IgG2, IgG3, and IgG4, based on structural differences
in the γ heavy chain. This review focuses on IgG, as all of the population PK analyses
included in the discussion were of therapeutic mAbs of the IgG type. All of the approved
therapeutic intact mAbs are also of the IgG isotype.
The structure of IgG is depicted in Figure 1-1A. The heavy and light chains of
IgG are made up of variable and constant domains based on sequence similarities
between different IgG molecules. The IgG molecule is comprised of three basic units:
two identical antigen binding fragments (Fabs) and the crystallizable fragment (Fc). The
variable heavy, constant heavy 1, variable light, and constant light domains make up the
Fab, and the Fc is made up of the constant heavy 2 and constant heavy 3 domains. The
whole IgG molecule has a molecular weight of 150 kDa, and intact mAbs of the same
isotype have an approximately similar molecular weight. Within the variable regions of
both the heavy chain and light chain, there are three sections called complementarity
determining regions (CDRs). These hypervariable regions are associated with the mAb’s
affinity and specificity for a given antigen. The structural diversity of the Fab allows
different IgG molecules to recognize a wide variety of antigens, while the ability to
trigger immune effector functions through interaction with Fcγ receptors and
complement, such as antibody-dependent cellular cytotoxicity (ADCC) and complementdependent cytotoxicity (CDC), are conferred upon by consistency in the Fc structure.
The Fc region of the mAb also interacts with another important Fc receptor for IgG, the
neonatal Fc receptor (FcRn), which acts in part as a salvage receptor protecting IgG from
intracellular catabolism. As will become evident later in the review, the Fab and Fc
regions are not only important to antibody function, but can significantly influence the
PK behavior of mAbs.
Muromonab-CD3 (Orthoclone OKT3), a murine IgG2a antibody against CD3
indicated for the treatment of acute organ rejection, became the first mAb approved for
therapeutic use in 1986. However, the use of mAbs of murine origin in the clinic has
been limited due to several factors including their short elimination half-lives and high
immunogenic potential. To overcome these limitations with murine mAbs, advances in
biotechnology such as recombinant engineering have facilitated the development of
chimeric, humanized, and fully human antibodies, which contain a larger content of
human protein sequence (11). These three structural classes of mAbs are depicted in
Figure 1-1B. In chimeric mAbs, the antibody is constructed by transferring murine
variable regions to constant regions of human origin. This reduces the murine content in
chimeric mAbs to about one-third. In humanized or CDR-grafted mAbs, the CDRs (and
possibly parts of the framework regions surrounding the CDRs) are of murine origin,
which makes up about 5-10% of the mAb. Although the immunogenic potential of a

2

Figure 1-1. Linear representation of the structure of immunoglobulin G (A) and the
different classes of therapeutic monoclonal antibodies (B). CDR = complementarity
determining region; CH1D, CH2D, and CH3D = constant heavy chain domains; CLD =
constant light chain domain; Fab = antigen binding fragment; Fc = crystallizable
fragment; VHD = variable heavy chain domain; VLD = variable light chain domain.
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mAb is expected to decrease with decreasing murine content
(murine>chimeric>humanized>human), all classes of therapeutic mAbs have the
potential to trigger the formation of human antibodies against the mAb (6). Such antimAb antibodies can have a significant effect on both the PK and PD of the therapeutic
mAb (7, 9). As will be discussed later in the review, the PK effect of the presence of
antibodies to the therapeutic mAb can be assessed by including this as a covariate in the
population model. Currently, most approved therapeutic mAbs are of the humanized
type. Fully human mAbs that have been approved by the FDA include adalimumab,
golimumab, panitumumab, and ustekinumab.
Population Pharmacokinetics
While a number of concepts related to population analysis are mentioned in this
review (e.g., between-subject variability and residual variability), a discussion of the
basic concepts and principles of population PK modeling is beyond the scope of this
report. For readers that are not familiar with population PK modeling, there are a number
of papers and books in the literature that provide an excellent review of the topic (12-16).
Results from the population PK analyses of therapeutic mAbs are summarized and split
into Tables 1-1 through 1-6. In some cases a population PK/PD analysis was performed,
and these are noted in Table 1-1. The only non-therapeutic mAb included in the tables is
HuCC49∆CH2, which was investigated in patients undergoing radioimmunoguided
surgery (17). The structural characteristics and pharmacologic target of the different
mAbs are listed in Table 1-1, as well as the patient population the study was conducted
in, and the model used to describe the PK of the mAb. Population parameter estimates
related to mAb absorption, distribution, elimination, and identified covariate effects are
presented in Tables 1-2 through 1-6. Of note is the fact that all of the population PK
analyses were of chimeric, humanized, or fully human antibodies, except for the murine
antibodies inolimomab and mabF19 (Table 1-1). Differences in the population PK of
murine mAbs and the other mAb types were observed and will be discussed later in the
review. While the patient populations in the studies cover a wide variety of clinical
indications, all of the studies were conducted in adult patients. A few population PK
analyses of mAbs have been conducted in pediatric patients including daclizumab (18)
and SB 209763 (19), but these studies were not included in this review for comparative
purposes. In the majority of the population PK studies, the nonlinear mixed effects
modeling was performed using NONMEM (Icon Development Solutions, Ellicott City,
MD) and the first-order conditional estimation method (FOCE) with or without the η-ε
interaction option (20). Other software and methods used in a couple of studies (21, 22)
included a conditional first-order method implemented in Winnonmix (Pharsight
corporation, Mountain View, NC), and the Monte Carlo parametric expectation
maximization (MCPEM) method implemented in an augmented version of ADAPT II
(Biomedical Simulations Resource, University of Southern California, Los Angeles, CA).
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Table 1-1.

Therapeutic monoclonal antibodies with published population pharmacokinetic analyses.

Antibody

Structure/Isotype

Target

Patient population

PK model

Alemtuzumab (23)
AMG 162 (denosumab) (24)†
ATM-027 (25)†
Basiliximab (26)
Basiliximab (27)
Bevacizumab (28)

CDR-grafted rat/human IgG1
Human IgG2
Humanized IgG1
Chimeric mouse/human IgG1
Chimeric mouse/human IgG1
CDR-grafted mouse/human IgG1

CD52
RANKL
Vβ 5.2/5.3 TCR
CD25
CD25
VEGF

2C NL
2C NL+L
2C L
2C L
2C L
2C L

Cetuximab (29)
Clenoliximab (30)†
CP-751, 871 (31)
Denosumab (32)†

Chimeric mouse/human IgG1
Chimeric macaque/human IgG4
Human IgG2
Human IgG2

EGFR
CD4
IGF-IR
RANKL

Efalizumab (21)†
Efalizumab (33)
Golimumab (34)
hu1124 (efalizumab) (35)†

CDR-grafted mouse/human IgG1
CDR-grafted mouse/human IgG1
Human IgG1
CDR-grafted mouse/human IgG1

CD11a
CD11a
TNF-α
CD11a

B-cell chronic lymphocytic leukaemia
Healthy postmenopausal women
Multiple sclerosis
Renal transplant
Liver transplant
Various solid tumors and colorectal,
non-small cell lung, and breast cancer
Head and neck cancer
Rheumatoid arthritis
Multiple myeloma and solid tumors
Healthy postmenopausal women and
breast cancer
Psoriasis
Psoriasis
Rheumatoid arthritis
Psoriasis

HuCC49∆CH2 (17)

TAG-72

Colorectal cancer

Infliximab (36)
Infliximab (37)
Inolimomab (38)†
mAbF19 (39)

CDR-grafted mouse/human
IgG1-CH2 domain deletion
Chimeric mouse/human IgG1
Chimeric mouse/human IgG1
Mouse IgG1
Mouse IgG

TNF-α
TNF-α
CD25
FAP

Matuzumab (40)

CDR-grafted mouse/human IgG1

EGFR

Ankylosing spondylitis
Ulcerative colitis
Acute graft-versus-host disease
Colorectal cancer and soft tissue
sarcoma
Pancreatic and various cancers
(primarily colorectal)

†
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2C NL
2C NL
2C NL+L*
2C NL+L
2C NL+L
1C L
2C L
2C NL+L
RMC
2C L
2C L
2C L
2C L
2C L
2C NL+L

Table 1-1 continued.
Antibody

Structure/Isotype

Target

Patient population

PK model

CDR-grafted mouse/human IgG1

IgE

TMDD

Panitumumab (42)

Human IgG2

EGFR

Pertuzumab (43)

CDR-grafted mouse/human IgG1

HER2

Rituximab (44)
Sibrotuzumab (45)

Chimeric mouse/human IgG1
CDR-grafted mouse/human IgG1

CD20
FAP

Trastuzumab (46)
Ustekinumab (47)

CDR-grafted mouse/human IgG1
Human IgG1

HER2
IL-12 and IL-23

Asthma, allergic rhinitis, and healthy
atopic subjects
Various solid tumors and colorectal,
non-small cell lung, and renal cancer
Breast cancer, ovarian cancer, and
solid malignancies
Rheumatoid arthritis
Colorectal and non-small cell lung
cancer
Breast cancer and solid tumors
Psoriasis

Omalizumab (41)

†

2C NL+L
2C L
2C L
2C NL+L
2C L
1C L

1C or 2C = one- or two-compartment model; CDR = complementarity determining region; EGFR = epidermal growth factor
receptor; FAP = fibroblast activation protein; HER2 = human epidermal growth factor receptor 2; IGF-IR = insulin-like
growth factor I receptor; L = model with linear elimination from the central compartment; NL = model with nonlinear
elimination from the central compartment; NL+L = model with parallel linear and nonlinear elimination pathways from the
central compartment; NL+L* = model with nonlinear and linear elimination pathways from the central and peripheral
compartments, respectively; RANKL = receptor activator of nuclear factor-κB ligand; RMC = receptor-mediated clearance
model; TAG-72 = tumor-associated glycoprotein-72; TCR = T-cell receptor; TMDD = target-mediated drug disposition
model; TNF-α = tumor necrosis factor alpha; VEGF = vascular endothelial growth factor.
†
Population pharmacokinetic/pharmacodynamic analysis.
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Table 1-2.
Population estimates and their between-subject variability [%RSE or confidence interval *,^] of absorption
related parameters.**
Antibody
Efalizumab (21)
Denosumab (24)
Denosumab (32)
Omalizumab (41)
Efalizumab (33)
Ustekinumab (47)

F†
0.564
0.747a
0.491b

[5.3]

F BSV (%CV)
51 [13]

Ka† (day-1)
0.242 [9.4]
0.132 [4.9]
0.174 [5.1]
0.48
[5.7]
0.191 [0.095-0.394^]
0.354 [0.277-0.499^]

Ka BSV (%CV)
44
[12]
NE
53
40
NE
NE

BSV = between-subject variability; F = absolute bioavailability; Ka = absorption rate constant; NE = not estimated; %RSE =
percent relative standard error.
* 90% or ^ 95% bootstrap confidence interval.
** Not available or not applicable estimates are blank.
†
F and Ka were determined following subcutaneous administration.
a. θF (theta estimate for calculation of bioavailability) (%RSE) was 2.96 (23); θF BSV was not estimated.
b. θF (%RSE) and θF BSV were 0.964 (7.9) and 68 %CV, respectively.
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Table 1-3.
Population estimates and their between-subject variability [%RSE or confidence interval *,^] of distribution
related parameters.**
Antibody
Sibrotuzumab (45)
Matuzumab (40)
Efalizumabi (35)
Efalizumab (21)
Denosumab (24)
Denosumab (32)
CP-751, 871 (31)
Panitumumab (42)
Cetuximab (29)
Alemtuzumab (23)
Clenoliximab (30)
Golimumab (34)
Inolimomab (38)
mAbF19 (39)
HuCC49∆CH2 (17)
Rituximab (44)
Trastuzumab (46)
Pertuzumab (43)
Bevacizumab (28)
Infliximab (36)
Infliximab (37)
Basiliximab (26)
Basiliximab (27)
ATM-027 (25)
Omalizumab (41)
Efalizumab (33)
Ustekinumab (47)

V1 (L)
4.13
3.72
5.14b
4.50c
2.38
2.42
4.02
3.95
2.83
11.3
3.58
3.07
2.76
3.13
3.46
2.98
2.95
2.74
2.66
3.06
3.29
3.72
5.47
2.8
5.9g
9.13g
15.7g, h

[3.7]
[3.0]
[8.6]
[3.5]
[7.4]
[7.0]
[4.0]
[3.83-4.10*]
[2.69-2.96*]
[8.92-16.4^]
[8.5]
[2.63-3.51^]
[26]
[11]
[3.09-3.84*]
[2.88-3.08^]
[2.67-3.27^]
[2.64-2.84^]
[2.57-2.76^]
[2.96-3.16^]
[3.02-3.58^]
[1.2]
[7.4]
[6.9]
[1.8]
[3.9-11.7^]
[15.1-16.2^]

V1 BSV (%CV)
20
[52]
22a [20]
39
[33]
52
[9.0]
16
37
22
[50]
k
34
[28-39*]
19
[13-22*]
84
[21]
37
26
[28]
d
68
[20]
37
[49]
23e [10-34*]
12
[9.5-14^]
29
[21-38^]
16
[13-19^]
17
[14-20^]
18f [16-19^]
22
[18-26^]
41
[18]
31
[32]
NE
13
29
[<10-3-44^]
33
[28-38^]
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V2 (L)
3.19
1.84
4.18‡
2.26‡
1.59‡
1.27
6.82
2.59
2.43
41.5
5.35‡
3.68
2.25
1.74‡, j
2.50
3.64‡
4.79‡
2.16‡
2.76‡
2.94
4.13
4.08‡
1.78‡
3.1

[8.8]
[9.0]

V2 BSV (%CV)
20
[52]
62a [28]

[5.8]
[24]
[2.30-2.87*]
[1.95-2.85*]
[21.3-73.2^]

NE
92
38
56
179

[2.71-4.75^]
[18]

45
NE

[1.52-3.69*]

NE

[2.63-3.24^]
[3.65-4.57^]

NE
NE

[19]

25

[49]
[27-49*]
[18-73*]
[28]
[40]

[38]

Vss (L)
7.32‡
5.56‡
9.32‡
6.76‡
3.97‡
3.69‡
10.84‡
6.54‡
5.26‡
52.8‡
8.93‡
6.75‡
5.01‡
4.87j
5.96‡
6.62‡
7.74‡
4.9‡
5.42‡
6.0‡
7.42‡
7.8‡
7.25‡
5.9‡

Table 1-3 continued.
Antibody
Sibrotuzumab (45)
Matuzumab (40)
Efalizumabi (35)
Efalizumab (21)
Denosumab (24)
Denosumab (32)
CP-751, 871 (31)
Panitumumab (42)
Cetuximab (29)
Alemtuzumab (23)
Clenoliximab (30)
Golimumab (34)
Inolimomab (38)
mAbF19 (39)
HuCC49∆CH2 (17)
Rituximab (44)
Trastuzumab (46)
Pertuzumab (43)
Bevacizumab (28)
Infliximab (36)
Infliximab (37)
Basiliximab (26)
Basiliximab (27)
ATM-027 (25)
Omalizumab (41)
Efalizumab (33)
Ustekinumab (47)

Q (L/day)
0.902
[9.6]
0.919
[7.6]
‡
2.46
0.437‡
0.533‡
0.629
[18]
0.7
[14]
0.390
[0.323-0.475*]
2.47
[1.49-4.58*]
25.2
[10.6-51.1^]
‡
0.877
0.42
[0.31-0.50^]
53.3
[52]
3.41
[18]
0.154
[0.122-0.191*]
‡
0.656
0.484‡
0.556‡
0.593‡
1.72
[1.14-2.6^]
7.14
[3.67-10.10^]
4.17‡
0.569‡
2.18
[170]
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Q BSV
(%CV)
NE
NE

NE
50
NE
97
NE
45
43d
NE
39

NE
NE

NE

[56]
[40-133*]

[52]
[425]
[24-54*]

Table 1-3 continued.
Antibody
Sibrotuzumab (45)
Matuzumab (40)
Efalizumabi (35)
Efalizumab (21)
Denosumab (24)
Denosumab (32)
CP-751, 871 (31)
Panitumumab (42)
Cetuximab (29)
Alemtuzumab (23)
Clenoliximab (30)
Golimumab (34)
Inolimomab (38)
mAbF19 (39)
HuCC49∆CH2 (17)
Rituximab (44)
Trastuzumab (46)
Pertuzumab (43)
Bevacizumab (28)
Infliximab (36)
Infliximab (37)
Basiliximab (26)
Basiliximab (27)
ATM-027 (25)
Omalizumab (41)
Efalizumab (33)
Ustekinumab (47)

K12 (day-1)
0.218‡
0.247‡
0.478
[24]
0.097
[21]
0.224
[12]
‡
0.260
0.0987‡
0.873‡
2.23‡
0.245
0.137‡
19.3‡
1.09‡
0.0445‡
0.22
0.164
0.203
0.223
0.562‡
2.170‡
1.12
0.104
0.779‡

K12 BSV
(%CV)

112
168
NE

[5.2]

12

[0.20-0.25^]
[0.135-0.191^]
[0.159-0.416^]
[0.134-0.501^]

NE
54
NE
NE

[14]
[38]

NE
68

[53]
[6.1]

[43-62^]

[45]
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K21 (day-1)
0.283‡
0.499‡
0.588
[11]
0.193
[13]
0.336
[13]
‡
0.495
0.151‡
1.02‡
0.607‡
0.164
0.114‡
23.7‡
1.96‡
0.0616‡
0.18
0.101
0.258
0.215
0.585‡
1.729‡
1.02
0.319
0.703‡

K21 BSV
(%CV)

NE
96
NE

[7.7]

[21]

28

[0.17-0.19^]
[0.0826-0.122^]
[0.203-0.480^]
[0.138-0.416^]

NE
67
25
NE

[57-78^]
[11-34^]

[31]
[25]

51
94

[29]
[33]

Table 1-3 continued.
BSV = between-subject variability; K12 and K21 = distribution rate constants from central to peripheral compartment and vice
versa, respectively; NE = not estimated; Q = intercompartmental clearance; %RSE = percent relative standard error; V1 or V2
= volume of the central or peripheral compartment, respectively; Vss = volume of distribution at steady state.
* 90% or ^ 95% bootstrap confidence interval.
** Not available or not applicable estimates are blank.
‡
Parameter derived from population estimates using the following equations: CLL or CLT = K10*V1; Q=K12*V1=K21*V2;
Vss=V1+V2.
a. Covariance of between-subject variability estimated; correlation coefficients: V1_V2 (0.777), V1_Vmax (0.875), V2_Vmax
(0.875).
b. Calculated for a 70 kg patient using V1 (73.4 ml/kg) and Vmax (39 μg/kg/day) population estimates.
c. Calculated for a 70 kg patient using V1 (64.3 ml/kg) and Vmax (26.9 μg/kg/day) population estimates.
d. Covariance of between-subject variability estimated; correlation coefficients: CL_V1 (-0.05), CL_Q (-0.76), V1_Q (-0.62).
e. Covariance of between-subject variability estimated; correlation coefficient: CL_V1 (0.729; [0.335-0.910*]).
f. Covariance of between-subject variability estimated; correlation coefficient: CL_V1 (0.342; [0.214-0.456^]).
g. Apparent clearance or volume of distribution (i.e., CL/F or V/F).
h. Covariance of between-subject variability estimated; correlation coefficient: CL/F_V/F (0.817).
i. Results reported for 2C NL+L model; a receptor-mediated clearance model was also investigated.
j. Vss (%RSE) and Vss BSV (%RSE) estimates were 4.87 L (9.2) and 31 %CV (45), respectively.
k. Covariance of between-subject variability estimated; correlation coefficient: CL_V1 (0.662; [0.396-1.02*]).
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Table 1-4.
Population estimates and their between-subject variability [%RSE or confidence interval *,^] of clearance related
**
parameters.
Antibody
Sibrotuzumab (45)
Matuzumab (40)
Efalizumab i (35)
Efalizumab (21)
Denosumab (24)
Denosumab (32)
CP-751, 871 (31)
Panitumumab (42)
Cetuximab (29)
Alemtuzumab (23)
Clenoliximab (30)
Golimumab (34)
Inolimomab (38)
mAbF19 (39)
HuCC49∆CH2 (17)
Rituximab (44)
Trastuzumab (46)
Pertuzumab (43)
Bevacizumab (28)
Infliximab (36)
Infliximab (37)
Basiliximab (26)
Basiliximab (27)
ATM-027 (25)
Omalizumab (41)
Efalizumab (33)
Ustekinumab (47)

Vmax (mg/day)
0.811
[25]
10.9
[14]
2.73b
[11]
c
1.88
[4.3]
0.0878 [7.5]
0.0895 [6.3]
2.42
[29]
12.1
[11.4-12.7*]
105
[81.6-159*]
24.5
[15.6-44.2^]
35.8
[4.2]

Vmax BSV
(%CV)
29
[50]
a
54
[38]
42
[51]
65
[8.1]
32
46
34
[210]
29j [24-33*]
15
[12-19*]
32
[32]
47
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Km (mg/L)
0.219
[57]
4.0
[30]
0.0973 [27]
0.033
[21]
0.164
[11]
0.192
[7.5]
1.22
[97]
0.426
[0.364-0.586*]
74
[38.2-163*]
0.338
[0.226-0.849^]
1.29
[23]

Km BSV
(%CV)
NE
NE
122 [74]
124 [6.8]
NE
NE
69
[94]
80j [59-100*]
NE
145 [37]
NE

CLint
(L/day)
3.70‡
2.73‡
28.1‡
57.0‡
0.54‡
0.47‡
1.98‡
28.4‡
1.42‡
72.5‡
27.8‡

Table 1-4 continued.
Antibody
Sibrotuzumab (45)
Matuzumab (40)
Efalizumab i (35)
Efalizumab (21)
Denosumab (24)
Denosumab (32)
CP-751, 871 (31)
Panitumumab (42)
Cetuximab (29)
Alemtuzumab (23)
Clenoliximab (30)
Golimumab (34)
Inolimomab (38)
mAbF19 (39)
HuCC49∆CH2 (17)
Rituximab (44)
Trastuzumab (46)
Pertuzumab (43)
Bevacizumab (28)
Infliximab (36)
Infliximab (37)
Basiliximab (26)
Basiliximab (27)
ATM-027 (25)
Omalizumab (41)
Efalizumab (33)
Ustekinumab (47)

CLL (L/day)
0.530
[9.6]
0.348
[4.1]
‡
0.535
0.513‡
0.066
[7.2]
0.0710
[4.5]
0.243
[8.3]
0.273
[0.258-0.294*]
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CLL BSV
(%CV)
57 [52]
24 [21]

25
32
59
28k

[34]
[19-37*]

Table 1-4 continued.
Antibody
Sibrotuzumab (45)
Matuzumab (40)
Efalizumab i (35)
Efalizumab (21)
Denosumab (24)
Denosumab (32)
CP-751, 871 (31)
Panitumumab (42)
Cetuximab (29)
Alemtuzumab (23)
Clenoliximab (30)
Golimumab (34)
Inolimomab (38)
mAbF19 (39)
HuCC49∆CH2 (17)
Rituximab (44)
Trastuzumab (46)
Pertuzumab (43)
Bevacizumab (28)
Infliximab (36)
Infliximab (37)
Basiliximab (26)
Basiliximab (27)
ATM-027 (25)
Omalizumab (41)
Efalizumab (33)
Ustekinumab (47)

CLT BSV
(%CV)

CLT (L/day)

K10 (day-1)
0.128‡
0.0935‡
0.104
[17]
0.114
[5.8]
‡
0.0277
0.0293‡

K10 BSV
(%CV)

21
50

[99]
[9.5]

35
42

[26]
[29]

0.0691‡

0.40
1.85
2.62
1.53
0.257
0.225
0.214
0.207
0.273
0.407
0.882‡
1.33‡
0.190
0.176g
1.29g
0.465g, h

[0.33-0.49^]
[19]
[15]
[1.36-1.71*]
[0.246-0.271^]
[0.213-0.238^]
[0.201-0.228^]
[0.188-0.226^]
[0.259-0.288^]
[0.388-0.427^]

[6.7]
[2.1]
[1.17-1.39^]
[0.448-0.480^]

44
43d
54
28e
28
43
31
26
34f
38

28
20
48
41
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[19]
[87]
[31]
[20-35*]
[24-32^]
[39-47^]
[27-34^]
[23-31^]
[30-37^]
[35-41^]

[24]
[45-51^]
[38-44^]

0.130‡
0.670‡
0.837‡
0.442‡
0.0862‡
0.0763‡
0.0781‡
0.0778‡
0.0892‡
0.124‡
0.237
0.243
0.0679‡

[19]
[9.1]

Table 1-4 continued.
BSV = between-subject variability; CLT = clearance; CLL = clearance of linear elimination pathway; CLint = intrinsic
clearance (calculated as Vmax/Km); K10 = elimination rate constant from central compartment; Km = concentration at halfmaximum elimination rate; NE = not estimated; %RSE = percent relative standard error; Vmax = maximum elimination rate;
Vss = volume of distribution at steady state.
* 90% or ^ 95% bootstrap confidence interval.
** Not available or not applicable estimates are blank.
‡
Parameter derived from population estimates using the following equations: CLL or CLT = K10*V1; Q=K12*V1=K21*V2;
Vss=V1+V2.
a. Covariance of between-subject variability estimated; correlation coefficients: V1_V2 (0.777), V1_Vmax (0.875), V2_Vmax
(0.875).
b. Calculated for a 70 kg patient using V1 (73.4 ml/kg) and Vmax (39 μg/kg/day) population estimates.
c. Calculated for a 70 kg patient using V1 (64.3 ml/kg) and Vmax (26.9 μg/kg/day) population estimates.
d. Covariance of between-subject variability estimated; correlation coefficients: CL_V1 (-0.05), CL_Q (-0.76), V1_Q (-0.62).
e. Covariance of between-subject variability estimated; correlation coefficient: CL_V1 (0.729; [0.335-0.910*]).
f. Covariance of between-subject variability estimated; correlation coefficient: CL_V1 (0.342; [0.214-0.456^]).
g. Apparent clearance or volume of distribution (i.e., CL/F or V/F).
h. Covariance of between-subject variability estimated; correlation coefficient: CL/F_V/F (0.817).
i. Results reported for 2C NL+L model; a receptor-mediated clearance model was also investigated.
j. Covariance of between-subject variability estimated; correlation coefficient: Vmax_Km (0.461; [0.136-0.746*]).
k. Covariance of between-subject variability estimated; correlation coefficient: CL_V1 (0.662; [0.396-1.02*]).
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Table 1-5.
*,^
].

Identified covariates and their estimated effects on pharmacokinetic parameters** [%RSE or confidence interval

Antibody
Sibrotuzumab (45)
Matuzumab (40)
Denosumab (24)
CP-751, 871 (31)
Panitumumab (42)

Cetuximab (29)
Alemtuzumab (23)

WGT

On Vmax
0.00934

[49]

WGTb
WGTb
WGTb
AGEb

0.6
1.11
0.621
-0.495

[27]
[74]
[0.488-0.725*]
[-0.688, -0.297*]

IBWa
WBCa
WBCb

0.0108
0.0216
0.194

[0.0077-0.0139*]
[0.0169-0.0296*]
[0.081-0.382^]

a

WGT
WGTa
WGTb

On CLL
0.0182
0.0087
0.918

[19]
[28]
[28]

WGTb
GDRf
LUNGf
RENALf
OTHERf

0.411
0.769
0.861
0.957
0.870

[0.261-0.572*]
[0.721-0.818*]
[0.799-0.937*]
[0.873-1.03*]
[0.792-0.956*]

CLL was 23% slower in females
Patients with colorectal or renal
cancer had a faster CLL than
patients with non-small cell lung
cancer or other types of cancer

CL was 39% faster in males

a

Notes

On CLT
Golimumab (34)
HuCC49∆CH2 (17)
Rituximab (44)
Trastuzumab (46)

Pertuzumab (43)

WGTc
BSAb
GDRe
METe
ECDb

0.75 fixed
1.02
0.39
0.221
0.041

[0.54-1.64^]
[0.17-0.63^]
[0.0611-0.429^]
[0.013-0.071^]

WGTb
ALBb
ALKPb

0.587
-1.01
0.169

[0.372-0.826^]
[-1.42,-0.632^]
[0.067-0.258^]
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CL was 22% faster in patients
with four or more metastatic
sites

Table 1-5 continued.
Antibody
Bevacizumab (28)

Infliximab (36)

Infliximab (37)

ATM-027 (25)
Omalizumab (41)
Efalizumab (33)

Ustekinumab (47)

On Vmax
WGTb
GDRe
ALBb
ALKPb
ASTb
CHEMe
WBCd
IRe

On CLT
0.368
0.264
0.726
0.133
0.0715
0.174
0.0106
0.419

[0.088-0.650^]
[0.132-0.398^]
[0.472-1.02^]
[0.070-0.206^]
[0.002-0.144^]
[0.096-0.244^]
[0.0051-0.0162^]
[0.215-0.662^]

ALBb
IRe
GDRe

-1.54
0.471
-0.236

[-1.94, -1.17^]
[0.28-0.831^]
[-0.291, -0.181^]

WGTb
WGTb
AGEb
LYMb
PASIb
OBSe
DOSEe
WGTb
DMe
IRe
ALBb
CRCLb
GDRe
ALKPb

0.911
0.754
0.218
0.165
0.220
0.0997
-0.240
0.840
0.287
0.355
-0.896
0.188
0.059
0.113

[15]
[0.511-0.956^]
[0.091-0.344^]
[0.065-0.274^]
[0.132-0.312^]
[0.015-0.211^]
[-0.292,-0.174^]
[0.731-0.956^]
[0.189-0.377^]
[0.172-0.540^]
[-1.09, -0.673^]
[0.128-0.251^]
[0.030-0.093^]
[0.065-0.161^]
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Notes
CL was 26% faster in males
CL in concomitant bolus-IFL
regimen was 17% slower
compared to other concomitant
chemotherapy regimens
combined
CL was 42% faster for patients
positive for antibodies against
infliximab
CL was 47% faster for patients
positive for antibodies against
infliximab
CL was 24% slower in females

Obese patients (BMI ≥30) had a
10% faster CL/F
Subjects receiving 2 mg/kg had
a 24% slower CL/F vs. the
1 mg/kg group
CL/F was 28.7% faster in
patients with diabetes
CL/F was 35.5% faster for
patients positive for antibodies
against ustekinumab
CL/F was 5.9% faster for
females

Table 1-5 continued.
Antibody
Sibrotuzumab (45)
Matuzumab (40)
Denosumab (24)
CP-751, 871 (31)
Panitumumab (42)
Cetuximab (29)
Alemtuzumab (23)
Golimumab (34)
HuCC49∆CH2 (17)
Rituximab (44)
Trastuzumab (46)
Pertuzumab (43)
Bevacizumab (28)

Infliximab (36)
Infliximab (37)
ATM-027 (25)
Omalizumab (41)
Efalizumab (33)

WGTa
WGTa
WGTb
WGTb
WGTb
GDRf
WGTa

On V1
0.0125
0.0044
0.783
0.630
0.526
0.831
0.0083

WGTb
WGTc
BSAb
GDRe
WGTb
ECDb
BSAb
WGTb
GDRe
ALBb
BSAb
GDRe
WGTb
GDRe
GDRe

0.86
1.0 fixed
0.73
0.17
0.556
0.105
1.16
0.411
0.221
-0.333
0.744
0.100
0.538
-0.137
0.250

[0.45-1.05^]
[0.08-0.26^]
[0.211-0.824^]
[0.0726-0.146^]
[0.890-1.45^]
[0.284-0.490^]
[0.173-0.285^]
[-0.461,-0.242^]
[0.510-0.978^]
[0.052-0.146^]
[0.394-0.700^]
[-0.197, -0.072^]
[24]

WGTb

0.658

[15]

[21]
[35]
[30]
[25]
[0.415-0.632*]
[0.792-0.871*]
[0.0057-0.0115*]

WGTa

On V2
0.0105

[40]

On Q

WGTb

2.21

[20]

Notes

V1 was 17% smaller in
females

[17]
WGTc

1.0 fixed

WGTc

0.75 fixed
V1 was 17% larger in
males

V1 was 22% larger in
males
V1 was 10% larger in
males
V1 was 14% smaller in
females
V1 was 25% larger in
males
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Table 1-5 continued.
Antibody
Ustekinumab (47)

WGTb
DMe
RACEe

On V1
0.807
0.132
-0.111

On V2
[0.707-0.905^]
[0.045-0.223^]
[-0.154, -0.070^]
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On Q

Notes
V/F was 13.2% larger
in patients with
diabetes
V/F was 11.1% smaller
for non-Caucasians
vs. Caucasians

Table 1-5 continued.
AGE = age; ALB = albumin; ALKP = alkaline phosphatase; AST = aspartate aminotransferase; BMI = body mass index;
BSA = body surface area; CHEM = concomitant chemotherapies; CLT = total clearance; CLL = clearance of linear
elimination pathway; CL/F = apparent clearance; COVref = reference/typical covariate value; CRCL = creatinine clearance;
DM = diabetes comorbidity; DOSE = dose group; ECD = serum level of shed HER2 receptor extracellular domain; F =
female; GDR = gender; IBW = ideal body weight; IFL = irinotecan, 5-fluorouracil, leucovorin regimen; IR = immune
response with development of antibodies to the therapeutic monoclonal antibody; LUNG = non-small cell lung cancer; LYM
= lymphocyte count; M = male; MET = number of metastatic sites; OBS = obesity; OTHER = other cancer types (see
referenced paper for details); PASI = psoriasis area and severity index score; Q = intercompartmental clearance; RENAL =
renal cancer; %RSE = percent relative standard error; V1 or V2 = volume of the central or peripheral compartment,
respectively; V/F = apparent volume of distribution; Vmax = maximum elimination rate; WBC = white blood cell count; WGT
= body weight.
* 90% or ^ 95% bootstrap confidence interval.
** Not available or not applicable estimates are blank.
Continuous covariate models:
a. Linear proportional (covariate centered); P = θ1 * (1 + θCOV * (COV-COVref)).
b. Power (covariate normalized); P = θ1 * (COV/COVref)**θCOV.
c. Allometric (covariate normalized); θCOV in power model fixed to 0.75 or 1.0.
d. Linear additive (covariate centered); P = θ1 + θCOV * (COV-COVref).
Categorical covariate models:
e. Linear proportional; P = θ1 * (1 + θCOV * COV) where COV is 0 or 1, for example.
f. Power; P = θ1 * θCOV**COV where COV is 0 or 1, for example.
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Table 1-6.

Residual variability estimates** [%RSE or confidence interval *,^].
Antibody
Sibrotuzumab (45)
Matuzumab (40)
Efalizumabb (35)
Efalizumab (21)
Denosumab (24)
Denosumab (32)
CP-751, 871 (31)
Panitumumab (42)
Cetuximab (29)
Alemtuzumab (23)
Clenoliximab (30)
Golimumab (34)
Inolimomab (38)
mAbF19 (39)
HuCC49∆CH2 (17)
Rituximab (44)
Trastuzumab (46)
Pertuzumab (43)
Bevacizumab (28)
Infliximab (36)
Infliximab (37)
Basiliximab (26)
Basiliximab (27)
ATM-027 (25)
Omalizumab (41)
Efalizumab (33)
Ustekinumab (47)

Proportional error (%CV)
9.3
[6.8]
13.4 [1.5]
11.7 [21]
35.9 [1.5]
35.9

Additive error (mg/L)
0.0491
[19]
0.312 fixed

2.66E-04
26
42.0
14.6a
21.2a
37.2
8.8
15.0
30.2
12.5
15.1
19.0
23
19.2
17.2
22.9
40.3
29.8
18.4
26.0
16.7
26.3
25.6

[6.9]
[36.3-48.4*]
[12.3-16.8*]
[18.8-23.7*]
[31.0-40.0^]
[29]
[23]
[7]
[31]
[12.5-17.6*]
[17.2-21.3^]
[21-24^]
[17.3-21.2^]
[15.8-19.0^]
[21.8-24.0^]
[38.3-42.2^]
[35]
[18]
[9.3]
[22.2-29.8^]
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0.03

[0.005-0.05*]

0.0647

[0.0372-0.114^]

19.1 dps/ml
0.54

[12.7-29.3*]
[0.4-0.64^]

2.27
7.2
2.89
0.0413
0.371
0.084
0.0084

[0.002-4.16^]
[0.093-10.3^]
[2.48-3.22^]
[0.0368-0.0497^]
[51]
[23]
[15]

1.58
0.085 fixed

[1.01-2.07^]

Table 1-6 continued.
%RSE = relative standard error.
* 90% or ^ 95% bootstrap confidence interval.
** Not available or not applicable estimates are blank.
a. Separate residual error models used per each clinical trial.
b. Results reported for 2C NL+L model; a receptor-mediated clearance model was also investigated.
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Antibody Absorption
Most mAbs that are approved or in development are administered intravenously
(IV), although other routes including subcutaneous (e.g., omalizumab, efalizumab,
adalimumab) and intramuscular (e.g., palivizumab) administration are used. Oral
administration of mAbs has been limited due to their large molecular weight and polarity,
as well as their susceptibility to denaturation and proteolytic degradation in the
gastrointestinal tract.
While the mechanism of absorption following subcutaneous (SC) or
intramuscular administration (IM) is not completely understood, it has been suggested
that mAbs are primarily absorbed via the lymphatic system. This presumption is
supported in part from a study in which the lymphatic absorption of 5-fluoro-2’deoxyuridine (molecular weight 0.246 kDa), inulin (5.2 kDa), cytochrome c (12.3 kDa),
and human recombinant interferon alpha-2a (19 kDa), was investigated following SC
administration in sheep (48). A positive linear relationship was observed between the
molecular weight of the compound and the proportion of the dose absorbed via the
lymphatics. Molecules larger than 16 kDa predominantly underwent lymphatic
absorption, while those under 1 kDa were primarily absorbed by the blood capillaries.
The molecular weights of the investigated compounds are much smaller compared to that
of IgG and intact therapeutic mAbs of the IgG type (~150 kDa), so extrapolation of the
observed linear relationship to mAbs should be made with caution. A sheep model was
also used in another study to investigate the contribution of the lymphatics to the
absorption and systemic availability of recombinant human erythropoietin alpha (30.4
kDa) following SC administration (49). This study reported an 84% and 75% recovery of
the administered dose in the peripheral and central lymph, respectively. Contrasting
results to the above studies in sheep were reported in an investigation of lymphatic
absorption of bovine insulin (5.6 kDa), bovine albumin (66 kDa), and recombinant
human erythropoietin alpha (30.4 kDa), following SC administration in a rat model (50).
The investigators found that for all three macromolecules, less than 3% of the
administered SC dose was recovered in the lymph. This study was conducted in rats
which may not be a good model for human SC absorption, so extrapolation of the results
to humans should be done with discretion. Drawing any conclusions about the lymphatic
absorption of IgG molecules based on the results of the aforementioned studies should by
done with caution since IgG molecules were not specifically investigated. There is still a
great deal of uncertainty regarding the physiological mechanisms involved in the
absorption of IgG following SC or IM administration, and in some aspects these
mechanisms may differ from other macromolecules, for example the potential
involvement of FcRn in this process (9).
Lymphatic absorption is believed to occur via convection, a process in which the
mAb is “pulled” along by the flow of interstitial fluid into the highly permeable
lymphatic capillaries where it is eventually returned back into the systemic circulation.
Prior to reaching the systemic circulation, proteolytic degradation may occur at the
injection site or during lymphatic transport, thereby reducing the bioavailable fraction of
the antibody (9). The flow of lymph through the lymphatic vessels is relatively slow, for
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example, the lymph flow rate is approximately 1-2 ml/kg/hr for the thoracic duct (51).
As a result, absorption of the mAb can take place over several days. Typical values for
time to reach maximal concentration following IM or SC administration range from 1-8
days, and absolute bioavailabilities generally range from 50-100% (6, 7).
The majority of the population PK studies were performed using concentration
data following IV administration, but SC data was available in a small number of studies.
These studies are listed in Table 1-2 along with population estimates and between-subject
variabilities for absolute bioavailability (F) and absorption rate constant (Ka). The
median (range) population estimate for Ka was 0.217 day-1 (0.132-0.48). Three different
studies reported estimates for F which included values of 49.1, 56.4, and 74.7%. These
population estimates for F and Ka are in agreement with the general absorption
characteristics of mAbs following IM or SC dosing. Estimates of between-subject
variability in F and Ka were large with values ranging from 40-53 %CV (Table 1-2),
although variability in these two parameters was not often estimated.
Antibody Distribution
The ability of mAbs to cross cell membranes is significantly hindered by their
large molecular weight and hydrophilicity/polarity. Given this, mAbs often exhibit a
small volume of distribution, and are believed to be largely confined to the vascular and
interstitial spaces. Other factors that influence the distribution characteristics of
antibodies include the distribution and density of the antibody target and morphology of
the vascular capillaries (i.e., continuous, fenestrated, and sinusoidal). The movement of
mAbs across or between cell membranes may occur via transcellular or paracellular
mechanisms, respectively (7, 52, 53).
The paracellular movement of mAbs occurs by means of convection, which is
simply the transport of mAbs within the movement of fluid flow. This fluid flow is set
up by the natural physiological exchange of fluids between the capillaries, interstitial
space, and lymphatics. Convection is believed to be the primary mechanism responsible
for the movement of mAbs from the vasculature to the interstitial space (9). Convection
also plays a role in the distribution of mAbs within the interstitial fluid, and facilitates the
transport of antibody out of the tissue as interstitial fluid enters the lymphatic capillaries.
Given that the paracellular pores of the lymphatic capillaries are much larger than those
in the vascular endothelium, it is assumed that the convective clearance of mAbs from the
tissue is much more efficient than the process of convective extravasation, thereby
maintaining relatively low mAb concentrations in the interstitial fluid (7, 9).
The transcellular movement of mAbs can occur via passive diffusion or
endocytosis. However, given the physiochemical properties of mAbs, it is likely that
passive diffusion does not play a significant role in their distribution. Endocytosis of
mAbs can take place through three main processes: phagocytosis, fluid-phase
pinocytosis, and receptor-mediated endocytosis (6). Virtually all cells in the body have
the ability to take up proteins and other macromolecules including mAbs from the
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surrounding fluid space via fluid-phase pinocytosis. Receptor-mediated endocytosis may
take place following binding of the mAb to a cell surface antigen or Fcγ receptors (7).
Another potential mechanism for extravasation of mAbs is transcytosis by
vascular endothelial cells (7, 52, 54, 55). Following fluid-phase pinocytosis by
endothelial cells, mAbs within the intracellular vesicle may bind to FcRn, which not only
protects the mAb from degradation, but eventually the mAb is recycled back into
systemic circulation or transcytosed into the interstitial space (54). The FcRn-mediated
transcytosis of IgG has been demonstrated in both endothelial and epithelial cells (56-62).
However, the importance of FcRn-mediated transcytosis of IgG in the distribution of
mAbs remains to be elucidated.
Following IV administration, the concentration-time profile of mAbs often
follows a bi-exponential decline, which can be best described using a two-compartment
PK model (11, 63). Accordingly, a two-compartment model was used in the majority of
the mAb population PK analyses (Table 1-1). In the few studies where a onecompartment PK model was used, concentration data was only available following SC
administration. The distribution phase of the mAbs in these studies may have been
masked by a slow absorption phase often observed for mAbs following SC
administration. An attempt was made in the population PK analyses of pertuzumab and
inolimomab to fit a three-compartment model to the concentration data, but this resulted
in an overparameterized model and did not show a significant improvement in fit versus a
two-compartment model (38, 43).
Population estimates and between-subject variabilities for distribution related PK
parameters are summarized in Table 1-3. Estimates for the volume of the central (V1)
and peripheral (V2) compartments were quite similar for the different mAbs with the
exception of alemtuzumab. Compared to other mAbs, alemtuzumab not only had a much
larger V1 and V2 (11.3 L and 41.5 L, respectively), but between-subject variability in both
of these parameters was also larger (84 %CV and 179 %CV, respectively) (23). It is
uncertain as to why these population parameter estimates for alemtuzumab are in stark
contrast to what was observed for many of the other therapeutic mAbs. The median
(range) estimate for V1 and V2 based on studies that used a two-compartment PK model
(excluding alemtuzumab) was 3.1 L (2.4-5.5) and 2.8 L (1.3-6.8), respectively. In
general, the estimates for V1 were approximately equal to plasma volume. Betweensubject variability was quantified for V1 in all but one of the population PK studies
(Table 1-3). The between-subject variability in V1 was usually moderate, as the median
(range) across all of the studies was 26 %CV (12-84). The values for volume of
distribution at steady state (Vss=V1+V2) suggest an apparently limited distribution outside
of the vascular space, and are consistent with the behavior of endogenous IgG. Based on
data from early IgG metabolism studies in humans (64), the mean serum IgG
concentration and total body IgG pool were 12 g/L and 1.06 g/kg body weight,
respectively, which for a 70 kg person equates to a volume of distribution of around 6.2 L
for IgG. Population estimates for intercompartmental clearance (Q) and the distribution
rate constants (K12 and K21) appeared to be less homogenous across the different mAbs
compared to V1 and V2. In general, the estimates for Q, K12, and K21, suggested a slow

25

transfer of mAb between the central and peripheral compartments. The median Q across
all of the studies that used a two-compartment model was 0.79 L/day. Between-subject
variability in V2, Q, K12, and K21 was often not estimated in the population PK models.
When estimated, between-subject variability in these parameters was usually moderate to
high. Volume of distribution corrected for SC bioavailability (V1/F) was estimated in the
population PK analyses of omalizumab, efalizumab, and ustekinumab, which have a
bioavailability F following SC dosing of around 62%, 50%, and 57%, respectively (33,
41, 47). After adjusting for F, the volume of distribution for omalizumab, efalizumab,
and ustekinumab are approximately 3.7, 4.6, and 9.0 L, respectively, which is in line with
the results for other mAbs.
When estimating Vss using a noncompartmental analysis or by fitting a
mammillary compartmental model to the data, the assumption is made that elimination of
the drug occurs at a site(s) in rapid equilibrium with plasma or the central compartment
(63, 65). For some mAbs this assumption may be valid. However, there may be
instances when a mAb undergoes significant elimination in peripheral tissues (e.g., via
receptor-mediated endocytosis). In these cases, the aforementioned methods of analysis
can lead to errors in estimating Vss (63, 65). Therefore, volumes of distribution reported
in the literature for mAbs should be interpreted with caution.
Antibody Clearance
The two general pathways by which drugs are eliminated from the body are
metabolism (e.g., catabolism) and excretion. However, the role of non-catabolic routes,
such as renal and biliary excretion, in the clearance of mAbs is negligible. The
glomerular filtration of mAbs is largely limited by their size, as the molecular cut-off
weight for filtration is approximately 70 kDa (66). While biliary excretion has been
reported for IgA, it does not appear to be a significant route for elimination of IgG (9,
67). The primary route by which antibodies are eliminated is cellular uptake followed by
proteolytic degradation. Therapeutic antibodies often exhibit two distinct catabolic
pathways (8): 1) a non-specific, linear (first-order) clearance pathway mediated by
interaction between the Fc region of the antibody and Fc receptors (i.e., FcRn and Fcγ
receptors) and 2) a nonlinear (target-mediated) clearance pathway mediated by the
specific interaction between the Fab region of the antibody and its pharmacologic target.
Fc-Receptor-Mediated Elimination
The previous use of non-specific with regards to the linear clearance pathway
reflects the notion that Fc-mediated elimination is a common pathway shared by both
endogenous IgG and therapeutic IgG mAbs with a functional human Fc domain.
Virtually all cells in the body have the ability to take up proteins and other
macromolecules from the surrounding fluid space via endocytosis (e.g., fluid-phase
pinocytosis). The formed endosome may subsequently be delivered to a lysosome, where
its contents undergo enzymatic degradation. However, unlike most other proteins in the
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endosome, a significant portion of IgG can be salvaged from lysosomal catabolism by an
FcRn-mediated mechanism in cells expressing FcRn (68-70).
Following cellular uptake of IgG, the environment inside the early endosome
becomes mildly acidic. IgG binds to FcRn in a pH dependent manner, and the decrease
in pH allows IgG to bind to FcRn expressed within the endosome. IgG that is bound to
FcRn is redirected to the cell surface, while unbound IgG is delivered to the lysosome for
degradation. This partitioning of IgG-FcRn complexes and unbound IgG into two
different pathways appears to occur within the sorting endosome (70). Once the IgGFcRn complex is transported to the cell surface, the affinity of IgG to FcRn decreases as
the result of the physiological pH, and IgG is released into the extracellular fluid. This
salvage pathway helps to explain the much longer elimination half-life of IgG (~21 days)
compared to that of the other immunoglobulin classes whose half-lives range from 2-10
days (6). While the IgG1, IgG2, and IgG4 subclasses exhibit a half-life of around 21
days, the half-life for IgG3 is only 7 days. The shorter half-life of IgG3 has been
attributed to binding differences to FcRn compared to the other IgG subclasses (8). As
the number of FcRn receptors is limited, the salvage pathway can be expected to be
capacity limited. This is supported by findings from a study by Morell et al., in which
shorter IgG half-lives were observed in patients with elevated serum IgG concentrations
compared to those with normal IgG levels (71). However, the doses commonly
administered for therapeutic mAbs are not likely to cause significant enough increases in
serum IgG concentrations that result in saturation of the FcRn receptor (72). Therapeutic
mAbs are commonly administered at doses <10 mg/kg, which would increase the total
body IgG by <1-2%, as humans typically possess 50-100 g of endogenous IgG (9).
Furthermore, as will be discussed later in the review, the estimates for total clearance in
mAbs with linear elimination characteristics and for the clearance of the linear
elimination pathway in mAbs with parallel linear and nonlinear elimination were quite
similar to the clearance of endogenous IgG. The FcRn receptor is expressed in a wide
variety of cells and tissues throughout the body including the vascular endothelium,
monocytes, macrophages, dendritic cells, hepatocytes, and epithelial cells of the intestine,
renal proximal convoluted tubules and upper airways (73, 74).
Another set of receptors that bind to the Fc portion of IgG are the Fcγ receptors.
These receptors play a significant role in mediating various immune effector functions
such as phagocytosis and antibody dependent cellular cytotoxicity (75). There are three
different classes of Fcγ receptors (i.e., FcγRI, II, III) and they differ with regards to their
cellular distribution, specificity for the different IgG subclasses, and affinity for
monomeric or immune-complexed IgG (10). The Fcγ receptors are expressed on a wide
variety of cells including monocytes, macrophages, dendritic cells, neutrophils, NK
(natural killer) cells, B cells, and hepatocytes (10, 73). Based on their innate roles in
immune responses, Fcγ receptors may be involved in the clearance of soluble mAbantigen immune complexes or cells opsonized by the mAb. However, the significance of
Fcγ receptor-mediated catabolism of mAbs is not as well understood as the role of FcRn.
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Target-Mediated Elimination
The interaction between a mAb and its pharmacologic target can contribute to the
elimination of the mAb. A concept often applied to the PK of mAbs is target-mediated
drug disposition in which the interaction between a drug and pharmacologic target
influences its PK characteristics (76, 77). Receptor-mediated endocytosis, an example of
target-mediated drug disposition, involves binding of the mAb to a receptor on the cell
surface, which triggers internalization and subsequent lysosomal degradation of the mAbreceptor complex. The number of receptors within the distribution space of the mAb is
limited, and therefore, the receptors may become saturated at therapeutic doses of the
mAb resulting in nonlinear clearance. The nonlinear clearance observed with many
mAbs is believed to be due to saturation of target-mediated clearance pathways (8). The
role that target-mediated clearance plays in the total clearance of the mAb is dependent
on a number of factors including the concentration and distribution of the receptor, and
rates of receptor internalization and turnover (8).
Therapeutic mAbs that bind to soluble antigens may also undergo target-mediated
elimination. One potential mechanism that has been suggested is in which the soluble
mAb-antigen complex binds to Fcγ receptors on cells such as monocytes and
macrophages, which subsequently triggers internalization and catabolism of the complex
(9). If this elimination mechanism was present for a given therapeutic mAb, then it
would be reasonable to anticipate that the clearance of the soluble mAb-antigen complex
would be greater compared to that for the unbound and free mAb. In a population PK/PD
analysis of omalizumab (an anti-IgE mAb), the apparent clearance of the omalizumabIgE complex was 0.32 L/day compared to 0.18 L/day for free omalizumab (41). The
nonlinear PK observed for mAbs, such as omalizumab and denosumab (24, 78, 79),
which target soluble antigens, suggests that saturable target-mediated mechanisms of
elimination are not only limited to mAbs with membrane bound antigens (9).
Clearance Models
The different PK models used in the population analyses are listed in Table 1-1.
In most studies compartmental PK models with linear, nonlinear, or parallel linear and
nonlinear elimination pathways were used to describe the PK of the mAb. In the
population PK/PD analyses of efalizumab (35) and omalizumab (41) more complex
mechanistically based target-mediated elimination models were applied. A commonly
used PK model that can be related to the distinct physiologic elimination pathways is a
two-compartment model with parallel linear and nonlinear elimination from the central
compartment, which is depicted in Figure 1-2A. In this PK model, the total clearance
(CLT) of the mAb is comprised of clearance from the nonlinear pathway (CLNL) plus that
of the linear pathway (CLL). Physiologically, the nonlinear pathway is thought to be
related to elimination of the mAb via saturable target-mediated mechanisms (e.g.,
receptor-mediated endocytosis), while the linear component represents elimination
pathways not saturable at therapeutic mAb concentrations such as Fc-mediated
elimination. The relationship between the clearance components of the model (CLL,

28

Figure 1-2. Pharmacokinetic behavior of a monoclonal antibody with parallel linear
and nonlinear elimination pathways. Schematic of a representative structural
pharmacokinetic model with parallel elimination pathways (A). Plot of clearance
dependence on serum concentrations (B). Simulated serum concentration-time profiles
(C) using the pharmacokinetic model in (A) after single IV bolus doses of 50, 100, 200,
400, 800, and 1600 mg. Parameter values of 18 mg/day (Vmax), 5 mg/L (Km), 0.4 L/day
(CLL), 4 L (V1), 3 L (V2), and 1.2 L/day (Q) were used for the simulation as well as for
the clearance versus concentration plot. C1 = concentration in central compartment; CLL
= clearance of the linear elimination pathway; CLNL = clearance of the nonlinear
elimination pathway (calculated as Vmax/(Km+C1)); CLT = total clearance (calculated as
CLNL+CLL); Km = concentration at which elimination is half maximum; Q =
intercompartmental clearance; V1 = volume of central compartment; V2 = volume of
peripheral compartment; Vmax = maximum elimination rate.
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CLNL, and CLT) and mAb concentration is described in Figure 1-2B. At low
concentrations total clearance is relatively unaffected by the mAb concentration, and
target-mediated elimination contributes a significant portion to the overall clearance of
the mAb (CLNL is approximately 7 times larger than CLL). With increasing
concentrations, total clearance decreases dramatically as the target-mediated elimination
pathway starts to become saturated. The concentration range at which this significant
decrease in total clearance occurs is dependent on the Kd (dissociation constant) and/or
EC50 of the mAb-receptor interaction, and lies for many mAbs in the range of 0.1-100
mg/L. At high concentrations, the total clearance approaches that of the first-order
process (CLL), while the contribution from the nonlinear pathway becomes negligible. A
biphasic clearance versus dose profile has been observed for several therapeutic mAbs
including cetuximab, trastuzuamb, and efalizumab (35, 79-82). Another characteristic of
this model is an S-shaped curve in the concentration-time profile (Figure 1-2C). This
may be observed at higher doses if concentrations are sampled for a prolonged time
period, and is due to an increase in total clearance coinciding with an increase in CLNL as
concentrations decrease. Given a two-compartment PK model with one linear and one
nonlinear elimination pathway, there are different structural variations that can be
conceived by varying the location (i.e., central or peripheral compartment) of the two
elimination pathways. Issues regarding identifiability and indistinguishability of these
different models has been investigated by Godfrey and colleagues (83). In most studies
that used a parallel elimination model, the configuration was one where both the linear
and nonlinear elimination pathways originated from the central compartment. However,
other structural variations were evaluated in the population PK analyses of matuzumab
and CP-751, 971 (31, 40).
The most frequent PK model used in the population analyses was a one- or twocompartment model with linear elimination (Table 1-1), which is inconsistent with the
observation that many therapeutic mAbs exhibit nonlinear clearance (6, 8). One reason
for this discrepancy may have been related to the doses (concentrations) studied in the
population PK analysis. Referring back to Figure 1-2B, the dose of the mAb may result
in concentrations that are high enough to saturate the target-mediated elimination
pathway. A compartmental model with linear elimination may adequately describe the
data at these high concentrations, as the nonsaturable Fc-mediated elimination pathway
becomes the major determinant of mAb clearance. Nonlinear clearance has been
observed for efalizumab and trastuzumab, and this was attributed to saturation of targetmediated clearance pathways via their respective targets, CD11a and HER-2 (33, 35, 79,
82). Contrary to these observations, two separate population PK analyses of efalizumab
and trastuzumab found that their PK was adequately described using a compartmental
model with linear elimination (33, 46). Based on PK data from dose escalation studies of
efalizumab (35) and trastuzumab (82), the doses of these mAbs investigated in the
aforementioned population PK analyses may have resulted in steady-state concentrations
where target-mediated clearance was saturated and thus the use of a PK model with linear
elimination was warranted. In a population PK analysis of bevacizumab in patients with
solid tumors, concentration data was pooled from a number of different clinical trials
where the dosing regimen for bevacizumab varied (28). The data from 10 patients that
received bevacizumab doses of 0.1 and 0.3 mg/kg were excluded from the analysis as
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clearance at these doses was faster, and these doses were not evaluated in further clinical
trials. The excluded set of patients represented a small fraction of the 491 patients
included in the population PK study. The final population PK model for bevacizumab
included a two-compartment model with linear elimination (28). The use of a PK model
with linear elimination rather than with nonlinear elimination seems reasonable in this
case, since the population PK model was used to describe bevacizumab concentrations at
clinically relevant doses which did not included the doses of 0.1 and 0.3 mg/kg excluded
from the analysis. The lowest dose group was also excluded in a population PK analysis
of golimumab, an antibody against tumor necrosis factor alpha (TNF-α), in patients with
rheumatoid arthritis (34). The dataset used to build the population PK model included 21
patients who received single IV doses of golimumab ranging from 0.3-10 mg/kg, while 3
patients who received 0.1 mg/kg were excluded from the analysis. The inclusion of data
from the 0.1 mg/kg group resulted in convergence difficulties, and it was believed that
this may be due to a significant influence of TNF-α mediated disposition at a very low
dose. The final population PK model for golimumab included a two-compartment model
with linear elimination (34).
Clearance Population Estimates
Population estimates and their between-subject variability for clearance related
PK parameters are summarized in Table 1-4. The estimates for the maximum elimination
rate (Vmax) and the mAb concentration at which elimination is at half maximum (Km)
varied considerably among the different therapeutic mAbs. As nonlinear clearance is
often attributed to target-mediated mechanisms, it can be expected that Vmax and Km will
be specific for a given mAb and its pharmacologic target. The Michaelis-Menten type
parameters (Vmax and Km) can be related to parameters of a full model of target-mediated
drug disposition (84, 85). While between-subject variability was always estimated for
Vmax, it was often not estimated for Km thereby treating it as a fixed value across
individuals. Given that Vmax is related to the number of pharmacologic targets within the
mAb distribution space and Km is related to the affinity of the mAb to its target, it is a
reasonable approach to hypothesize that physiologically there is more variability in Vmax
among individuals than in Km. Between-subject variability in Vmax was typically
moderate to high with a median (range) value of 34 %CV (15-65 %CV) across the
studies. When estimated, variability in Km tended to be quite large with most estimates
being greater than 100 %CV. For mAbs with population estimates of Vmax and Km, their
intrinsic clearance (CLint) was calculated as Vmax/Km and is reported in Table 1-4. All of
the therapeutic mAbs in Table 1-4, for which CLint was calculated, bind to a cell surface
antigen. The pharmacologic target for denosumab, receptor activator of nuclear factorκB ligand (RANKL), is expressed not only in a membrane-bound form but also in a
soluble form (86, 87). An interesting observation was made regarding the relationship
between CLint and the location (i.e., blood or tissue) of the cell membrane target.
Sibrotuzumab, matuzumab, cetuximab, denosumab, and CP-751,871 all bind to cell
membrane antigens primarily expressed in tissue, and their calculated CLint values ranged
from 0.47-3.70 L/day. On the other hand, efalizumab, alemtuzumab, and clenoliximab,
target different CD antigens largely expressed on white blood cells, and their CLint was
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much larger with values ranging from 27.8-57.0 L/day. Mechanistically, the larger CLint
observed for mAbs that target blood cells may be due to a larger number of antigens
within their primary distribution space compared to mAbs with membrane bound targets
in tissue. Panitumumab, cetuximab, and matuzumab are all anti-EGFR (epidermal
growth factor receptor) mAbs, but the CLint for panitumumab (28.4 L/day) was much
larger compared to that for cetuximab (1.42 L/day) and matuzumab (2.73 L/day) (Table
1-4). It is uncertain as to why these differences in CLint exist between the anti-EGFR
mAbs, but one could hypothesize that the larger CLint observed for panitumumab is in
part due to its higher affinity for EGFR (Kd=5 x 10-11 M) compared to cetuximab (Kd=39
x 10-11 M) and matuzumab (Kd=34 x 10-11 M) (88-90).
Assuming a volume of distribution of 6.2 L and an elimination half-life of 21 days
for IgG (64) (with the exception of the IgG3 subclass), the clearance for endogenous IgG
is approximately 0.21 L/day. The population estimates for CLL were relatively close to
the clearance of endogenous IgG, as the median (range) CLL estimate was 0.31 L/day
(0.066-0.535 L/day). The discrepancy between CLL values and the clearance for
endogenous IgG may be due in part to different affinities of the therapeutic mAbs to the
FcRn receptor and Fcγ receptor subtypes compared to IgG. The population clearance
estimates for several of the mAbs were around 0.2 L/day, and thus quite close to the
clearance for endogenous IgG. This suggests that either these mAbs do no exhibit
saturable target-mediated clearance or that clearance via this pathway was negligible at
the concentrations studied in the population analysis.
The population clearance estimates for inolimomab, mAbF19, HuCC49∆CH2,
and basiliximab, were much larger than those for other mAbs. In the case of the first
three mAbs listed, their increased clearance may have been due to impaired binding to
the FcRn receptor, which protects IgG from proteolytic degradation (55). Both
inolimomab and mAbF19 are murine IgG mAbs (38, 39). The rapid elimination of
murine mAbs in humans has been attributed to the lack of binding of murine IgG to the
human FcRn receptor (91). No indication was given in the population PK analyses of
inolimomab and mAbF19 if antibodies against these therapeutic mAbs were measured
and/or detected (38, 39). Considering that inolimomab and mAbF19 are murine mAbs,
an immune response and formation of antibodies against the mAbs could be another
potential reason for the larger clearance estimates compared to other therapeutic mAbs.
HuCC49∆CH2 is a humanized IgG1 mAb, but is different in that it has a deletion in the
constant heavy 2 domain to minimize immunogenicity (17). The authors suggested that
the increased clearance in HuCC49∆CH2 may have been due to the constant heavy 2
domain deletion, which could have affected binding to the FcRn receptor (17). This
appears to be a valid argument as the FcRn receptor binds to a site on IgG formed
between the constant heavy 2 and constant heavy 3 domains (10).
The population PK of basiliximab has been investigated in patients with kidney
(26) and liver (27) transplants, and the clearance in liver recipients was found to be larger
compared to kidney receipients. One likely explanation for the larger clearance in liver
transplant patients is the additional route of basiliximab clearance through drained ascites
fluid (27, 92).
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Apparent clearance (CL/F) was estimated in the population PK analyses of
omalizumab, efalizumab, and ustekinumab (Table 1-4), which have an F following SC
dosing of around 62%, 50%, and 57%, respectively (33, 41, 47). After adjusting for F,
the clearance of omalizumab, efalizumab, and ustekinumab, are approximately 0.11,
0.65, and 0.27 L/day, respectively. The between-subject variability in CLL and CLT,
much like the variability in Vmax, was moderate to large with estimates ranging from 2059 %CV.
Covariates
Identified covariates in population analyses of therapeutic mAbs and their
estimated effects on PK parameters are presented in Table 1-5. Covariates were
commonly identified for the PK parameters Vmax, CLL, CLT, and V1. No covariates were
found to influence Km, which is not unexpected. As Km reflects the intrinsic affinity of
the mAb to its target, commonly evaluated covariates such as those related to
demographics, size measurements, and blood chemistry/hematology labs would not be
expected to have an effect on Km. Polymorphic expression of the target could
theoretically have an effect on the Km, but this type of genetic information has not been
incorporated into any population PK models published to date for therapeutic mAbs.
Polymorphic expression in the gene that encodes the FcγIIIa receptor (FCGR3A) has
been associated with better clinical and/or biological response in non-Hodgkin’s
lymphoma patients treated with rituximab (93, 94), Crohn’s disease patients treated with
infliximab (95), and patients with breast cancer receiving trastuzumab therapy (96).
Demographic and Anthropometric Measurements
Size covariates are probably the most frequently identified and clinically relevant
covariates in population PK analyses, and are well established as predictors of systemic
exposure for small-molecule drugs as well as therapeutic mAbs (13). Based on the
findings summarized in Table 1-5, measures of body size were clearly the most
commonly identified covariates found to influence the PK of therapeutic mAbs. This is
not surprising since PK parameters such as clearance and volume are often functions of
body size (97). Measures of body size that were frequently evaluated as covariates
include body weight (WGT), ideal body weight (IBW), and body surface area (BSA).
Common practice in the mAb population PK analyses was to evaluate different size
covariates during the covariate modeling process to identify which, if any, were the most
influential and should remain in the model. Of the different measures of body size, WGT
was the most common size covariate included in the final population PK model (Table
1-5). In most studies, the effect of body size on a PK parameter was modeled using a
power function and the exponent in the function was treated as an estimable parameter.
However, in a population PK analysis of HuCC49∆CH2 in colorectal cancer patients, the
exponent was fixed to commonly used allometirc values of 0.75 for clearance terms and
1.0 for volume terms (17).
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The use of fixed dosing versus body size-based dosing for therapeutic mAbs in
adults was recently addressed by Wang et al. (98). A simulation study was carried out
using published population PK and/or PD models for 12 therapeutic mAbs, and the
performance of the two dosing strategies in reducing PK and/or PD variability was
investigated. The two dosing approaches performed similarly across the 12 mAbs
investigated with fixed dosing being better for some mAbs and body size-based dosing
for others. Based on the findings, the authors recommended using fixed dosing in firstin-human studies, and once sufficient data is available to assess the effect of body size on
the PK/PD of the mAb, these findings can be used in part to determine the appropriate
dosing strategy for subsequent phase 3 studies (98).
Other demographic variables besides body size that were often evaluated as
covariates included age, gender, and race. Even after adjusting for body size, gender was
identified as a predictor of CLL, CLT, and V1 in a small number of studies (Table 1-5).
The effect of gender on the PK of ustekinumab and infliximab was relatively small and
not considered to be clinically relevant (36, 47). In the population PK analyses of
bevacizumab and rituximab, the evaluation of gender as a covariate found that males had
a larger CLT and V1 (values ranged from 17%-39% larger) (28, 44). However, based on
the prescribing information for these two mAbs, no dose adjustments for gender are
recommended based on similar efficacy and safety profiles in males and females (99,
100). Race was evaluated as a covariate in a number of population PK studies including
bevacizumab (28), cetuximab (29), pertuzumab (43), and alemtuzumab (23), but was not
found to influence the PK of any of these mAbs. The percentage of non-Caucasian
patients was small in many studies, and may have precluded the ability to identify any
possible differences between race groups. In population PK studies of infliximab (36)
and golimumab (34) race was not investigated as a covariate because most patients were
Caucasian. The only study where race was identified as a covariate was a population PK
analysis of ustekinumab in psoriasis patients (47). The V1/F for ustekinumab was found
to be 11.1% lower in non-Caucasian patients versus that for Caucasians, but this was not
considered to be clinically relevant. Age was identified as a covariate in only the
population PK analyses of efalizumab and panitumumab (33, 42). Age was found to
have an opposite effect in the two studies, as age was positively correlated with CL/F in
the efalizumab analysis, and in the panitumumab analysis age was negatively correlated
with Vmax.
Receptor Number and Disease-Related Factors
As many therapeutic mAbs undergo receptor-mediated endocytosis following
binding to their target, it can be expected that the number of receptors within the
distribution space of the mAb would affect its clearance. Covariates related to receptor
number may include flow cytometry measurements (e.g., receptor density and receptorpositive cell counts) and analysis of biopsy samples using immunohistochemistry or
fluorescence in situ hybridization. Patient status and disease severity could also be
related to receptor number, as one could hypothesize that for some conditions a patient
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with more severe disease would have a higher receptor expression. Time or duration of
treatment is another variable that may be related to receptor number if administration of
the therapeutic mAb results in down modulation of its target over time.
Omalizumab and efalizumab are excellent examples where the effect of targetmediated elimination was accounted for using a more complex mechanistic-based
population PK/PD model (35, 41). Similarly, a population PK/PD analysis in patients
with B-cell chronic lymphocytic leukemia found that alemtuzumab exhibited nonlinear
clearance attributable to saturation of target-mediated clearance mechanisms (23). The
only covariate found to influence the PK of alemtuzumab was white blood cell (WBC)
count, which was a strong positive predictor of Vmax. This could be expected as
alemtuzumab targets CD52, an antigen present on the cell surface of WBCs including
lymphocytes and monocytes. The WBC count for each patient was updated over time
when possible, and WBC counts were shown to generally decrease following repeated
administration of alemtuzumab. Therefore, alemtuzumab exhibited both time- and
concentration-dependent clearance (23). An interesting use of time as a covariate was
applied in a population PK analysis of rituximab in patients with non-Hodgkin’s
lymphoma (101). The authors hypothesized that an observed increase in rituximab halflife over time was due to a decrease in clearance as B cell (CD19+) count and/or tumor
burden also decreased. The PK of rituximab was described using a two-compartment
model with two clearance pathways, where the clearance of one pathway remained
constant while the other clearance decreased over time as a first-order process. A
covariate analysis found that patients with higher CD19 counts or larger measurable
tumor lesions at baseline had a larger initial time-varying clearance (101).
Trastuzumab is a humanized IgG1 mAb that targets the human epidermal growth
factor receptor 2 (HER2). The extracellular domain (ECD) of HER2 can be shed from
the cell surface into the systemic circulation (soluble antigen), thereby providing an
additional site for trastuzumab binding (46). In a population PK analysis of trastuzumab
in patients with HER2 positive metastatic breast cancer, several variables were
investigated as potential covariates including HER2 overexpression by
immunohistochemistry (IHC), number of metastatic sites, and serum concentrations of
the ECD of HER2 (46). All of the covariates were baseline values, hence no timevarying covariates were used. The number of metastatic sites was identified as the most
influential covariate on clearance, which was 22% higher in patients with four or more
sites. The baseline concentration of ECD was found to positively influence both CLT and
V1. Patients with ECD concentrations of 200 ng/ml or greater had a 14% and 40% larger
CLT and V1, respectively, compared to patients with a median ECD concentration of 8.23
ng/ml. The impact of ECD levels on the CLT of trastuzumab is in line with nonclinical
studies that suggested that the trastuzumab-ECD complex has a higher clearance than
unbound trastuzumab (46). Potential reasons why ECD had an effect on V1 were not
addressed in the paper. HER2 overexpression based on IHC was not retained in the final
model as a significant covariate.
According to the prescribing information for bevacizumab, a population PK
analysis found that patients with a high tumor burden (at or above the median value of
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tumor surface area) had a clearance of 0.249 L/day versus 0.199 L/day in patients with
tumor burdens below the median (99). Tumor burden could not be evaluated as a
covariate in a recently published population PK analysis of bevacizumab, because data
was not available in all of the clinical trials included in the analysis (28). However,
albumin and alkaline phosphatase were found to positively influence the clearance of
bevacizumab, and both were correlated with tumor burden in this study. Assessments of
physical performance and disease severity using scoring systems such as the Karnofsky
performance scale, Psoriasis Area and Severity index (PASI), and Bath Ankylosing
Spondylitis Disease Activity index, are commonly evaluated as covariates in population
PK studies of mAbs used in areas of oncology and immunology (29, 36, 40, 46). The
only study to identify one of these scoring systems as a covariate was a population PK
analysis of efalizumab, where PASI was found to have a modest effect on CL/F (33).
Pharmacokinetic Drug Interactions
Pharmacokinetic drug-drug interactions between therapeutic mAbs and
conventional small-molecule drugs are usually not expected, since mAbs are presumably
not substrates for cytochrome P-450 enzymes or drug transporters such as P-glycoprotein.
As such, many of the clinical PK drug interaction studies that have been conducted
between therapeutic mAbs and small-molecule drugs did not identify any interaction
(102). However, there have been a small number of clinical studies where smallmolecule drugs were found to have an effect on the PK of the mAb or vice versa (102).
Since therapeutic mAbs are often administered with other treatments, concomitant
medication was evaluated as a potential covariate in several of the population PK
analyses. In all but one of the studies, concomitant medication was not found to
influence the PK of the mAb. Examples of mAbs where concomitant medication was not
identified as a covariate in the population PK analysis include cetuximab (29), rituximab
(44), trastuzumab (46), and infliximab (36). Concomitant chemotherapy was identified
as a covariate in a population PK analysis of bevacizumab (28). The clearance of
bevacizumab when administered with the bolus-IFL (irinotecan/5fluorouracil/leucovorin) regimen was 17% lower compared to all other concomitant
chemotherapy regimens combined, however, bevacizumab clearance when administered
as monotherapy did not differ from that when administered with the bolus-IFL regimen.
The effect of the concomitant chemotherapy on the clearance of bevacizumab was
minimal and does not likely necessitate any dosage adjustments.
Dosage Level
A therapeutic mAb may be known to exhibit nonlinear clearance based on prior
PK studies, but the concentration data available in a current population PK analysis may
not support a more complex PK model with nonlinear clearance. However, if
concentration data in the population analysis is available from multiple dose groups, the
nonlinear clearance of the mAb could be accounted for in part by evaluating dose as a
predictor of clearance. Such an approach was taken in a population PK analysis of
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efalizumab in psoriasis patients who received weekly SC doses of 1 mg/kg or 2 mg/kg
(33). Efalizumab has been shown to exhibit nonlinear clearance attributable to saturation
of target-mediated elimination mechanisms (35), and accordingly, various onecompartment models with linear, nonlinear, and parallel linear and nonlinear elimination
pathways were evaluated in the study (33). A one-compartment model with linear
elimination was found to adequately describe the PK of efalizumab, as the limited
concentration data did not support the PK models with nonlinear elimination. Dose was
investigated as a covariate on CL/F, and it was found that patients in the 2 mg/kg group
had a 24% lower CL/F versus patients in the 1 mg/kg group. Dose group was also found
to be a predictor of clearance in a population analysis of the mAb ING-1 in patients with
advanced adenocarcinomas (103). The PK of ING-1 was investigated across four IV
dose levels ranging from 0.03 to 1.0 mg/kg. The clearance of ING-1 was noted to
decrease as the dose was increased, but the data did not support a PK model with
nonlinear elimination. Therefore, a one-compartment model with linear elimination was
selected with dose included as a covariate on clearance. The clearance of ING-1
decreased from 56.7 to 21.8 mL/kg/day in the 0.03 mg/kg and 1.0 mg/kg dose groups,
respectively.
For a therapeutic mAb that exhibits nonlinear PK due to saturable target-mediated
mechanisms, the ability to detect and adequately characterize the nonlinearity in a
population analysis is largely dependent on the availability of concentration-time data
from a wide range of doses. However, as often encountered in drug development,
concentration-time data may only be available from clinical studies where the doses
studied (which may be clinically and therapeutically relevant) are high enough to saturate
the nonlinear target-mediated elimination of the therapeutic mAb, thereby making it
difficult to detect and characterize the nonlinear PK. In such a case, if the population PK
model is to be used for describing/predicting concentrations at doses where the nonlinear
elimination pathway is at or near saturation, then using a PK model with linear
elimination would be a reasonable approach as the Fc-mediated elimination pathway
becomes the major determinant of the mAb clearance (see Figure 1-2B).
Immunogenicity
As therapeutic mAbs are exogenous proteins, they can elicit an immune response
resulting in the formation of endogenous antibodies against the mAb. The
immunogenicity of a therapeutic mAb can be influenced by several factors including the
structure and murine content of the antibody, immune status of the patient (e.g.,
immunocompetent or immunosuppressed), dose level, dosing frequency, and dosing route
(104). The formation of antibodies as the result of an immune response can have a
significant effect on the PK, efficacy, and safety of a therapeutic mAb (104, 105). A
population PK analysis of infliximab in patients with ankylosing spondylitis found that
patients positive for antibodies against infliximab had a 42% higher clearance than the
remaining patients (36). However, when concentrations below the lower limit of
quantification (LLOQ) were imputed as one-half of the LLOQ (originally these values
were removed from the dataset), patients positive for antibodies against infliximab had a
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77% higher clearance. The influence of antibody formation on the clearance of
infliximab was found to have a much more pronounced effect in a population analysis
conducted in patients with inflammatory bowel disease (22). In this study, patients with
antibodies against infliximab had an approximately 170% higher clearance versus other
patients. Another population PK analysis of infliximab in patients with ulcerative colitis,
found that patients who developed antibodies against infliximab had a 47% higher
clearance than those who did not (37). The formation of antibodies was also identified as
an important covariate in a population PK analysis of ustekinumab, where psoriasis
patients with a positive immune response had a 36% higher CL/F (47).
Blood Chemistries
Blood chemistry tests related to hepatic and renal function were often evaluated as
potential covariates in the population PK analyses, but were rarely identified as
covariates. In the population PK analyses of pertuzumab (43), bevacizumab (28), and
ustekinumab (47) blood chemistries were found to influence the PK of the mAb (Table
1-5). The effect of blood chemistries on CLT and V1 in these studies was in general
minimal and not likely to be clinically relevant. It should be noted that in many of the
population PK analyses the effect of marked hepatic and renal impairment could not be
sufficiently evaluated, because patients included in the studies typically had adequate
hepatic and renal function. A population PK analysis of infliximab in patients with
ulcerative colitis found albumin to be a negative predictor of CLT (37). Similar
observations were made in population PK studies of pertuzumab and ustekinumab (43,
47). In addition to IgG, the FcRn also binds and protects albumin from intracellular
catabolism, thereby playing an important role in the homeostasis of both IgG and albumin
(72, 106). The authors of the infliximab analysis suggested that a higher albumin
concentration could be an indicator of an increased number of FcRn and a related
reduction in the rate of infliximab elimination (37).
Disease and Comorbidities
Only a small number of population PK studies investigated the effect of disease or
comorbidities on the PK of the mAb. The potential effect of disease on the PK of
infliximab was investigated in a population analysis of patients being treated for either
Crohn’s disease or ulcerative colitis (22). No difference in the PK of infliximab was
observed between patients with Crohn’s disease (n=30) and ulcerative colitis (n=3), but
the small number of patients with ulcerative colitis may have precluded the ability to
detect a possible difference. A number of comorbidities including diabetes, hypertension,
and hyperlipidemia, were investigated as covariates in a population PK analysis of
ustekinumab in psoriasis patients (47). This study found that patients with diabetes had a
28.7% and 13.2% higher CL/F and V/F for ustekinumab, respectively. The reason
behind the effect of diabetes on the PK of ustekinumab is uncertain, but the authors
suggested that altered lymphatic flow and particle transport, altered capillary
permeability, increased interstitial fluid volume, and accelerated clearance of the
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antibody resulting from increased glycation could be potential mechanisms (47). Based
on efficacy and safety data, the authors did not recommend that dose adjustments be
made for diabetes. The potential effect of cancer type was investigated in a population
PK analysis of panitumumab in cancer patients with various solid tumors (42). Patients
with non-small cell lung cancer or other types of cancer had a smaller CLL (~13-14%)
compared to patients with colorectal or renal cancer (42). The reason for the difference
in CLL between the different types of cancer is uncertain and was not addressed by the
authors.
Residual and Interoccasion Variability
Residual variability in most of the population PK studies was modeled using
either a proportional or a combined additive and proportional error model. In a few
studies, an exponential error model was used to describe residual variability (29, 31, 35).
Estimates of residual variability from the mAb population PK studies are summarized in
Table 1-6. Residual variability in the population PK analyses tended to be small to
moderate. Based on the values in Table 1-6, the median (range) proportional residual
error across all of the studies was 21.2 %CV (8.8-42). The proportional residual errors
were relatively comparable across the different studies, while the additive residual errors
were notably different. The additive component of a residual variance model often
corresponds to the lower limit of quantification of an assay. Therefore, the large
differences in the additive residual errors may be due in part to the different analytical
assays used for different mAbs.
Residual variability can be dependent on a number of patient or study related
factors, and these can be incorporated into the residual variance model as covariates (13).
In most of the mAb population PK analyses, a simple residual error model with no
covariates was used. However, in a population PK analysis of cetuximab, separate
residual error models were used for the two clinical studies included in the analysis (29).
This was done because of the unbalanced sampling design of the two studies (i.e.,
extensive versus sparse sampling), and their performance in different clinical settings.
In addition to between-subject and residual variability, another source of random
variability that can be incorporated into the population PK model is interoccasion
variability (IOV). The inclusion of IOV on model parameters was investigated for only a
few mAbs. In a recent population PK analysis of matuzumab, IOV was included on CLL
(40). Each infusion of matuzumab (up to the eighth infusion) was defined as one
occasion. Interoccasion variability in CLL was 23 %CV; however, this was very close to
the estimated between-subject variability in CLL of 24 %CV. The incorporation of
interoccasion variability was also found to improve the model in a population PK
analysis of sibrotuzumab (45). Although sibrotuzumab was administered as an IV
infusion, IOV was found to be best included in the disposition on F1 or the
“bioavailability” in the central compartment. Interoccasion variability in F1 was 13
%CV, and was lower than between-subject variability in the PK parameters which ranged
from 20-52 %CV.
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Conclusion
A review of the literature has shown that the population PK of different
therapeutic mAbs are quite similar despite differences in their pharmacologic targets and
being studied in different patient populations and disease states. A two-compartment
model was used in the majority of the population analyses to describe the disposition of
the mAb. Population estimates for V1 and V2 were typically small with a median (range)
of 3.1 L (2.4-5.5) and 2.8 L (1.3-6.8), respectively. The estimated between-subject
variability in V1 was usually moderate with a median (range) of 26 %CV (12-84).
Between-subject variability in other distribution related parameters such as V2 and Q
were often not estimated. Although the most frequent PK models used in the population
analyses were models with linear elimination, other models with nonlinear or parallel
linear and nonlinear elimination pathways were also applied as many therapeutic mAbs
are eliminated via saturable target-mediated mechanisms. Population estimates of Vmax
and Km, the parameters characterizing Michaelis-Menten-type saturable elimination
pathways, varied considerably among the different therapeutic mAbs. However,
estimates for CLT in mAbs with linear elimination characteristics and CLL in mAbs with
parallel linear and nonlinear elimination were quite similar among the different mAbs and
typically ranged from around 0.2-0.5 L/day, which is relatively close to the estimated
clearance of endogenous IgG of 0.21 L/day. The between-subject variability in Vmax,
CLT, and CLL was moderate to large with estimates ranging from 15-65 %CV. Measures
of body size were the most commonly identified covariates found to influence the PK of
therapeutic mAbs.
The similarities in the population PK of therapeutic mAbs are likely in part due to
general structural features that are shared among most therapeutic mAbs as IgG
molecules such as a functional human Fc region. One could hypothesize that targetbinding specific PK parameters such as Vmax and Km are likely to be influenced by the
interaction between a given therapeutic mAb and its target and thus show high variability
among different mAbs, while the differences among parameters such as CLL, V1, V2, and
Q that are thought to be largely affected by the general structural features of mAbs are
minimal. In fact, the biggest differences observed in the population PK between the
considered mAbs were for population estimates of Vmax and Km. For the most part, no
significant differences were observed in the population PK of murine, chimeric,
humanized, and fully human therapeutic mAbs. The most notable difference observed
between the different classes of mAbs was the larger population clearance estimates for
the murine mAbs.
The PK characteristics of mAbs are very dissimilar compared to traditional smallmolecule drugs (11, 79), and tend to be more complex as mAbs often exhibit targetmediated drug disposition and nonlinear PK (4), which is oftentimes species-dependent
and substantially complicates extrapolation of mAb PK characteristics from animal
models to humans. When analyzing the population PK of a mAb it is therefore not only
important to have a general understanding about the PK of mAbs, but to also understand
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the biology and pharmacology of the system. The complex PK characteristics of mAbs
pose a significant challenge to a pharmacometrician performing a population PK analysis,
as complex models are often evaluated to describe the mAb’s PK, and the use of such
models may be further complicated by limited concentration data. However, the similar
population PK profiles of different therapeutic mAbs are an aspect of this class of
biologics that can be used to the advantage of a more informed data analysis. The results
of the studies summarized herein should be of value as they provide a general concept of
what to expect with regard to applicable structural PK models, commonly identified
covariates, and plausible estimates for typical population estimates, covariate effects,
between-subject variability, and residual variability, which could be used for example to
aid in choosing initial estimates or setting parameter boundaries. The compiled results
from the population PK studies could also serve a more practical purpose and be used to
construct informative priors for a Bayesian data analysis or for constructing parameter
uncertainty distributions to simulate PK data for a prototypical therapeutic mAb. The
ability to include prior information could prove to be particularly useful for mAbs as they
often exhibit complex PK, and the use of complex PK models (e.g., parallel linear and
nonlinear elimination pathways) may not be fully supported by available concentration
data in datasets with sparse sampling and/or a limited number of dosage groups.

42

CHAPTER 2. RESEARCH HYPOTHESES
Cetuximab is a therapeutic mAb directed against EGFR and is indicated in the
treatment of squamous cell carcinoma of the head and neck (SCCHN). The PK of
cetuximab has been well characterized in phase I studies indicating that it exhibits
nonlinear elimination, but these studies have mainly been limited to noncompartmental
analyses (80, 81, 107), and the population PK of cetuximab has not been published in the
literature except in abstract format for an analysis conducted for regulatory purposes
(108, 109). I hypothesized that (I) nonlinear mixed effects modeling can be used to
develop a population PK model that could adequately predict the systemic exposure of
cetuximab in patients with SCCHN. Furthermore, I hypothesized that (II) covariates can
be identified that are significant predictors for cetuximab systemic exposure. To address
these hypotheses, I obtained cetuximab concentration-time data from two clinical trials in
patients with SCCHN (110, 111), and a population PK analysis of the data with covariate
analysis was carried out in Chapter 3.
The population PK analysis found that the PK of cetuximab was best described
using a two-compartment model with nonlinear elimination. During the analysis, a
number of issues and challenges were encountered which were likely the result of an
attempt to describe this nonlinearity. The difficulty characterizing the nonlinear
elimination of cetuximab was likely due to limitations of the clinical study designs, but
may also have been due to the use of the FOCE estimation method in NONMEM
throughout the analysis. It is known that FOCE, in addition to the first-order (FO) and
Laplacian (LAP) estimation methods in NONMEM, can be inaccurate when dealing with
highly nonlinear models such as the PK model with nonlinear elimination used to
describe the PK of cetuximab (112). These estimation methods in NONMEM linearize
the nonlinear mixed effects model (e.g., a population PK model) with regards to the
between-subject random effects and then parameter estimates are obtained based on the
linear approximation to the nonlinear model (13, 113). Therefore, I hypothesized that
(III) other parameter estimation methods that do avoid linearization lead to more accurate
parameter estimates and better characterization of the nonlinear PK encountered with
monoclonal antibodies such as cetuximab.
One available method for parameter estimation without linearization is a full
Bayesian analysis using Markov Chain Monte Carlo (MCMC) methods such as that
implemented in the software package WinBUGS (114). One advantage of Bayesian
MCMC methods over the FO, FOCE, and LAP methods in NONMEM is that the
Bayesian MCMC methods do not rely on analytical approximations of the nonlinear
mixed effects model, but instead use Monte Carlo integration techniques to obtain
parameter estimates for the exact model (115, 116). Another advantage of Bayesian
MCMC methods is the ability to include prior knowledge about the model parameters
into the Bayesian model.
Nonlinear elimination is a common characteristic of the PK of therapeutic mAbs
(6, 8), and accordingly, PK models with nonlinear elimination were used in almost half of

43

the population PK analyses of therapeutic mAbs published in the scientific literature
(Table 1-1). Therefore, the question of how well other population estimation methods
perform in evaluating the nonlinear elimination of cetuximab is also relevant for other
therapeutic mAbs. This notion is supported by the fact that similar difficulties
encountered during the cetuximab analysis were also reported in population PK analyses
of other therapeutic mAbs (Chapter 1).
To address my third hypothesis, I conducted a simulation study comparing the
parameter estimation performance of the FO, FOCE with interaction (FOCE-I), and LAPI methods in NONMEM and a Bayesian MCMC method in WinBUGS when applied to
population PK modeling of therapeutic mAbs with nonlinear PK. The Bayesian MCMC
method was evaluated with uninformative and informative priors, which were obtained
from population PK analyses of therapeutic mAbs in the literature. I evaluated the
estimation methods under a dose-ranging design (informative study design) and four
different single dose level designs at different dose levels (uninformative study designs).
I made the following three subhypotheses: (IIIa) Under all study designs the FO method
is less accurate and precise compared to the other estimation methods; (IIIb) When
sufficient data is available to characterize the nonlinear PK of the therapeutic mAb, as in
the case of the informative design, the estimation performance of FOCE-I, LAP-I, and
Bayesian MCMC (with both sets of priors) is adequate and comparable for all methods;
(IIIc) Under the less-than-optimal (uninformative) study designs the estimation
performance of the FOCE-I and LAP-I methods declines compared to the informative
study design, while the formal inclusion of prior information with the Bayesian MCMC
method provides a clear performance advantage over the other methods.
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CHAPTER 3. POPULATION PHARMACOKINETICS OF CETUXIMAB IN
PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND
NECK*
Introduction
Cetuximab is a recombinant, human/mouse chimeric IgG1 mAb that binds
specifically to the extracellular domain of the human EGFR (also known as ErbB1/HER1) (117). By binding to EGFR, cetuximab prevents the binding of endogenous
ligands such as epidermal growth factor and transforming growth factor-α (118). This
blockade prevents EGFR signaling which is intricately involved in multiple processes
involved in tumor growth and metastasis, such as cell proliferation, cell differentiation,
cell survival, cell migration, tumor angiogenesis, and DNA repair (119, 120). Cetuximab
can also induce internalization and subsequent degradation of EGFR, leading to
downregulation of cell surface EGFR and a reduction in EGFR signaling (121, 122).
Cetuximab is currently indicated in SCCHN and EGFR-expressing metastatic colorectal
cancer (108). It is approved as a single agent in both cancers, and in combination therapy
with radiation therapy for SCCHN and with irinotecan for colorectal cancer.
In early phase I studies, attempts to characterize the PK of cetuximab indicated
that it exhibits nonlinear or Michaelis-Menten type elimination (81, 123). This
nonlinearity was attributed to saturation of the EGFR-mediated endocytosis of
cetuximab, a clearance pathway that entails internalization and degradation of the
EGFR/cetuximab complex (80). While this nonlinear elimination pathway seems to be
largely saturated at therapeutic concentrations, a second, nonspecific elimination pathway
that is not saturable at therapeutic concentrations seems to be the major determinant for
cetuximab elimination during therapy with approved cetuximab doses (109). The
resulting elimination half-life estimates at therapeutic concentrations range between 66
and 97 hr at the approved dosing regimen of 400 mg/m2 initial dose followed by weekly
doses of 250 mg/m2, but increase from 33.3 to 119.4 hr after single cetuximab doses of
20 to 500 mg/m2 (109).
Although cetuximab concentrations have been correlated with antitumor activity
(124), most reports on cetuximab PK have been limited to noncompartmental analyses,
and the population PK of cetuximab has not been published in the literature except in
abstract format for an analysis conducted for regulatory purposes (108, 109).
Thus, this chapter describes a population PK analysis based on data from two
clinical trials in patients with SCCHN. The objectives of this analysis were 1) to
determine the typical population PK parameters for cetuximab and their between-subject
variability, and 2) to identify covariates that are significant predictors for cetuximab
*This chapter adapted with permission. Dirks NL, Nolting A, Kovar A, Meibohm B.
Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of
the head and neck. J Clin Pharmacol 2008;48(3):267-78.
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systemic exposure and to assess their potential implications for clinical dosing.
Methods
Study Design and Patient Population
Cetuximab serum concentration-time data were obtained from two studies, EMR
62202-008 (study A) and EMR 62202-016 (study B), that are described elsewhere in
detail (110, 111). Both studies were conducted in compliance with the Declaration of
Helsinki and the Guidelines for Good Clinical Practice. Written informed consent was
obtained from all subjects.
Study A was a randomized, multi-center phase I/II study (n=53) to evaluate the
safety and tolerability of cetuximab (Erbitux®) in combination with platinum and 5fluorouracil (5-FU) as first-line treatment in patients with recurrent and/or metastatic
SCCHN, and to evaluate the PK of cetuximab under coadministration with platinum
(110). Main inclusion criteria were stage III/IV recurrent or metastatic disease not
suitable for local therapy, Karnofsky performance status ≥70, and adequate hematologic,
liver, and renal function. Cetuximab was administered as an initial dose of 400 mg/m2
infused over 2 hours, followed by weekly doses of 250 mg/m2 given over 1 hour.
Patients were randomized to receive either cisplatin 100 mg/m2 on day 2 of the
chemotherapy cycle or carboplatin AUC 5 (target area under the curve of 5 mg/mL*min)
on day 1 of the cycle. 5-FU was administered as a continuous infusion on day 1 for the
duration of 120 hours at the assigned dose levels of 600, 800, and 1000 mg/m2/day.
Chemotherapy (5-FU and platinum) cycles were repeated every 3 weeks. The primary
treatment phase duration was 6 weeks (2 cycles), but patients were allowed to continue
with treatment if they benefited from the initial treatment phase. Of the 53 patients
enrolled into the study, 38 completed the primary treatment phase. Peak and trough
cetuximab concentrations were obtained at weeks 2-4 of therapy. In addition to the peak
and trough obtained on week 4, a full concentration-time profile was obtained with
sampling at 3, 6, 10, 24, 48, 72, 96 and 168 hours after the start of cetuximab
administration.
Study B was a multi-center phase II study (n=103) to evaluate the efficacy and
toxicity of cetuximab (Erbitux®) monotherapy in patients with platinum-refractory
recurrent and/or metastatic SCCHN, and to investigate the PK of cetuximab (111). Main
inclusion criteria were stage III/IV recurrent or metastatic disease, a Karnofsky
performance status ≥60, progressive disease documented by CT or MRI on platinumbased therapy, and adequate hematologic, liver, and renal function. Patients were to
receive cetuximab as an initial infusion of 400 mg/m2 followed by weekly infusions of
250 mg/m2 for at least six weeks, if possible. If they responded to treatment or had stable
disease, treatment was continued until disease progression, clinical deterioration, or
unacceptable side effects were observed. On occurrence of disease progression or
clinical deterioration salvage treatment was offered with cetuximab (250 mg/m2 weekly)
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plus the same platinum regimen the patient was on prior to receiving cetuximab
monotherapy. Of the 103 patients treated with cetuximab monotherapy, 53 subsequently
received combination therapy. Cetuximab peaks and troughs were obtained at weeks 1,
4, and 6 during monotherapy. If the patient entered the combination therapy phase,
cetuximab peaks and troughs were obtained again at weeks 1, 4, and 6 after switching to
combination therapy. A sample was also taken at the end-of-study visit, which was up to
six weeks after the last dose of cetuximab was administered. The total study period
ranged from 0.1 to 56 weeks with a median of 14 weeks.
Assay Methodology
Cetuximab serum concentrations were determined using a validated sandwich
enzyme-linked immunosorbent assay (ELISA). In brief, serum samples were diluted by a
factor of 500 and added to microtiter plates coated with the extracellular domain of
EGFR, which served as the capture antigen. After incubation, plates were washed with
buffer and further incubated with rabbit anti-human IgG conjugated with horseradish
peroxidase, which binds to the cetuximab immobilized in the microtiter plates. Unbound
conjugate was removed, and tetramethylbenzidine, a substrate for horseradish peroxidase,
was added. Tetramethylbenzidine was oxidized to a colored product, the absorbance of
which, was measured by a plate reader at 450 nm. This absorbance was directly related to
the cetuximab concentration in the serum sample. The lower and upper limits of
quantification were 0.5 ng/mL and 15 ng/ml for the diluted cetuximab samples,
corresponding to 0.25 and 7.5 µg/mL for undiluted samples. Serum samples with higher
concentrations of cetuximab were further diluted to fit into the linear calibration range.
Accuracy of the assay was between 98.5 to 104%, the precision ranged from 2.2 to 6.3%.
Population Pharmacokinetic Analysis
The population PK analysis was performed by nonlinear mixed effects modeling
using a NMQual (Metrum Institute, Augusta, ME) installation of NONMEM (version V,
level 1.1; Icon Development Solutions, Ellicott City, MD) under Compaq Visual Fortran
(version 6.5; Compaq Corporation, Houston, TX). Xpose (125), Census (126), and SPlus (version 7.0; Insightful Corporation, Seattle, WA) were used for data management
and visualization. The FOCE method within NONMEM was used throughout the model
building process (20). Across the two studies, the majority of the concentration
measurements were within the first 8 weeks of cetuximab therapy. Therefore, the
database was split with concentration data obtained during the first 8 weeks used for
model building (‘the model building dataset’), and the remaining data for model
qualification (‘the model evaluation dataset’). Sampling times in the model evaluation
data set ranged from week 10 to 43. The structural model was evaluated using only the
densely sampled data from study A. The covariate model was subsequently built using
data from both studies. All concentration data was log transformed prior to the analysis,
and the residual variance model was modified accordingly (transform-both-sides
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approach). Log transformation of the data stabilized the convergence of the structural
models and resulted in shorter run times.
Six structural models including one- or two-compartmental models with linear,
nonlinear, or parallel linear and nonlinear elimination pathways were evaluated based on
minimization of the Akaike Information Criterion (AIC) value, precision and plausibility
of parameter estimates, and a number of goodness-of-fit plots. The AIC was defined in
terms of the objective function value (OFV) and number of parameters (p) in the model:
AIC=OFV+2p. Prior information about the PK of cetuximab from phase I and phase II
trials, such as the presence of nonlinear elimination, was also taken into account while
building the structural model.
Between-subject variability in cetuximab PK parameters was assumed to follow a
lognormal distribution, and was modeled according to an exponential error model.
During the model building procedure, between-subject variability for parameters was
assumed to be uncorrelated, and only the diagonal elements of the variance-covariance
matrix were estimated. Once the final model was determined, the addition of covariance
terms was evaluated. Due to the unbalanced sampling design of the two studies and their
performance in different clinical settings, separate residual error models were used per
study. Residual variability was modeled using a log transformed exponential error
model.
Twenty-one potential covariates were evaluated. The covariates were comprised
of 1) demographic and anthropometric measurements: gender, age, ethnicity, WGT, IBW
(127), BSA, and clinical study; 2) blood chemistry and hematology measurements: blood
urea nitrogen, serum creatinine, creatinine clearance, total bilirubin, albumin, aspartate
and alanine aminotransferases, and WBC count; 3) concomitant therapy and disease
related factors: EGFR expression, presence of human anti-chimeric antibodies,
concomitant platinum and/or 5-FU therapy, Karnofsky function score, and duration of
cetuximab therapy. Covariates were updated over time in the observation records for
each patient when the respective data were available. Before building the covariate
model, all potential covariates were plotted against each other to identify any high
intercorrelation, as to avoid simultaneous inclusion of correlated predictors (128).
The covariate model was built using a stepwise forward addition/backward
deletion modeling approach (129). Inclusion of a covariate-parameter relationship was
based on the likelihood ratio test. The criteria for including a covariate in the model
during the forward addition steps was a decrease in the OFV of 3.84 (p<0.05). During
the backward deletion steps, an OFV change of 10.83 (p<0.001) was required for a
covariate to remain in the model. A more stringent criterion was used during the
backward deletion steps because of the multiple comparisons made during the forward
portion of stepwise covariate modeling. Covariate modeling was also guided by
goodness-of-fit plots and changes in between-subject variability.
A stratified approach to the univariate analysis was taken during the forward
addition step of the covariate modeling, in that size covariates (IBW, WGT, BSA) were
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first evaluated and included in the model. Once the effect of size on cetuximab PK had
been accounted for, the remaining covariates were evaluated in the model. The stratified
approach was taken as correlation often exists between size covariates and non-size
covariates (e.g., gender and weight) (97). Such correlations can mask covariate
relationships, and lead to difficulties interpreting the effects of two correlated covariates.
Stepwise backward deletion was conducted once the full model was established.
Relationships between continuous covariates and PK parameters were modeled
using linear proportional (Eq. 3-1) and power (nonlinear) models (Eq. 3-2) with the
covariate (COV) normalized to the population median for the dataset. Categorical
covariates were modeled as shown in Eq. 3-3:

P  1  (1   2  [COV  Median])

Eq. 3-1

2

 COV 
P  1  

 Median 

Eq. 3-2

P  1  (1   2  COV )

Eq. 3-3

where the θ’s are the parameters to be estimated, and θ1 represents the typical value of a
PK parameter (P) in an individual with the median value for the covariate.
Model Qualification
The ability of the final population PK model to adequately describe the observed
data in the model building dataset was evaluated using a predictive check. Cetuximab
peak and trough concentrations at week 4 of therapy served as the metrics of interest.
The final population PK model and parameter point estimates were used to perform
Monte Carlo (parametric) simulations of the metrics of interest. The model evaluation
dataset with concentration data beyond week 8 was used to evaluate the ability of the
final population PK model to predict cetuximab concentrations in an independent dataset.
Nonparametric bootstrap analysis was used to evaluate the precision and stability of the
final model parameter estimates. Patients were randomly sampled with replacement from
the model building dataset used for building the population PK model to create bootstrap
datasets with the same sample size as the original. A stratified sampling approach was
used in that the ratio of patients from the two studies was kept constant.
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Results
Data
A total of 143 patients provided evaluable PK data for the population analysis, 47
from study A and 96 from study B. Table 3-1 summarizes the demographics for these
patients. The majority of patients (138/143) had EGFR expressing tumors determined by
immunohistochemical evaluation. The presence of human anti-chimeric antibodies was
not detected in any of the patients participating in the two studies.
The initial cetuximab dataset consisted of 1,142 concentration measurements.
There were 86 baseline observations prior to the first cetuximab administration, which
were defined as zero and removed from the dataset before log transformation. After
splitting the database into a model building and a model evaluation dataset, 912
concentrations remained for building the population PK model, 530 from study A and
382 from study B. Due to the unbalanced sampling schedule between the two studies,
study A patients contributed a median of 13 data points per individual, while study B
patients contributed a median of 4 data points per individual.
Structural Model
Cetuximab serum concentrations were best described by a two-compartment
model with nonlinear elimination, based on AIC values and goodness-of-fit plots.
Compared to a one- or two-compartment model with linear elimination, the
corresponding model with nonlinear elimination resulted in further reduction of the AIC
value. The goodness-of-fit plots indicated that the nonlinear model provided a better fit
to lower concentrations (<75 µg/mL) than the linear model. In addition, the results from
prior PK studies supported the use of a nonlinear elimination model (80, 81, 123).
Addition of a second, linear elimination pathway to the nonlinear model resulted in no
change in the OFV. The goodness-of-fit plots between the nonlinear model and parallel
elimination model were very similar. This lack of improvement in fit to the data with the
parallel elimination model led to selection of the more parsimonious nonlinear model as
the structural base model. Regardless of the elimination pathways, a two-compartment
model always provided a better fit to the data than a one-compartment model based on
AIC values and goodness-of-fit plots. The two-compartment nonlinear elimination
model was parameterized in terms of Vmax, Km , V1, V2, and Q.
The initial structural model was unable to account for between-subject variability
in both Vmax and Km, even after addition of a covariance term for both parameters. Based
on the hypothesis that physiologically there should be more variability among individuals
with regard to Vmax than Km, the Km parameter was treated as a fixed value across all
subjects, which resulted in an OFV increase of only 0.3 points and improvement of the
precision for the estimate of between-subject variability in Vmax.
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Table 3-1.

Patient characteristics.

Characteristics
Gender (male/female)
Ethnicity (caucasian/unknown)
Study (A/B)
Concomitant 5FUa (yes/no)
Concomitant platinuma (yes/no)
Age
Duration of cetuximab therapy (week)
Weight (kg)
BSA (m2)
IBW (kg)
White blood cell count (109/L)
Blood urea nitrogen (mg/dl)
Serum creatinine (mg/dl)
Creatinine clearance (ml/min)
Total bilirubin (mg/dl)
Albumin (g/dl)
Aspartate aminotransferase (U/L)
Alanine aminotransferase (U/L)
Karnofsky function score

N
120/23
131/12
47/96
47/96
89/54

Median

Range

56
6
60
1.7
64.2
6.8
23
0.9
74
0.5
3.9
18
14
80

23-77
1-54
34-113
1.2-2.2
43.3-81.3
1.7-41.8
4-106
0.4-1.9
22-167
0.2-1.4
1.3-4.8
5-150
1-64
60-100

a. Patient received concomitant 5-fluorouracil (5-FU) or platinum chemotherapy at some
point during the trial.
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Once the base model was determined, data from study A and B were pooled
together for the covariate modeling. Separate residual error models were used for each
study, which added stability to the minimization procedure and resulted in a change in
objective function value (∆OFV) of -32.8, as well as a decrease in between-subject
variability estimates for all parameters.
Covariate Model
The effect of covariates on cetuximab PK was first investigated for size measures
with the purpose of identifying which, if any, are the most influential. The ∆OFV
indicated that linearly related IBW (∆OFV -29) was the most important size covariate for
Vmax versus BSA (∆OFV -14) and WGT (∆OFV -9). Inclusion of IBW reduced the
between-subject variability in Vmax from 23.6% to 17.9% (%CV). Based on ∆OFV,
linearly related WGT was found to be the most important size covariate on both V1 and
V2. Inclusion of WGT on V1 resulted in a ∆OFV of -22.7, and a decrease in betweensubject variability for V1 from 21% to 18.3%. Adding WGT as a covariate on V2 resulted
in a ∆OFV of -9.7, and a decrease in between-subject variability for V2 from 54.1% to
46.6%. No effect of size covariates was identified for Q or Km.
The remaining covariates were screened using general additive modeling (130)
and plots of individual empirical Bayes estimates of the parameters versus each of the
covariates. The general additive modeling only identified WBC as a covariate on Vmax,
while graphical analysis identified the same relationship as well as a potential effect of
gender on Vmax, V1, and V2. Modeling Vmax as a linear function of WBC resulted in a
∆OFV of -37.0 and decreased the between-subject variability for Vmax further to 15.3%.
No effect of gender was identified for Vmax (∆OFV -0.3) or V2 (∆OFV -2.4). Adding
gender as a covariate for V1 resulted in a ∆OFV of -6.4, but reduced the between-subject
variability only from 18.7% to 17.8%. The estimated difference in V1 between males and
females was small (13.5% smaller V1 for females). Subsequently, the effect of gender on
V1 did not pass the criterion for backward deletion and was removed from the model.
The effect of WGT on V2 was also removed during the backward deletion step, but all
other covariates were retained in the model. The addition of covariance terms between
Vmax and the volume parameters was investigated with the final model, but did not result
in any improvement.
The final population PK model and parameter estimates are presented in Table
3-2. The NONMEM control stream and run output for the final population PK model are
included in Appendix A. Goodness of fit plots for the final model are shown in Figure
3-1, and model-predicted and measured cetuximab concentration-time profiles for
representative patients are provided in Figure 3-2. The estimates for Vmax and Km for a
typical patient with median covariate values, as defined in the model, were 4.38 mg/hr
and 74 µg/mL, respectively. Between-subject variability in the parameters was relatively
small for Vmax (15.4%) and V1 (18.6%), but was larger for V2 (56.4%) and Q (97.2%).
IBW and WBC accounted for almost 35% of the total variability in Vmax, while WGT

52

Table 3-2.

Final population pharmacokinetic model and its parameter estimates with bootstrap-derived 90% confidence intervals.
Parameter

Model

Vmax [mg/hr]

θ1 x (1+θ2 x (IBW-64)
+θ3 x (WBC-6.8))

Km [µg/mL]
V1 [L]
V2 [L]
Q [L/hr]

θ1

θ2
θ3
θ4
θ4
θ5 x (1+θ6 x (WGT-60)) θ5
θ6
θ7
θ7
θ8
θ8

Parameter
estimate

Parameter
90%CI

BSV
(%CV)a

BSV
90%CI

4.38

3.40, 6.64

15.4

12.0, 19.1

0.0108
0.0216
74
2.83
0.0083
2.43
0.103

0.0077, 0.0139
0.0169, 0.0296
38.2, 163.3
2.69, 2.96
0.0057, 0.0115
1.95, 2.85
0.062, 0.191

----b
18.6

12.5, 22.2

56.4
97.2

18.0, 72.8
40.2, 133

Residual variability (%CV)a [90%CI]: Study A: 14.6 [12.3, 16.8]
Study B: 21.2 [18.8, 23.7]
CI = confidence interval; BSV = between-subject variability; IBW = ideal body weight (kg); WBC = white
blood cell count (109/L); WGT = body weight (kg).
a. Approximate %CV calculated as  2 100 where ω2 is the between-subject variance estimate.
b. BSV not estimated for Km.

53

Figure 3-1. Goodness-of-fit plots for the final model. Plot of population and individual predicted versus observed cetuximab
concentrations and plot of conditional weighted residuals versus population predicted concentrations and time (days).
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Figure 3-2. Cetuximab serum concentration-time profile in six representative patients (patient ID indicated) over a period of 28
days after initiation of therapy with a dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Measured serum concentrations
are indicated by open circles, model-based population and individual predicted concentration-time profiles by dashed and solid lines,
respectively.

56

accounted for approximately 10% of the variability in V1. The estimate of the
proportional residual variance for study A (14.6%) was less than that for study B
(21.2%), which may be attributed to the highly unbalanced sampling designs of the two
studies.
Model Qualification
The precision of model parameter estimates was assessed by 500 nonparametric
bootstrap replicates. As shown in Table 3-2, the 90% confidence intervals were
relatively tight and indicated good precision of most parameter estimates. The median
population estimates obtained from the nonparametric bootstrap were generally within
5% of the estimates from the final model (data not shown), indicating that the final
population model was stable. Furthermore, the 95% confidence intervals for the covariate
effects did not overlap with zero, indicating the statistical significance of the covariates
included in the final model.
The model was further evaluated using a predictive check for the model building
dataset and simulation of concentrations in the model evaluation data set. For both model
qualification methods, 500 Monte-Carlo simulated datasets were created and compared to
the observed peak and trough concentrations at week 4 for the model building dataset
(Figures 3-3 and 3-4) and beyond week 8 for the model evaluation dataset (Figure 3-5),
respectively. The model adequately described general tendencies of peak and trough
concentrations and the between-subject variability of peaks at week 4 in the model
building data set (Figures 3-3 and 3-4) and beyond week 8 of therapy in the model
evaluation data set (Figure 3-5). Figure 3-3, however, indicates that the model
overpredicted the between-subject variability in trough concentrations at week 4 at the
lower concentrations, suggesting that one or more of the variance components of the
model were over-estimated. This is reflected in Figures 3-4 and 3-5 where less than 10%
of the trough observations fell outside the simulated 90% prediction interval.
For the model evaluation dataset, the median prediction error and median absolute
prediction error were calculated using the individually predicted and observed
concentrations beyond week 8. The median prediction error was -0.1% and 0.3% and the
median absolute prediction error was 2.9% and 6.8% for peak and trough concentrations,
respectively, indicating that the predictions were generally unbiased and relatively
precise.
Discussion
Therapeutic mAbs often exhibit nonlinear PK presumably attributable to targetmediated elimination pathways via interaction with their antigen (6). The binding of
cetuximab to the membrane receptor EGFR presents a specific, saturable elimination
mechanism by which the cetuximab/EGFR complex is internalized and either degraded
or recycled with recurrence of the receptor at the cell surface (109). This receptor-
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Figure 3-3. Results of the predictive check for peak and trough concentrations at week
4 of therapy. The histogram plot shows the distribution of peak (top panel) and trough
(bottom panel) quartiles (Q1: 25th percentile; Q2: median; Q3: 75th percentile) for 500
simulated datasets, and the vertical lines indicate the quartiles for the observed data. The
z-value represents the fraction of the quartiles of the simulated data that are larger than
the corresponding observed quartile.
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Figure 3-4. Scatterplot of the results from the predictive check of peak and trough
concentrations at week 4 of therapy in the model building dataset. The solid lines
indicate the peak and trough 5th, 50th, and 95th percentiles determined from all 500
simulated datasets. Observed data is plotted as individual points.
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Figure 3-5. Results of the simulation of concentrations in the model evaluation dataset
beyond week 8 of therapy. The solid lines indicate the peak and trough 5th, 50th, and 95th
percentiles determined from all 500 simulated datasets. Observed data is plotted as
individual points.
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mediated endocytosis likely contributes a significant portion to the total clearance of
cetuximab, given that EGFR is widely expressed in a variety of tissues. Panitumumab,
another mAb targeted towards EGFR, also exhibits nonlinear PK attributed to saturation
of EGFR-mediated clearance (131). The effect of target-mediated clearance on
therapeutic mAbs has also been observed for other membrane targets (8, 30).
The saturable, nonlinear PK of cetuximab has been well characterized in phase I
studies (80, 81, 123), where cetuximab clearance was shown to decrease with increasing
doses in the range of 20 to 200 mg/m2. Likewise, in the current population analysis, I
found that a two-compartment model with nonlinear elimination provided the best fit to
the data. Phase I studies also showed that at doses of 200 mg/m2 and greater (up to 500
mg/m2), the estimated clearance for cetuximab levels off (80, 81, 109). The biphasic
nature of cetuximab clearance versus dose suggests the presence of a nonsaturable firstorder process in parallel to the EGFR-mediated elimination described above (109). This
nonspecific linear elimination process is common for all antibodies, and is likely due to
slow proteolytic degradation from interaction between the Fc region of the antibody and
Fc-receptors on hepatic cells or cells of the reticuloendothelial system (8, 109). An
attempt was made to model this parallel elimination process by building a model with
both linear and nonlinear elimination pathways as it has previously been used in the PK
analysis of other therapeutic mAbs, including sibrotuzumab and panitumumab (45, 131).
The parallel elimination model did not offer a significant improvement in describing the
data over the simpler nonlinear model likely because the data did not support the more
complex model. Certainly, a limitation to this analysis was that dose escalation data was
not available as all patients included in the analysis were treated at the same clinically
approved dose level. Such data might have supported the more complex parallel
elimination model, and even helped further define the population estimates and betweensubject variability for Vmax and Km.
Based on the final population PK model, cetuximab distributes into a central
compartment volume (V1) of 2.83 L for a patient weighing 60 kg, which is approximately
equal to the plasma volume. The volume of distribution at steady-state (Vss=V1+V2) of
5.26 L for a 60 kg patient suggests an apparently limited distribution outside the vascular
space, which is in line with the results from cetuximab phase I studies (80, 81, 109), and
consistent with the behavior of endogenous IgG and other therapeutic mAbs (6, 132).
Nevertheless, cetuximab is able to distribute to its target as evidenced by
immunohistochemistry studies and EGFR tyrosine kinase assays, which showed almost
complete EGFR saturation in tumor tissue samples obtained from patients with SCCHN
receiving the approved doses of cetuximab (133).
The results of the predictive check and simulations revealed that the population
PK model adequately described the central tendencies of peak and trough concentrations
at week 4 in the model building data set and beyond week 8 in the model evaluation
dataset. The model was able to adequately account for the between-subject variability in
peak concentrations, but the variability in trough concentrations was overpredicted
towards lower concentrations as indicated by the disparity between the 25th percentiles
(Q1) for observed and simulated trough concentration data in Figure 3-3. Given that Vmax
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significantly influences trough concentrations, overestimation of the between-subject
variability in Vmax may be the cause for this deviation.
Binding of cetuximab to EGFR induces internalization of the receptor, which is
believed to lead to EGFR down-regulation (109). Given the role EGFR plays in the
elimination of cetuximab, one might hypothesize that with down-regulation of EGFR,
there may also be a decrease in cetuximab clearance over time. Based on the Monte
Carlo simulations for the model evaluation dataset, however, the population PK model
was able to adequately describe cetuximab peak and trough concentrations beyond 8
weeks of therapy. This finding suggests that the elimination PK of cetuximab remains
relatively stable over time during prolonged therapy. It is further supported by findings
from a phase I study, where no statistically significant change in clearance values was
found between the first and fourth weekly dose of cetuximab (81).
An interesting and unexpected covariate relationship identified in my analysis is
the influence of WBC count on Vmax. There is evidence in the literature, however, that
lymphocytes, monocytes, macrophages, and neutrophils do express EGFR (134-136).
This suggests that these cells may be involved in the receptor-mediated clearance of
cetuximab. The final population PK model predicted a 2.2% change in Vmax per unit
(109/L) change in WBC from the median WBC (6.8 109/L). Over the normal range of
WBC (~4-11 109/L), the typical value for Vmax would vary from 4.1 to 4.8 mg/hr,
representing a -6.4% and +9.6% change from the population mean Vmax, respectively.
The modest change in Vmax over the range of normal WBC would not likely necessitate a
change in dosing, even in patients who develop leukopenia due to concomitant
chemotherapy.
Size covariates are probably the most frequently identified covariates in
population PK analyses, and are well established as predictors of systemic exposure for
small molecule drugs as well as therapeutic mAbs (13). In this study, three different size
covariates (IBW, WGT, and BSA) were evaluated. IBW was found to be a better
predictor of Vmax than BSA and WGT. As interactions with EGF- as well as Fc-receptors
resulting in receptor-mediated endocytosis are assumed to be the major elimination
pathways of cetuximab (137), my results suggest that the number of these receptors in its
distribution space is better reflected by IBW than any of the other body size measures.
This observation is not unexpected as the elimination capacity of at least the liver and the
reticuloendothelial system as major sites of Fc-receptor-mediated elimination of mAbs
are only marginally affected by deviations of weight from IBW. The final model
predicted a 1.1% change in Vmax per kg IBW deviation from the median IBW of 64 kg.
The estimated changes from the typical population Vmax (4.38 mg/hr) for patients with
IBW varying from the observed minimum (43.3 kg) to the maximum IBW (81.3 kg) were
-22.4% (3.4 mg/hr) and +18.7% (5.2 mg/hr), respectively.
Although Vmax as a direct determinant of cetuximab clearance is best predicted by
IBW, clinical dosing of cetuximab is currently performed based on BSA following the
traditional standard practice of dosing in oncology (109). To visualize the impact of
dosing based on BSA rather than IBW, consider a 6 foot tall male patient whose body
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weight is 77.6 kg, which is also his IBW. Based on BSA calculated according to DuBois
(138), his cetuximab maintenance dose would be 498 mg (250 mg/m2). Now suppose the
above patient has lost 20% weight (62 kg body weight; 80% of IBW) or even 35% body
weight (50.4 kg body weight; 65% of IBW). His BSA-based cetuximab maintenance
dose would be 453 mg (at 62 kg) or 415 mg (at 50.4 kg), i.e. 9.1% or 16.7% lower, but
my population PK model would predict the same Vmax for both situations, leading to a
reduced systemic exposure of cetuximab in the underweight patient. The modest impact
of this effect, however, indicates that the approved BSA-based dosing regimen for
cetuximab provides consistent systemic exposure in clinical use even in subjects with
substantial deviation between their actual body weight and IBW. Only in very extreme
cases of severe underweight, standard dosing might need to be adjusted to avoid
underdosing of the patient.
The potential clinical relevance of this finding is supported by the prominence of
underweight in patients with advanced stages of solid tumors, including SCCHN. In fact,
in the patient population used for this analysis, almost 25% of the patients weighed less
than 80% of IBW. A comparison of the trough concentrations at 4 weeks and beyond in
these patients with the troughs of the other patients in my analysis indicated that the
troughs were indeed lower in the underweight group (median 48.2 vs. 62.4 µg/mL,
p=0.014). This finding supports the selection of IBW as predictor for cetuximab
elimination rather than BSA or WGT. My results are furthermore in agreement with a
previous report that suggests the dosing based on BSA may have limitations for some
therapeutic mAbs (45).
Fracasso et al. recently reported a correlation between cetuximab trough levels
and antitumor response on cetuximab monotherapy (107). Patients with partial
response/stable disease tended to have higher average trough levels compared to those
with progressive disease (mean 60.7 vs. 33.2 µg/mL, p=0.002). Although these study
results were based on a small number of patients (n=33) with different cancer types
(predominantly colorectal, breast and head and neck carcinomas), they highlight the
potential relevance of adequate systemic exposure, and thus dosing, for achieving
antitumor response in cetuximab pharmacotherapy. Further studies, however, are needed
to clearly define an optimal systemic exposure range for cetuximab.
The population estimates for Vmax and Km are in agreement with findings from
other PK analyses of cetuximab (123, 139). The PK parameter estimates of my final
model are also in line with a previous population analysis of cetuximab PK for regulatory
purposes where a two-compartment model with nonlinear elimination was also used (109,
140). This population analysis for regulatory purposes included nineteen clinical studies
in various cancer types. The similar results of the two population analyses suggest that
cetuximab PK are not different in patients with SCCHN compared with other cancer
types. My analysis did not identify an effect of concomitant chemotherapy,
cisplatin/carboplatin and 5-fluorouracil, on cetuximab PK which is in agreement with
several earlier clinical trials (81, 141). Furthermore, I could not detect differences in
cetuximab PK for patients receiving cetuximab as first-line treatment during the
recurrence or metastatic stage of SCCHN (study A) as compared to patients pretreated
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with at least one line of chemotherapy during this stage (study B). Although several of
the tested covariates were not found to influence the PK of cetuximab (e.g., gender,
ethnicity, renal and hepatic function), it should be noted that the majority of the studied
patients were male, Caucasian, and had adequate hepatic and renal function. Therefore
the impact of these covariates on the PK of cetuximab remains to be elucidated.
In summary, I developed a population PK model for cetuximab that characterized
the nonlinear PK of this therapeutic mAb. IBW and WBC count were identified as
predictors for cetuximab clearance. The currently approved BSA-based dosing of
cetuximab provides adequate exposure in most patients, but may require adjustments in
cases with extreme deviations of their body weight from their IBW.
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CHAPTER 4. COMPARATIVE PERFORMANCE OF BAYESIAN MARKOV
CHAIN MONTE CARLO AND MAXIMUM LIKELIHOOD POPULATION
ESTIMATION METHODS WHEN APPLIED TO NONLINEAR
PHARMACOKINETICS OF MONOCLONAL ANTIBODIES
Introduction
In Chapter 3, a population PK analysis of cetuximab, an anti-EGFR therapeutic
mAb, was performed in patients with SCCHN. The final population PK model, which
incorporated a two-compartment model with nonlinear elimination, was able to
adequately describe the nonlinear PK of cetuximab at the currently approved dosage
regimen. During the population PK analysis, various issues were encountered which
were likely the result of an attempt to describe this nonlinearity. During evaluation of the
different structural PK models, the one- and two-compartment models with nonlinear or
parallel linear and nonlinear elimination pathways exhibited convergence difficulties and
prolonged run times. The convergence of these PK models was stabilized and run times
reduced by log transforming the data and using separate residual error models per clinical
study. Limitations with the final population PK model included the inability to quantify
between-subject variability simultaneously in Vmax and Km, the relatively low precision in
Km compared to other model parameters in the bootstrap analysis (Table 3-2), and the
predictive check showed that the model overpredicted the between-subject variability in
trough concentrations at week 4 at the lower concentrations (Figure 3-3). Since trough
concentrations are largely influenced by Vmax, the deviation in the predictive check may
have been due to an overestimation of the between-subject variability in Vmax.
The difficulty characterizing the nonlinear elimination of cetuximab and the
apparent bias in one or more of the parameter estimates were likely due to limitations of
the clinical study designs and possibly the population estimation method used. One
drawback of the two clinical studies included in the analysis was that dose escalation data
was not available as all patients were treated at the same dose level. Another drawback
was the unbalanced sampling design of the two studies, as the majority of patients (96 of
143) provided only peak and trough concentrations while the remaining patients provided
a full concentration-time profile in addition to peak and trough concentrations. The
FOCE method in NONMEM was used throughout the model-building process, and it is
known that the first-order approximation methods can be inaccurate when dealing with
highly nonlinear models such as the PK model with nonlinear elimination used to
describe the PK of cetuximab (112). Therefore, it was questioned whether or not the use
of another population estimation method in the cetuximab analysis would have led to
more accurate parameter estimates and better characterization of the nonlinear PK of
cetuximab (e.g., allowed between-subject variability in Km to be estimated).
Nonlinear elimination is a common characteristic of the PK of therapeutic mAbs
(6, 8), and accordingly, PK models with nonlinear elimination were used in almost half of
the population PK analyses of therapeutic mAbs published in the scientific literature
(Table 1-1). The question of how well other population estimation methods would have
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performed in evaluating the nonlinear elimination of cetuximab is therefore relevant for
other therapeutic mAbs. This question is also relevant for other therapeutic mAbs,
because similar difficulties encountered during the cetuximab analysis were also reported
in population PK analyses of other therapeutic mAbs. These difficulties included
challenges in detecting and characterizing nonlinear elimination due to study design
limitations, convergence difficulties with PK models with nonlinear elimination, and the
inability to estimate between-subject variability in Km (Chapter 1, Table 1-4). It is
estimated that half of all current projects in new drug development are biologics, with
mAbs being the predominant class of biologics under clinical study (1). According to a
report by Reichert, in 2008 there were over 200 mAbs undergoing clinical study (2).
With the growing number of therapeutic mAbs in drug development and reaching FDA
approval, the challenges with population PK modeling of therapeutic mAbs with
nonlinear PK will continue to remain an issue.
A number of studies have evaluated the performance of different estimation
methods for population PK modeling, and in most of these studies a one-compartment
model with IV bolus or first-order input and first-order (linear) elimination was used for
comparison (142-147). Studies by Hashimoto et al. (148) and Sheiner and Beal (149)
evaluated estimation methods in NONMEM for population PK modeling of nonlinear PK
data at steady-state. However, both studies used PK models that have not been used in
population PK analyses of therapeutic mAbs. Sheiner and Beal used only the MichaelisMenten model where the dosage rate was assumed to be equal to the elimination rate and
concentrations were at steady-state. A one-compartment model with nonlinear
elimination was used in the analysis by Hashimoto et al. Although Hashimoto et al. used
a PK model with nonlinear elimination, in most of the therapeutic mAb population PK
analyses a two-compartment model was used (Table 1-1). Bauer et al. recently evaluated
various population estimation methods and software when applied to different PK/PD
models (150). One of the PK models included in the study was a one-compartment
model with parallel linear and nonlinear elimination pathways. While this clearance
model has been used in several therapeutic mAb population PK analyses, again in most
cases a two-compartment model was used. Also, only one data set was simulated for
each PK/PD model in the analysis by Bauer et al., so the population estimation methods
could not be systematically evaluated. Therefore, little work has been done evaluating
population estimation methods using PK models that are representative of the typical
disposition characteristics of therapeutic mAbs.
In the current chapter, a simulation study was conducted to compare the
parameter estimation performance of the approximate maximum likelihood methods in
NONMEM and a full Bayesian MCMC method in WinBUGS for population PK
modeling of therapeutic mAbs with nonlinear PK. A review of the literature in Chapter 1
showed that the population PK of different therapeutic mAbs are quite similar. The
findings from published therapeutic mAb population PK analyses were used in the
present study to define aspects of the candidate population PK simulation model in order
to simulate PK data for a representative therapeutic mAb. The software NONMEM was
included in this study as it is the most widely used software for population PK/PD
modeling (151). WinBUGS was chosen as the Bayesian MCMC method provides a
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different approach compared to the estimation methods in NONMEM to solving the
population PK problem (152), and there is a growing interest in applying full Bayesian
methods in population PK modeling. In addition, the Bayesian MCMC method allowed
investigation of the utility of including prior information in a population PK analysis.
The Bayesian MCMC method was evaluated with both uninformative and informative
priors, which were obtained from population PK analyses of therapeutic mAbs in the
literature. The performance of the different population estimation methods was evaluated
under different clinical study designs commonly encountered during drug development,
and the sensitivity of estimation error to parameter uncertainty was also explored.
Methods
Overview of Methodology Steps
The methodology for this study can be divided into two main steps: simulation
and estimation. An overview of the simulation and estimation steps is illustrated in
Figure 4-1. Simulation of replicate data sets was performed with uncertainty included
simultaneously on all parameters in the population PK model. The software program R
(Version 2.7.2; http://www.r-project.org/) (153) was used to randomly sample 1000
values for each parameter from their respective uncertainty distributions, which were then
combined to create 1000 full sets of simulation parameter values for the population PK
model. Each full set of simulation parameter values was used to simulate one replicate
data set under a given study design template, therefore, 1000 replicate data sets were
created per study design. Parameter estimates were then obtained for each replicate using
the estimation methods of interest which included three methods in NONMEM (FO,
FOCE-I, LAP-I) and a Bayesian MCMC method in WinBUGS. The estimation
performance of the methods was evaluated under five different study design scenarios.
NONMEM was used to simulate the concentration data sets, and the R package MIfuns
(Metrum Institute, Augusta, Maine) (154) was used to automate the creation of replicate
NONMEM simulation control streams by systematically substituting in a set of
simulation parameter values. The population PK model, study designs, and parameter
uncertainty distributions used for performing the simulations are described in the
following sections. Example computer codes used for the simulation and estimation
steps are provided in Appendix B.
Population Pharmacokinetic Model
The published findings from population PK analyses of therapeutic mAbs and
their general PK behavior (Chapter 1) were used to define the population PK model for
this study in terms of model structure and fixed and random effect parameters. For
purposes of this study it was assumed that the administered drug was a therapeutic human
IgG1 mAb indicated in the area of oncology that targets a cell membrane receptor
primarily expressed in tissue. Therapeutic mAbs often exhibit two distinct elimination
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Sampled 1000 values from each simulation
parameter uncertainty distribution
Combined sampled values to create 1000 full sets of
simulation parameter values for the population PK model
Table of Simulation Parameter Values

Each row represents 1 full set of simulation parameter values

Each set of simulation parameter values was used to simulate 1 replicate data
set under a given study design template (n=number of replicates simulated)

Informative
Study Design
n=1000

Uninformative
Study Design
(200 mg dose level)
n=1000

Uninformative
Study Design
(500 mg dose level)
n=1000

Uninformative
Study Design
(600 mg dose level)
n=1000

Uninformative
Study Design
(800 mg dose level)
n=1000

Obtained parameter estimates for each replicate data set using the following
estimation methods: FO, FOCE-I, LAP-I, and Bayesian MCMC with
informative and uninformative priors

Figure 4-1.

Overview of the methodology of the simulation and estimation steps.
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pathways which includes a linear (first-order) clearance pathway mediated by interaction
with Fc-receptors and a nonlinear clearance pathway attributable to saturable targetmediated mechanisms (e.g., receptor-mediated endocytosis) (Chapter 1). Therefore, it
was believed that the theoretical mAb for this study was also eliminated via these two
pathways. A commonly used PK model in population PK analyses of therapeutic mAbs
that can be related to the two distinct physiologic elimination pathways is a twocompartment model with parallel linear and nonlinear elimination from the central
compartment (Table 1-1, Figure 1-2A). Accordingly, the same structural PK model was
used for the simulation/estimation steps in this study. The use of a two-compartment
model was further supported by the fact that a two-compartment model was used in the
majority of therapeutic mAb population PK analyses (Table 1-1). The PK model was
parameterized in terms of Vmax, Km, CLL, V1, V2, and Q. Under the condition that the
absolute bioavailability of the administered dose is known, the parameters for the
aforementioned PK model have been shown to be globally identifiable (83). The
therapeutic mAb in this study was administered as an IV infusion so bioavailability was
assumed to be 1. This route of administration was chosen as most therapeutic mAbs that
are approved or in development are administered IV (Chapter 1). The parallel
elimination PK model was defined in terms of the differential equations below:
C1  X1/V1
C 2  X 2 /V2
dX1/dt  -Vmax * C1/(K m  C1 ) - CL L * C1 - Q * C1  Q * C 2
dX 2 /dt  Q * C1 - Q * C 2
where X1 and X2 represent the mAb amount in the central and peripheral compartments,
respectively.
The population PK model included between-subject variability for all model
parameters except Km and Q. Between-subject variability in the parameters Vmax, CLL,
V1, and V2, was assumed to follow a lognormal distribution and was modeled using an
exponential error model. The exclusion of between-subject variability for Km and Q in
the population PK model is in line with the literature, as between-subject variability in
both parameters was often not estimated in population PK analyses of therapeutic mAbs
(Tables 1-3 and 1-4). Given that Km is related to the affinity of the mAb to its target, it is
a reasonable approach to hypothesize that physiologically there is negligible variability in
Km among individuals. Although between-subject variability in Q was not modeled,
variability in Q can be considered to be intrinsically included in the between-subject
variability for V1 and V2 since the volume parameters can be defined in terms of Q (e.g.,
V1 = Q/K12).
Body weight (kg) was included in the population PK model as a predictor of Vmax,
CLL, V1, and V2. The choice of body weight as a covariate was supported by the
observation that body weight was the most commonly identified covariate in therapeutic
mAb population PK analyses, and it was often found to be a predictor of the
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aforementioned parameters (Table 1-5). The inclusion of a covariate in the model also
allowed for evaluating the performance of the estimation methods in estimating a
covariate effect. Correlation among the between-subject random effects was modeled
using a fixed effect (i.e., weight as a predictor of Vmax, CLL, V1, and V2) rather than a
random effect. Any remaining variability after accounting for the covariate effect was
assumed to be uncorrelated. This approach to handling the correlation between the
random effects was in part based on the findings from the population PK analyses of
sibrotuzumab (45) and matuzumab (40). In the sibrotuzumab analysis, weight was
included in the population PK model as a covariate for Vmax, CLL, V1, and V2. No
correlation was modeled between the random effects for these parameters, although a
shared variance term was included in the model between V1 and V2. In the matuzumab
analysis, weight was included in the population PK model as a covariate for CLL and V1.
Correlation between the random effects was modeled for V1 and V2, Vmax and V2, and
Vmax and V1, but no correlation was modeled between CLL and V1. The relationship
between body weight and the PK parameters was modeled using a power model with the
individual patient weight normalized to a weight of 72 kg as shown in the following
equation:
 Weight (kg) 

P  θ * 
1  72 kg 

θ2

where the θs are the parameters to be estimated, and θ1 represents the typical value of a
PK parameter (P) in an individual with a body weight of 72 kg. In most population PK
analyses of therapeutic mAbs, the effect of body size (including weight) on a PK
parameter was modeled using a power function (Table 1-5).
Residual variability was modeled using an exponential error model. An
exponential error model was used to prevent simulation of negative concentrations.
Residual variability in most of the therapeutic mAb population PK studies was modeled
using either a proportional or a combined additive and proportional error model (Chapter
1). Although an exponential error model was used in this study, the simulation
uncertainty distribution for the standard deviation of residual variability (see next section)
encompassed a low to moderate range of variability (~10-20 %CV), and within this
range, an exponential error model closely approximates a proportional error model.
There were a total of 15 parameters in the population PK model, and the same model was
used for both simulation and estimation steps.
Simulation Parameter Uncertainty Distributions
Simulation of the replicate data sets was performed with uncertainty included
simultaneously on all parameters in the population PK model. A review of the literature
in Chapter 1 showed that the population PK of different therapeutic mAbs are quite
similar. In order to simulate concentration data for a prototypical mAb, the simulation
parameter values selected from the uncertainty distributions needed to be realistic and
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representative of the population PK characteristics of therapeutic mAbs. Therefore, the
published findings from over 20 population PK analyses of therapeutic mAbs were used
to define the simulation parameter uncertainty distributions (Chapter 1, Tables 1-3
through 1-6). In general, a two-step approach was taken in specifying the uncertainty
distributions. First, the literature reported parameter values were summarized by
calculating summary statistics and creating plots of the parameter values. This
information aided in selecting an appropriate type of statistical distribution to describe the
parameter uncertainty. After the type of distribution was selected, the second step was to
simulate a large number of parameter values from the uncertainty distribution using the
summary statistics as initial values for the distribution parameters (e.g., mean and
variance). Histograms of the simulated parameter values were created and compared
against the literature reported values. The distribution parameters were then adjusted as
needed so that the uncertainty distribution adequately reflected the parameter estimates
reported in the literature. The approach to specifying the simulation parameter
uncertainty distributions was generally to use parameter values reported from population
PK analyses of therapeutic mAbs that used a two-compartment model with parallel linear
and nonlinear elimination or only nonlinear elimination from the central compartment.
However, the final parameter uncertainty distributions were checked visually to make
sure that they were representative of parameter values reported from all therapeutic mAb
population PK analyses that used a two-compartment PK model regardless of the
clearance model. The findings published from population PK analyses that used a onecompartment PK model were not taken into account in specifying the uncertainty
distributions.
The approach to specifying the simulation uncertainty distributions for Vmax and
Km differed from the methodology described above. Population estimates for Vmax and
Km varied considerably between different therapeutic mAbs (Table 1-4), which can be
expected as Vmax and Km will be specific for a given mAb and its pharmacologic target.
Therefore, it was not reasonable to use all reported population estimates for Vmax and Km
to specify their respective simulation uncertainty distributions. Instead, the geometric
means of the lognormal uncertainty distributions for Vmax (18 mg/day) and Km (5.0 mg/L)
were selected based on reported values from the population PK analysis of matuzumab
where a two-compartment model with parallel linear and nonlinear elimination was used
(40) (Table 1-4). The population estimates of Vmax and Km for matuzumab were 10.9
mg/day and 4.0 mg/L, respectively. The variances selected for the uncertainty
distributions for Vmax and Km allowed for a small but reasonable amount of variability in
the simulation parameter values, since these parameters are specific for the theoretical
mAb and its target. The expected CLint for the theoretical mAb based on the geometric
means of the simulation uncertainty distributions for Vmax and Km was 3.6 L/day, which
is in line with other therapeutic mAbs that target cell membrane antigens primarily
expressed in tissue (Table 1-4). As discussed in Chapter 1, therapeutic mAbs with cell
membrane targets primarily expressed in tissue had similar CLint values that were also
much smaller compared to mAbs whose cell membrane target was largely expressed on
blood cells.
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A lognormal uncertainty distribution was used for most of the parameters in the
population PK model since PK parameters often follow this type of distribution. The
population values for Vmax and Km, between-subject standard deviations for V1 and V2,
and the standard deviation of residual variability were all randomly sampled from
lognormal distributions. The population values for CLL, V1, V2, and Q were drawn from
a multivariate lognormal distribution. The decision to use a multivariate distribution for
CLL, V1, V2, and Q, and not univariate distributions was based on observed correlations
between estimates for these parameters reported in population PK analyses of mAbs
where a two-compartment parallel elimination model was used (Tables 1-3 and 1-4). The
between-subject standard deviations for Vmax and CLL and the coefficients for the weight
effect were sampled from uniform distributions. A uniform distribution was used for the
weight effect on Vmax, CLL, V1, and V2, because this type of distribution appeared to
describe the estimates reported in the literature for the effect of weight on these
parameters better than a lognormal distribution. While a lognormal distribution was
considered for the between-subject standard deviations for Vmax and CLL, a uniform
distribution was used because there was interest in evaluating the performance of the
estimation methods in cases of low and high between-subject variability in Vmax and CLL.
By using a uniform distribution, this ensured that a larger number of parameter values
would be sampled from the extremes of the range specified for the simulation uncertainty
distribution. The range of the uncertainty distributions used for the Vmax and CLL
between-subject standard deviations were based on the minimum and maximum values
observed in the literature for the parameters (Table 1-4).
Although the same uncertainty distributions were defined for some parameters
(e.g., Vmax and CLL between-subject standard deviations), the parameter values were
sampled from independent distributions. The exception to this was the coefficient value
for the magnitude of the weight effect, which was assumed to be the same for the volume
related parameters (V1 and V2) and the same for the clearance related parameters (Vmax
and CLL). The simulation parameter uncertainty distributions are defined below, where
~N(μ,σ2) denotes that the parameter follows a normal distribution with a mean (μ) and
variance (σ2), and ~U(a,b) refers to a uniform distribution with lower (a) and upper (b)
limits. In the case of the multivariate normal distribution, the term  refers to a vector
of means and Σ is the variance-covariance matrix.

Fixed Effects
ln K m  ~ N  ln5.0 mg/L , 0.01

ln Vmax  ~ N  ln(18.0 mg/day), 0.01

 

lnCL L , V1 , V2 , Q  ~ N  , 

72

ln CL L  ln0.47 L/day
 


 ln V1    ln4.3 L  



 ln V2    ln2.7 L  
 


 ln Q   ln0.97 L/day

0.042
 0.021

0.057

0.014

0.021
0.019
0.039
0.045

0.057
0.039
0.132
0.182

0.014
0.045
0.182

0.488

Weight effect on Vmax and CL L ~ U0.4, 1.0
Weight effect on V1 and V2 ~ U 0.4, 1.0 

Between-Subject Variability
(Distributions defined for standard deviation)

Vmax  ~ U0.15, 0.65

CL L  ~ U 0.15, 0.65

ln V1   ~ N  ln 0.25, 0.04

ln V2   ~ N  ln 0.25, 0.04

Residual Variability
(Distribution defined for standard deviation)
ln   ~ N  ln 0.15, 0.04

Individual patient weights were simulated simultaneously with concentration data
for each replicate data set, since weight was included in the population PK model as a
covariate. Given that the mAb in this study was assumed to be for therapeutic use in the
area of oncology, the goal was to simulate patient weights that were representative of a
population of adult cancer patients. Patient weights were assumed to follow a lognormal
distribution with a variance of 0.04 and a mean weight that was randomly sampled from
the following uncertainty distribution:



ln(population mean weight) ~ N ln72 kg , 6.25E-4



Therefore, the mean patient weight was different for each replicate data set, but
the variability in patient weights remained the same. Specification of the uncertainty
distribution for the mean patient weight was based on median weights reported in
population PK analyses of therapeutic mAbs in cancer patients (Table 1-1). The decision
to use 0.04 as the between-subject variance for patient weight was based on the
variability of patient weights in the cetuximab population PK analysis (Chapter 3). In
addition, patient weights were available from a study by Sparreboom et al. (personal
communication) where the PK of different anticancer drugs was evaluated in over 1,200
adult cancer patients (155). This data was also taken into account when specifying the
variability for patient weights and the uncertainty distribution for the mean patient
weight.
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Study Designs

Replicate data sets were simulated under two different study designs typically
encountered during drug development: a dose-ranging design (‘informative design’) and
a single dose level design (‘uninformative design’). The study templates were designed
to be representative of what one might see in typical phase I/II studies of therapeutic
mAbs in drug development. The study designs used herein were similar in nature to a
number of clinical studies included in the population PK analyses of various therapeutic
mAbs (21, 23, 29, 30, 40, 45).
In the informative design there were six dose groups with six patients per group.
The therapeutic mAb was administered weekly for 4 weeks as a 1 hr IV infusion at doses
of 50, 100, 200, 400, 800, or 1600 mg. Peak and trough mAb concentrations were
obtained at weeks 2 and 3, and on weeks 1 and 4 a full PK concentration-time profile was
obtained with concentrations sampled at 1, 3, 6, 10, 24, 48, 72, 96, and 168 hours after
the start of the infusion. This sampling schedule resulted in 22 data points per patient.
The selection of the dose levels was based on simulations of concentrations at the
sampling time points using the means and midpoints of the simulation uncertainty
distributions. The dose levels for the informative study design were selected because
they resulted in concentration ranges that were below and above the Km. The software
program PopED (Version 2.06; http://poped.sourceforge.net/) (156) was also used to aid
in the selection of dose levels for the informative design. Attempts were made to
simultaneously optimize dose levels and sampling times using PopED, but this was not
feasible due to prolonged run times, so only the dose levels were optimized. Given the
similarities in population PK between the theoretical mAb for this study and matuzumab
(including population estimates for Vmax and Km), the sampling times reported for three
phase I trials included in the population PK analysis of matuzumab (40) were taken into
account in selecting the sampling times for the informative (and uninformative) study
design.
In the uninformative design there were 36 patients and all were treated at the same
dose level. There were 4 different versions of the uninformative design with patients
treated at different dose levels of 200, 500, 600, or 800 mg. Just as with the informative
design, simulations were used to help select dose levels for the uninformative design.
The dose levels were selected so that the concentration ranges would either be
below/around (200 mg) or above (500, 600, and 800 mg) the Km, thereby making it more
difficult to detect and characterize the nonlinear elimination of the mAb. The dosing and
sampling schedules were the same as in the informative design except for the full PK
concentration-time profile at week 1 which was removed, resulting in 13 data points per
patient.
Estimation Methods

The estimation methods evaluated in this study included approximate maximum
likelihood methods available in NONMEM and a Bayesian MCMC method with two
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different sets of priors (informative and uninformative). The estimation methods
evaluated in NONMEM (Version VI, level 2.0; Icon Development Solutions, Ellicott
City, Maryland) (20) were FO, FOCE-I, and LAP-I. Computer resources included a
computer grid, with each node running NetBSD 3.1 (64bit) on AMD64 processors, and
the GNU Fortran compiler GCC-3.3.3 (GNU Project; http://www.gnu.org/). NMQual 6.3
(Metrum Institute, Augusta, Maine; http://code.google.com/p/nmqual/) was used to track
all code patches/options and install the NONMEM software. Simulation of the replicate
data sets was also carried out using NONMEM and the computer grid. The twocompartment parallel elimination PK model was implemented in NONMEM using the
subroutine ADVAN6 TRANS1 TOL=8. The default boundary test in NONMEM was
disabled for all parameters in the population PK model by specifying the
NOTHETABOUNDTEST, NOOMEGABOUNDTEST, and NOSIGMABOUNDTEST
options in the $ESTIMATION record. If an estimation run crashed or minimization
terminated, up to four restarts were allowed in which the TOL or initial estimates were
adjusted according to a predefined protocol. All runs that reported parameter estimates,
including those where minimization terminated, were used in the analysis. The initial
estimates used for NONMEM are shown below, and for most parameters the initial
estimates were within 20-100% of the mean or the midpoint of their respective simulation
parameter uncertainty distribution:
Fixed Effects

Vmax = 28.8 mg/day

Km = 10.0 mg/L

CLL = 0.72 L/day

V1 = 3.0 L

V2 = 2.0 L

Q = 1.8 L/day

Weight~Vmax = 0.8

Weight~CLL = 0.8

Weight~V1 = 0.8

Weight~V2 = 0.8

Between-Subject Variability
(Initial estimates shown for standard deviation)

Vmax ω = 0.4

CLL ω = 0.4

V1 ω = 0.4

V2 ω = 0.4

Residual Variability
(Initial estimate shown for standard deviation)

σ = 0.4
The population PK model was also implemented in WinBUGS (version 1.4.3;
http://www.mrc-bsu.cam.ac.uk/bugs/) (114) using BUGSModelLibrary (version 1.1;
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Metrum Institute, Augusta, Maine; http://code.google.com/p/bugsmodellibrary/) (157), a
prototype PK/PD model library developed for use with WinBUGS. The use of
BUGSModelLibrary also required the installation of WBDev (http://www.winbugsdevelopment.org.uk/wbdev.html) (158) and the BlackBox Component Builder (version
1.5; Oberon Microsystems, Zurich, Switzerland; http://www.oberon.ch/blackbox.html).
Data management, launching WinBUGS, and analysis of the MCMC samples was done
using R with the R packages coda (159) and a modified version of R2WinBUGS (160)
contributed by W.R. Gillespie (Metrum Research Group, Tariffville, CT). WinBUGS
was run on a Thinkmate VSX i20S4-T with 2 Intel quad-core Xeon 5345 2.33GHz
processors and 16 GB RAM. The operating system was Microsoft Windows Server 2003.
The Bayesian MCMC method was evaluated with uninformative (vague) priors.
The rationale behind specifying the uninformative priors is as follows. For Vmax, Km,
CLL, V1, V2, and Q, the geometric means of their respective uninformative priors were
set to the initial estimates used for NONMEM. By assuming a lognormal prior
distribution for these parameters and using a variance of 10,000 (SD=100), the priors can
be considered vague since the 95% confidence interval would be approximately 0 and +∞
on the linear scale. Uniform priors were specified for the weight effects, which is the
same type of distribution used for their simulation parameter values, but the range of the
uniform priors was increased to 0 to 5. The range in the case was constrained to be
positive, as one would not expect weight to be a negative predictor of clearance and
volume parameters. Although some informativeness was imparted in the priors by doing
this, the range of the uniform distributions was large enough to be considered weakly
informative. Uniform priors with a large range of 1.0E-4 to 1.0E4 were specified for the
standard deviations of between-subject variability and residual variability. The
uninformative priors for the random effects were chosen based on recommendations from
a paper by A. Gelman in which various uninformative prior distributions for variance
parameters in hierarchical models are discussed (161).
The Bayesian MCMC method was also evaluated with informative priors. A
review of the literature in Chapter 1 indicated that many characteristics of the population
PK of currently used therapeutic mAbs are quite similar. Therefore, the idea was that the
published findings from the population PK analyses of therapeutic mAbs could be used
as prior information for the population model parameters. The rationale and
methodology used to specify the informative priors was similar to that used for the
simulation parameter uncertainty distributions. Although the literature was used in
specifying both the informative priors and simulation parameter uncertainty distributions,
the distribution parameter values for the informative priors differed somewhat from the
simulation uncertainty distributions, as the priors were updated with additional
therapeutic mAb population PK studies that were published or found in the literature
from the time the simulation uncertainty distributions were specified. The types of
distributions used for the model parameters were the same for the informative priors and
the simulation uncertainty distributions. The exception to this was the between-subject
standard deviation for Vmax and CLL, where lognormal priors were used since the
reasoning behind using a uniform distribution for the simulation uncertainty distributions
no longer applied for the estimation step. Although a Wishart distribution is commonly

76

used in Bayesian modeling as a prior for the variance-covariance matrix of the betweensubject random effects, in this case, lognormal distributions were used since it was
assumed that between-subject variability was uncorrelated to keep consistent with the
assumptions made for the simulation model.
As previously mentioned, the population estimates for Vmax and Km varied
considerably between different therapeutic mAbs (Table 1-4). This can be expected as
Vmax and Km will be specific for a given mAb and its pharmacologic target. Therefore, it
was not plausible to use reported population estimates for Vmax and Km as prior
information. However, in Chapter 1 it was observed that therapeutic mAbs with cell
membrane targets primarily expressed in tissue had similar CLint values that were also
much smaller compared to mAbs whose cell membrane target was largely expressed on
blood cells. In the current study, it was assumed that the theoretical mAb targets a cell
membrane receptor primarily expressed in tissue. Thus, the CLint values (Table 1-4) for
other therapeutic mAbs (e.g., sibrotuzumab, matuzumab, cetuximab, and CP-751,871)
that also bind to cell membrane antigens primarily expressed in the tissue were used as
prior information for the CLint of the theoretical mAb. In addition to CLint, an
informative prior was specified for Km, and then Vmax was determined as a secondary
parameter as CLint * Km. In order to specify an informative prior for Km, an assumption
had to be made that prior information was available during drug development of the
theoretical mAb. It was assumed that a single dose, dose escalation, first-in-man study of
the theoretical mAb had been conducted, and Km was estimated from a standard twostage PK analysis of the concentration data (a population PK analysis could have been
conducted as well). In addition, Km may have been estimated in pre-clinical PK studies
in animals, and this information could be used in the prior for Km. During drug
development, in vitro binding studies are commonly performed for the mAb and its
pharmacologic target, and this could be used as prior information for Km although the Kd
and Km are often not similar. A lognormal prior was used for Km with a geometric mean
of 10 mg/L and a variance of 1.38, which resulted in a 95% confidence interval of
approximately 1 and 100 mg/L on the linear scale. This seemed like a reasonable degree
of informativeness for Km given the realistic availability of prior information from the
previously mentioned scenarios.
In WinBUGS, the variability of a normal distribution is defined in terms of
precision (inverse of variance), or in the case of a multivariate normal distribution a
precision matrix (inverse of covariance matrix) is used. However, for the uninformative
and informative prior distributions described below, the uncertainty is defined in terms of
variance or a covariance matrix so that comparisons can be easily made with the
simulation parameter uncertainty distributions. The notations used for the simulation
uncertainty distributions also apply for the prior distributions.
Uninformative Priors
Fixed Effects

lnVmax  ~ N  ln(28.8 mg/day),10000

ln K m  ~ N  ln 10.0 mg/L , 10000
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ln CL L  ~ N  ln(0.72 L/day), 10000

ln V1  ~ N  ln(3.0 L), 10000

ln V2  ~ N  ln(2.0 L), 10000

ln Q  ~ N  ln(1.8 L/day), 10000

Weight effect on Vmax ~ U0, 5.0

Weight effect on CL L ~ U 0, 5.0 

Weight effect on V1 ~ U0, 5.0 

Weight effect on V2 ~ U 0, 5.0 

Between-Subject Variability
(Distributions defined for standard deviation)



Vmax  ~ U 1.0E -4 , 1.0E 4



CL L  ~ U 1.0E -4 , 1.0E 4 

V1  ~ U1.0E -4 , 1.0E 4 

V2  ~ U1.0E -4 , 1.0E 4 

Residual Variability
(Distribution defined for standard deviation)

 ~ U 1.0E -4 , 1.0E 4 
Informative Priors

Fixed Effects
ln K m  ~ N  ln 10.0 mg/L , 1.38

ln CL int  ~ N  ln(2.4 L/day), 0.25

 

ln CL L , V1 , V2 , Q  ~ N  , 
ln CL L  ln 0.25 L/day

 

 ln V1    ln 3.6 L  



 ln V2    ln2.6 L  

 

 ln Q   ln0.80 L/day

0.855
0.266

0.305

0.234

Weight effect on Vmax ~ U0.25, 1.25

0.266
0.090
0.125
0.089

0.305
0.125
0.349
0.140

0.234
0.089
0.140

0.317

Weight effect on CL L ~ U0.25, 1.25
Weight effect on V2 ~ U0.25, 1.25

Weight effect on V1 ~ U0.25, 1.25
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Between-Subject Variability
(Distributions defined for standard deviation)
ln CL L   ~ N  ln 0.35, 0.16

ln Vmax   ~ N  ln 0.35, 0.16
ln V1   ~ N  ln0.25, 0.16

ln V2   ~ N  ln0.25, 0.16

Residual Variability
(Distribution defined for standard deviation)
ln  ~ N  ln0.20 , 0.16

Due to prolonged run times, WinBUGS was only evaluated under the informative
and uninformative 600 mg dose level study designs, and the number of estimation runs
was limited to 100 replicate data sets. WinBUGS was run with three MCMC chains for
250,000 iterations with a burn-in phase of 25,000 and every 25th sample was retained.
Therefore, a total of 27,000 MCMC samples were retained for analysis. The length of the
burn-in phase was determined by performing a number of trial runs (n=15) with different
simulated replicate data sets (under both the informative and uninformative 600 mg study
designs), and convergence was monitored by visualization of the MCMC chain histories
and the use of Gelman-Rubin-Brooks plots (162). The trial runs were also performed
with both uninformative and informative priors. Since the data sets were different for
each Bayesian MCMC run, a conservative number was chosen for the burn-in phase to
increase the likelihood that convergence had been reached in all runs. The trial runs were
also used to determine an adequate number of iterations for sampling after the burn-in
phase. For purposes of this study, it was believed that 250,000 iterations for each MCMC
chain would be an adequate number to sufficiently characterize the posterior median,
which was chosen as the summary statistic of interest to calculate the parameter bias and
precision. For example, had the 2.5 and 97.5 percentiles of the posterior distribution been
of interest, then it is likely that more MCMC samples would be needed to characterize the
tails of the posterior distribution. An adequate number of MCMC samples after the burnin phase was also assessed by using the Monte Carlo error, which is similar to the
standard error of the mean but adjusted for autocorrelation between the parameters. A
Monte Carlo error of less than 5% of the standard deviation of the MCMC samples was
considered to be sufficient for this study.
The BUGSModelLibrary offers a choice of two different ordinary differential
equation solvers, and the Runge-Kutta 4th/5th order method was used for this analysis.
Initial estimates for the three MCMC chains were interdispersed by 25%. When
uninformative priors were used, the initial estimates for one of the MCMC chains were
set equal to those used for NONMEM. When informative priors were used, the initial
estimates for one of the MCMC chains were set equal to the means and midpoints of the
informative prior distributions, which were comparable to the initial estimates used for
NONMEM.
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Evaluation of Estimation Performance

The estimation results from NONMEM differ from WinBUGS, as NONMEM
provides maximum likelihood estimates while WinBUGS provides full posterior
probability distributions of the parameters. In order to make comparisons between
NONMEM and WinBUGS with regards to estimation performance, the median of the
posterior distributions was chosen as the point estimate. The parameter values used to
simulate each replicate data set were considered to be the true parameter values. The
difference between the parameter estimate and true value was calculated as the percent
estimation error:
Percent Estimation Error 

ParameterEstimate - ParameterTrue 
ParameterTrue

 100

The percent estimation errors were summarized for each estimation method under
a given study design by calculating bias and precision. Bias was calculated as the median
percent estimation error (MPE), and precision was calculated as the median absolute
percent estimation error (MAPE):
 ParameterEstimate - ParameterTrue 

 100
MPE  Median 
ParameterTrue





 ParameterEstimate - ParameterTrue 
MAPE  Median Absolute value
 100 
ParameterTrue



A global sensitivity analysis was performed to evaluate the dependence of
simulation conclusions on parameter uncertainty. The sensitivity analysis was visualized
by plotting the percent estimation error vs. the specific value of simulation model
parameters for each trial replicate. The plots were then viewed for trends in the
estimation error when viewed across the range of parameter uncertainty employed for the
simulations. These sensitivity plots were created for each simulation model parameter.
Predictive checks were performed to assess whether the observed parameter
biases would result in predictions that deviate significantly from the “true model”. For
purposes of the predictive check, the means and midpoints of the simulation parameter
uncertainty distributions were assumed to be the true parameter values. The true
parameter values were then altered based on the parameter biases observed in the
analysis. Monte Carlo simulations were performed with both the true and biased
parameter values using a template data set from one of the study designs. The median
and 90% prediction interval of simulated concentrations during the week 4 full
concentration-time profile served as the metrics by which the true model predictions and
analysis-derived predictions were compared.
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Results

Under all study designs, the FO method generally produced larger bias and lower
precision for the model parameters compared to the other estimation methods. Therefore,
the following discussion of the results is based on the findings for the FOCE-I, LAP-I,
and Bayesian MCMC methods. The discussion is also focused on the results from the
informative and uninformative 600 mg dose level study designs, as these were the two
designs under which both NONMEM and WinBUGS were evaluated and could be
compared. Results for the NONMEM estimation methods under the uninformative 200,
500, and 800 mg dose level study designs can be found in Appendix C (Tables C-1 and
C-2). MCMC chain histories, probability densities of the posterior distributions of the
model parameters, and Gelman-Rubin-Brooks plots for representative estimation runs
using both sets of Bayesian priors under the informative and uninformative 600 mg dose
designs are also presented in Appendix C (Figures C-1 through C-3).
Informative Study Design

Bias and precision of the population PK model parameters under the informative
study design are summarized in Tables 4-1 and 4-2, and boxplots of percent estimation
errors of the model parameters are shown in Figure 4-2. It should be noted that for the
random effect parameters (i.e., between-subject variability and residual variability) bias
and precision was calculated with respect to the variance term. No appreciable bias was
observed for the estimation methods, as the MPE was less than ±25% (ranged from -24%
to 21%) for all parameters. Bias was comparable across the estimation methods for a
given parameter, with the most noticeable difference being the smaller bias for the V2
between-subject variance when uninformative or informative Bayesian priors were used
compared to FOCE-I and LAP-I. For each estimation method, parameter bias tended to
be larger for the between-subject variances compared to other model parameters.
Good precision was observed for the estimation methods, as the MAPE was less
than 52% (ranged from 3% to 52%) for all model parameters. Under each estimation
method, the degree of precision varied among the parameters as a lower precision (i.e.,
larger MAPE) was observed for the covariate effects and between-subject variances
compared to other parameters in the model. Precision was similar across the estimation
methods for a given parameter, but Bayesian MCMC (particularly with informative
priors) produced noticeably better precision in the covariate effects and the V2 betweensubject variance compared to FOCE-I and LAP-I. The differences in parameter precision
between the estimation methods were also evident in the boxplots in Figure 4-2 for the
aforementioned parameters.
Bias and precision of the PK parameter estimates for Bayesian MCMC with
uninformative priors were comparable to that when informative priors were used, which
can be expected given the informativeness of the data under the dose escalation study
design.
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Table 4-1.
Bias (median percent estimation error) in the population pharmacokinetic model parameters under the informative
study design.
Parameter

FO

FOCE-I

LAP-I

Vmax
Km
CLL
V1
V2
Q
WGT~Vmax
WGT~CLL
WGT~V1
WGT~V2
Vmax BSV (ω2)
CLL BSV (ω2)
V1 BSV (ω2)
V2 BSV (ω2)
Residual variance (σ2)

-3.6
17
0.12
-2.8
21
17
-0.59
-3.8
0.027
-0.77
-30
18
-4.6
121
16

4.5
2.9
-0.61
-0.83
-0.46
-1.5
-0.32
0.47
1.5
-1.3
-8.1
-13
-8.6
-18
-0.65

0.67
1.3
-2.2
-1.2
-1.3
-0.79
-0.037
-0.024
1.4
-1.3
-8.4
-12
-7.8
-24
-0.76

B-MCMC
[UP]
-5.6
-1.1
0.46
0.32
3.2
-0.25
8.7
1.5
4.3
11
21
4.3
1.5
2.8
0.82

B-MCMC
[IP]
-3.0
1.2
-0.062
0.062
2.3
-0.50
1.4
6.9
3.5
5.4
1.4
-9.5
-2.3
-0.59
1.3

B-MCMC = Bayesian Markov Chain Monte Carlo; BSV = between-subject variance; IP = informative priors; UP = uninformative
priors; WGT = weight.

82

Table 4-2.
Precision (median absolute percent estimation error) in the population pharmacokinetic model parameters under the
informative study design.
Parameter

FO

FOCE-I

LAP-I

Vmax
Km
CLL
V1
V2
Q
WGT~Vmax
WGT~CLL
WGT~V1
WGT~V2
Vmax BSV (ω2)
CLL BSV (ω2)
V1 BSV (ω2)
V2 BSV (ω2)
Residual variance (σ2)

19
32
11
3.7
22
17
88
77
26
61
43
39
19
121
16

11
11
7.9
2.9
5.7
5.2
47
51
21
37
25
27
17
48
4.0

11
11
8.6
3.1
6.0
5.5
49
52
21
39
25
26
18
49
4.0

B-MCMC
[UP]
11
9.4
9.5
3.2
7.2
5.0
28
40
21
30
37
30
19
43
3.8

B-MCMC
[IP]
9.5
8.8
7.8
2.7
6.4
4.7
14
20
16
15
25
23
17
28
3.3

B-MCMC = Bayesian Markov Chain Monte Carlo; BSV = between-subject variance; IP = informative priors; UP = uninformative
priors; WGT = weight.
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Figure 4-2. Boxplots of percent estimation errors for the population pharmacokinetic
model parameters under the informative study design. Outliers are not shown for
visualization purposes and made up <10% of the data for each parameter-estimation
method combination. The median percent estimation error corresponds to the calculated
parameter bias. Note that the y-axis scale differs from one boxplot to another. BMCMC = Bayesian Markov Chain Monte Carlo; IP = informative priors; UP =
uninformative priors.
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Select plots from the global sensitivity analysis under the informative study
design are shown in Figure 4-3 for the covariate effects and between-subject variances.
Similar results were observed in the global sensitivity analysis for FOCE-I and LAP-I,
therefore plots for FOCE-I are only shown. For each estimation method, with the
exception of when informative Bayesian priors were used, the sensitivity plots showed
that for all parameters the percent estimation errors were insensitive to uncertainty in the
values of the simulation parameters. In other words, no trends were observed in the
parameter estimation errors when viewed across the range of parameter uncertainty
employed for simulating the replicate data sets. In the case of informative priors, the
sensitivity plots for the weight effect and the between-subject variance for Vmax, CLL, and
V2 showed an increase in bias as simulation parameter values were selected further away
from the mean or midpoint of their respective informative prior distribution. For
reference, the geometric means of the informative priors for the between-subject
variability in Vmax, CLL, and V2 in terms of variance were 0.1225, 0.1225, and 0.0625,
respectively. The midpoints of the informative priors for the covariate weight effect were
each 0.75.
Predictive checks showed that the parameter biases observed under the
informative study design for FOCE-I, LAP-I, and Bayesian MCMC with informative and
uninformative priors would not result in predictions that differed significantly from the
true model. This was expected given the relatively small parameter biases seen in Table
4-1. For the true and biased parameter values, 1000 data sets were simulated using an
informative study design template data set, and the simulated concentrations during the
full concentration-time profile at week 4 of therapy were then compared. As seen in
Figures 4-4 and 4-5 for FOCE-I and Bayesian MCMC with uninformative priors, the
analysis-derived median and 90% prediction interval for concentrations during week 4
were almost identical to the true model predicitons across all dose levels in the
informative study design. Similar plots were observed for LAP-I and Bayesian MCMC
with informative priors (not shown).
Uninformative 600 mg Dose Level Study Design

Bias and precision of the population PK model parameters under the
uninformative 600 mg dose level study design are summarized in Tables 4-3 and 4-4, and
boxplots of percent estimation errors for the model parameters are shown in Figure 4-6.
The bias for most parameters under FOCE-I and LAP-I was less than ±20%. Parameter
biases were comparable between FOCE-I and LAP-I, although LAP-I produced a
noticeably smaller bias for Vmax and the between-subject variance for Vmax and V2
compared to FOCE-I. The largest parameter biases (MPE) observed under FOCE-I were
for Vmax (42%), Km (129%), Vmax between-subject variance (-40%), and V2 betweensubject variance (-100%), while the largest biases observed under LAP-I were for Km
(143%) and V2 between-subject variance (-53%). When informative Bayesian priors
were used, the bias for all parameters was less than ±10%, with the only exception being
Km which had an MPE of 34%. The use of informative priors produced smaller biases
for most of the model parameters compared to FOCE-I and/or LAP-I, and this was
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Figure 4-3. Global sensitivity analysis results from the informative study design. Plots are shown for selected parameters where
the percent estimation error is plotted relative to the specific value of the simulation model parameter for each replicate. The red line
indicates a LOESS smoothing curve. Panels A-D show sensitivity plots for the between-subject variances for Vmax, CLL, V1, and V2,
respectively. Panels E-H show sensitivity plots for the weight effect on Vmax, CLL, V1, and V2, respectively. Note that the y-axis scale
differs from one plot to another. BSV = between-subject variance; IP = informative priors; %PE = percent estimation error; UP =
uninformative priors.
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Figure 4-4. Simulated prediction intervals for concentrations during week 4 of therapy
based on the true parameter values and biased parameter values derived from the FOCE-I
results under the informative study design. The true model and analysis-derived
predictions are indicated by the solid black lines and dashed red lines, respectively. The
three lines represent the 5th, 50th, and 95th percentiles determined from 1000 simulated
data sets. The simulations were carried out using an informative study design template
data set. Simulated prediction intervals are shown separately for each dose group.
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Figure 4-5. Simulated prediction intervals for concentrations during week 4 of therapy
based on the true parameter values and biased parameter values derived from the
Bayesian MCMC (with uninformative priors) results under the informative study design.
The true model and analysis-derived predictions are indicated by the solid black lines and
dashed red lines, respectively. The three lines represent the 5th, 50th, and 95th
percentiles determined from 1000 simulated data sets. The simulations were carried out
using an informative study design template data set. Simulated prediction intervals are
shown separately for each dose group.
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Table 4-3.
Bias (median percent estimation error) in the population pharmacokinetic model parameters under the uninformative
600 mg dose level study design.
Parameter

FO

FOCE-I

LAP-I

Vmax
Km
CLL
V1
V2
Q
WGT~Vmax
WGT~CLL
WGT~V1
WGT~V2
Vmax BSV (ω2)
CLL BSV (ω2)
V1 BSV (ω2)
V2 BSV (ω2)
Residual variance (σ2)

75
446
-21
-4.0
23
20
-18
-17
-1.9
46
-75
-1.9
-6.0
57
6.9

42
129
-12
-1.4
0.23
3.4
3.8
-18
-0.28
21
-40
-0.92
-7.1
-100
-2.6

12
173
-6.5
-1.3
-2.0
2.2
5.2
-11
-0.23
18
5.9
-4.9
-5.9
-53
-2.3

B-MCMC
[IP]
7.4
34
-5.9
-0.43
4.7
2.6
9.6
4.7
0.63
3.1
-8.4
0.77
-8.7
-2.4
0.40

B-MCMC = Bayesian Markov Chain Monte Carlo; BSV = between-subject variance; IP = informative priors; WGT = weight.
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Table 4-4.
Precision (median absolute percent estimation error) in the population pharmacokinetic model parameters under the
uninformative 600 mg dose level study design.
Parameter

FO

FOCE-I

LAP-I

Vmax
Km
CLL
V1
V2
Q
WGT~Vmax
WGT~CLL
WGT~V1
WGT~V2
Vmax BSV (ω2)
CLL BSV (ω2)
V1 BSV (ω2)
V2 BSV (ω2)
Residual variance (σ2)

100
446
26
4.5
29
24
119
101
27
120
100
61
22
100
8.3

54
129
17
3.3
16
16
99
83
23
102
81
32
20
100
5.2

53
173
16
3.3
17
17
97
73
24
112
79
28
19
100
5.7

B-MCMC
[IP]
25
38
9.5
2.9
9.8
12
18
16
17
19
43
17
19
30
4.6

B-MCMC = Bayesian Markov Chain Monte Carlo; BSV = between-subject variance; IP = informative priors; WGT = weight.
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Figure 4-6. Boxplots of percent estimation errors for the population pharmacokinetic
model parameters under the uninformative 600 mg dose level study design. Outliers are
not shown for visualization purposes and made up <10% of the data for each parameterestimation method combination. The median percent estimation error corresponds to the
calculated parameter bias. Note that the y-axis scale differs from one boxplot to another.
B-MCMC = Bayesian Markov Chain Monte Carlo; IP = informative priors.

98

-60 -40

0

20

FOCE-I

LAP-I

B-MCMC
[IP]

99
40

60

LAP-I

20

60

FOCE-I
-10

-60

-20

0

20

-5

0

5

% Estimation Error

-40

10

40

LAP-I

0

40

% Estimation Error

FOCE-I

-20

% Estimation Error

-60 -40 -20

% Estimation Error
-100

0

100

200

500

1000

% Estimation Error

0

% Estimation Error

1500

300

Vm ax

B-MCMC
[IP]

B-MCMC
[IP]

Km

FOCE-I

CLL

FOCE-I

V2

FOCE-I

LAP-I

LAP-I

LAP-I

B-MCMC
[IP]

V1

B-MCMC
[IP]

Q

B-MCMC
[IP]

0

100 200 300

Weight~CLL

-300

-100

% Estimation Error

200
0
-200
-400

% Estimation Error

400

Weight~Vm ax

FOCE-I

LAP-I

B-MCMC
[IP]

FOCE-I

B-MCMC
[IP]

Weight~V2

200
0
-400

-200

% Estimation Error

50
0
-50
-100

% Estimation Error

400

100

Weight~V1

LAP-I

FOCE-I

LAP-I

B-MCMC
[IP]

FOCE-I

CLL Betw een-Subject Variance

50
0
-50

% Estimation Error

600
400
200

-100

0

% Estimation Error

B-MCMC
[IP]

100

Vm ax Betw een-Subject Variance

LAP-I

FOCE-I

LAP-I

B-MCMC
[IP]

FOCE-I

Figure 4-6 continued.

100

LAP-I

B-MCMC
[IP]

600
400
0

200

% Estimation Error

0
-50

% Estimation Error

800 1000

V2 Betw een-Subject Variance

50

V1 Betw een-Subject Variance

FOCE-I

LAP-I

B-MCMC
[IP]

FOCE-I

0
-10
-20

% Estimation Error

10

20

Residual Variance

FOCE-I

LAP-I

B-MCMC
[IP]

Figure 4-6 continued.

101

LAP-I

B-MCMC
[IP]

particularly evident for Vmax, Km, the weight effect on CLL and V2, and the betweensubject variance for Vmax and V2 (Table 4-3 and Figure 4-6).
FOCE-I and LAP-I produced similar results with regards to parameter precision,
but both estimation methods exhibited low precision as almost half of the model
parameters had a MAPE greater than 50%. These parameters included Vmax, Km, the
weight effect on Vmax, CLL, V2, and the between-subject variance for Vmax and V2. When
informative Bayesian priors were used, the MAPE was less than 30% for all parameters
with the exception of Km (38%) and Vmax between-subject variance (43%). Compared to
FOCE-I and LAP-I, the use of informative priors resulted in greater parameter precision
and smaller MAPEs for all model parameters. This was most apparent for Vmax, Km, the
weight effect on Vmax, CLL, V2, and the between-subject variance for Vmax and V2 (Table
4-4). The differences in parameter precision between the estimation methods were also
evident in the boxplots in Figure 4-6, as the variability in the percent estimation errors for
the aforementioned parameters was dramatically smaller when informative priors were
used compared to FOCE-I and LAP-I.
The results for the estimation methods were also compared between the
informative and uninformative 600 mg dose level study designs to evaluate the
performance of the methods as the amount of information in the dataset decreased and the
nature of the study design made it more difficult to detect and characterize the nonlinear
elimination of the therapeutic mAb. The estimation performance of the methods was
adequate and comparable under the informative study design, considering that the bias
and precision for all model parameters was less than ±25% and 52%, respectively. Under
the uninformative 600 mg dose level study design, the performance of FOCE-I and LAPI decreased as the bias and precision for many of the parameters significantly increased to
±40-173% and 53-173%, respectively, while Bayesian MCMC with informative priors
produced results that were comparable to those under the informative study design.
Select global sensitivity analysis plots are shown in Figure 4-7 for the betweensubject variance and weight effect parameters. For FOCE-I, LAP-I, and Bayesian
MCMC with informative priors, the sensitivity plots showed that for most parameters the
percent estimation errors were insensitive to uncertainty in the values of the simulation
parameters. However, for each estimation method, trends were observed in the
sensitivity plots for certain parameters. For FOCE-I and LAP-I, an increasing trend
towards underpredicting the V2 between-subject variance was observed as smaller
simulation parameter values were selected for the V2 between-subject variance. A
similar observation was made for the Vmax between-subject variance under FOCE-I,
where an increasing trend towards underpredicting the variance was observed as smaller
between-subject variances for Vmax were selected from the simulation uncertainty
distribution. When informative Bayesian priors were used, the sensitivity plots for the
weight effect and the between-subject variance for Vmax, CLL, and V2 showed an increase
in bias as simulation parameter values were selected far away from the mean or midpoint
of their respective informative prior distribution. Similar plots were observed for these
parameters in the global sensitivity analysis under the informative study design when
informative Bayesian priors were used (Figure 4-3).
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Figure 4-7. Global sensitivity analysis results from the uninformative 600 mg dose level study design. Plots are shown for selected
parameters where the percent estimation error is plotted relative to the specific value of the simulation model parameter for each
replicate. The red line indicates a LOESS smoothing curve. Panels A-D show sensitivity plots for the between-subject variances for
Vmax, CLL, V1, and V2, respectively. Panels E-H show sensitivity plots for the weight effect on Vmax, CLL, V1, and V2, respectively.
Note that the y-axis scale differs from one plot to another. BSV = between-subject variance; IP = informative priors; %PE = percent
estimation error.
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Predictive checks showed that the parameter biases observed under the
uninformative 600 mg dose level study design for FOCE-I, LAP-I, and Bayesian MCMC
with informative priors (Table 4-3) can result in predictions that differ significantly from
the true model depending on the doses (concentrations) at which the predictions are made
(Figures 4-8 through 4-10). For the true and biased parameter values, 1000 data sets
were simulated using an uninformative study design template with different dose levels
of 50, 100, 200, 400, 600, or 800 mg, and the simulated concentrations during the full
concentration-time profile at week 4 of therapy were then compared. Although the
parameter values used for the simulations were based on the biases observed under the
uninformative 600 mg dose level study design, the predictive checks were carried out at
other doses in addition to 600 mg to investigate how the analysis-derived predictions
would perform when extrapolated to other dose levels. For FOCE-I, LAP-I, and
Bayesian MCMC with informative priors, the analysis-derived median and 90%
prediction interval for concentrations during week 4 were quite similar to the predictions
based on the true model at dose levels of 400 mg and greater. At the lower dose levels
(50, 100, and 200 mg), the analysis-derived median and 90% prediction interval under
each estimation method for the peak concentration at week 4 were very similar to the true
model prediction. This can be expected given that the peak concentrations are largely
determined by V1, and the estimation methods produced negligible bias in both V1 and
the between-subject variance for V1. At the lower dose levels, the FOCE-I and LAP-I
derived predictions for concentrations later in week 4 (e.g., the trough concentration)
began to deviate from the true model, while the predictions based on Bayesian MCMC
with informative priors remained closer to the true model. The trough concentrations are
largely determined by the total clearance of the mAb, which in the parallel elimination
PK model, is determined by the clearance from the nonlinear pathway (CLNL) plus that of
the linear pathway (CLL). A large bias was observed for Km under FOCE-I and LAP-I of
129% and 173%, respectively, while the use of informative priors resulted in a much
smaller bias of 34%. These differences in the bias for Km were likely the main reason for
the predictive check observations, given that for each estimation method much smaller
biases were observed for parameters related to Vmax and CLL compared to Km. An
overprediction of Km would cause a decrease in CLint, and consequently the CLNL and
total clearance would decrease over the range of concentrations in which the nonlinear
pathway is not saturated. This decrease in total clearance would result in overprediction
of trough concentrations which is what was observed in Figures 4-8 and 4-9 for the
FOCE-I and LAP-I derived predictions.
The Bayesian MCMC method with uninformative priors was not investigated
under the uninformative 600 mg dose level study design, because all of the initial
estimation runs under this scenario failed to run to completion. This could be expected,
as the uninformative nature of the data sets simulated under the 600 mg dose level study
design may not have supported the use of the vague priors specified in this study.
However, if the originally specified vague priors were constrained to more biologically
plausible values, but enough uncertainty retained so the priors could still be considered
weakly informative, then the estimation runs would run to completion. The use of the
biologically plausible but weakly informative priors was not further investigated in the
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Figure 4-8. Simulated prediction intervals for concentrations during week 4 of therapy
based on the true parameter values and biased parameter values derived from the FOCE-I
results under the uninformative 600 mg dose level study design. The true model and
analysis-derived predictions are indicated by the solid black lines and dashed red lines,
respectively. The three lines represent the 5th, 50th, and 95th percentiles determined
from 1000 simulated data sets. The simulations were carried out at different dose levels
using an uninformative study design template data set.

109

500

400 m g

600

10

650

500

550

600
Time (hr)

600 m g

800 m g

650

500

Time (hr)

650

100

Time (hr)

600

650

100

200 m g
Concentration (mg/L)
550

600
Time (hr)

100
500

550

Time (hr)

Concentration (mg/L)

550

10

650

10
500

1

Concentration (mg/L)

10
1

600

100

550

1

Concentration (mg/L)

500

Concentration (mg/L)

100 m g

0.1

Concentration (mg/L)

50 m g

550

600

650

Time (hr)

Figure 4-9. Simulated prediction intervals for concentrations during week 4 of therapy
based on the true parameter values and biased parameter values derived from the LAP-I
results under the uninformative 600 mg dose level study design. The true model and
analysis-derived predictions are indicated by the solid black lines and dashed red lines,
respectively. The three lines represent the 5th, 50th, and 95th percentiles determined
from 1000 simulated data sets. The simulations were carried out at different dose levels
using an uninformative study design template data set.
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Figure 4-10. Simulated prediction intervals for concentrations during week 4 of therapy
based on the true parameter values and biased parameter values derived from the
Bayesian MCMC (with informative priors) results under the uninformative 600 mg dose
level study design. The true model and analysis-derived predictions are indicated by the
solid black lines and dashed red lines, respectively. The three lines represent the 5th,
50th, and 95th percentiles determined from 1000 simulated data sets. The simulations
were carried out at different dose levels using an uninformative study design template
data set.
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study in order to maintain consistency in the methodology, since these priors would have
differed from the vague priors used under the informative study design.
Discussion

Nonlinear elimination is a common characteristic of the PK of therapeutic mAbs
(6, 8), and accordingly, PK models with nonlinear elimination were used in almost half of
the population PK analyses of therapeutic mAbs reported in the literature (Table 1-1). It
was also common in the population PK analyses to use a two-compartment model to
describe the distribution of the therapeutic mAb. It is estimated that half of all current
projects in new drug development are biologics, with mAbs being the predominant class
of biologics under clinical study (1). As the number of therapeutic mAbs undergoing
drug development and gaining FDA approval continue to increase, it is important that
currently available estimation methods used for population PK modeling be evaluated
when applied to therapeutic mAbs with nonlinear PK. The challenge with detecting and
characterizing nonlinear PK is not only dependent on the study design, but also on the
estimation method used for the population PK analysis (163). However, little work has
been done evaluating population estimation methods using PK models that are
representative of the typical disposition characteristics of therapeutic mAbs, as most
method comparison studies used a one-compartment model with linear elimination for
comparison (142-147). In the current study, I evaluated the FO, FOCE-I, and LAP-I
methods in NONMEM and a full Bayesian MCMC method in WinBUGS with both
uninformative and informative priors in population PK modeling of therapeutic mAbs
with nonlinear PK. The structural PK model used for the simulation of trial replicates
was a two-compartment model with parallel linear and nonlinear elimination pathways,
which was also used in the population PK analyses of several therapeutic mAbs (Table
1-1). Furthermore, to my knowledge this is the first study to have systematically
evaluated the formal inclusion of prior information with Bayesian MCMC methods when
used for population PK modeling.
Given the similar population PK characteristics of therapeutic mAbs (Chapter 1),
the idea was that the published findings from the population PK studies could not only be
used to define the parameter uncertainty distributions for simulation of the trial replicates,
but could also be used as prior information in a Bayesian analysis. With regards to the
simulation parameter uncertainty distributions, it was important that the values sampled
from the distributions were realistic and representative of the population PK parameters
observed for therapeutic mAbs in order to simulate concentration data for a prototypical
mAb. As shown in Figure 4-11, the probability density plots for the parameter
uncertainty distributions adequately characterized the parameter estimates reported in
published population PK analyses of therapeutic mAbs. Population estimates for Vmax
and Km are not shown in Figure 4-11 for their respective uncertainty distributions since
both parameters are specific for a given mAb and pharmacological target, and as
discussed in Chapter 1, Vmax and Km varied considerably among the different therapeutic
mAbs. The probability density plots for the Bayesian informative prior distributions (not
shown) differed somewhat from those for the simulation uncertainty distributions, as the
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Figure 4-11. Probability density plots of the parameter uncertainty distributions used
for simulation of the trial replicates. The red vertical dashes represent parameter
estimates reported in published population PK analyses of therapeutic mAbs (see Tables
1-3 through 1-6). In some of the plots the red dashes are staggered for visualization
purposes. SD = standard deviation.
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Bayesian informative priors were updated with additional population PK studies of
therapeutic mAbs that were published or found in the literature after the simulation of the
replicate data sets had been performed. However, the Bayesian informative priors still
adequately described the population PK parameter estimates reported in the literature for
therapeutic mAbs. Figure 4-12 shows a scatterplot matrix of parameter values drawn
from the multivariate lognormal simulation uncertainty distribution defined for the
parameters CLL, V1, V2, and Q, so that the correlations between the parameters can be
visualized.
An issue that had to be addressed during this study was how to compare the
parameter estimation output from NONMEM and WinBUGS. While NONMEM
provides maximum likelihood estimates (i.e., point estimates), WinBUGS provides the
full posterior marginal distributions of the MCMC sampled values of the model
parameters. Summary statistics (e.g., mean, median, standard deviation, and 2.5 and 97.5
percentiles) and probability density plots of the posterior marginal distributions can then
be obtained. Consideration was given to using the posterior mean, median, or mode, as
the point estimate for calculating bias and precision of the parameter estimates for the
Bayesian MCMC method. Since the maximum likelihood estimate is the mode of the
likelihood, the closest analog in a Bayesian analysis to a maximum likelihood estimate
would be the mode of the posterior distribution. However, estimating the mode from
MCMC samples of a continuous variable can be problematic, and is not always reliable
as this requires the probability density of the posterior distribution to be estimated from
the MCMC samples and then the mode of the estimated density is used. For a
symmetrical posterior distribution, the mean, median, and mode would all be
approximately equal; however, for many of the model parameters a positively skewed
posterior distribution was observed. Given the skewed nature of the posterior
distributions, the posterior mean was typically larger than the mode and median.
Therefore, for purposes of comparing the parameter estimation performance of
WinBUGS and NONMEM, the posterior median was selected as a comparable metric to
the maximum likelihood estimates provided by NONMEM. The posterior median was
also used in a study by Bennett and Wakefield, in which the estimation performance of a
Bayesian MCMC method in the software package POPKAN was compared to the FOCE
method in NONMEM and a two-step algorithm within another software package
PPHARM (142).
Another issue that had to be addressed in this study was that due to prolonged run
times it was not feasible to evaluate the estimation performance of WinBUGS under each
of the dose levels used for the uninformative study design. For this reason, WinBUGS
was evaluated only under the 600 mg dose level uninformative design. This dose level
was selected for the reason that if the theoretical mAb in this study was undergoing drug
development, a similar dose might be selected for entering phase II studies. The
approach to selecting the 600 mg dose level was to first simulate one replicate data set
under the informative study design using the means and midpoints of the simulation
parameter uncertainty distributions. A noncompartmental analysis was then performed
on the simulated concentration-time data. As shown in Figure 4-13, there is a dosedependent decrease in clearance, which can be expected given the nonlinear PK of the
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Figure 4-12. Scatterplot matrix of parameter values drawn from the multivariate
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theoretical mAb. Assuming that the theoretical mAb is eliminated via a saturable targetmediated mechanism (i.e., receptor-mediated endocytosis), then theoretically, the
asymptotic decrease of the clearance of the mAb would be the result of saturating the
pharmacologic target. Looking at Figure 4-13, the clearance of the mAb begins to level
off somewhere around the 600 mg dose level. These findings could be used as the basis
for recommending a dose of around 600 mg for future phase II studies. This rationale
was similar to that used in a phase I study of cetuximab, where the maintenance dose
recommendation for future phase II studies was based on the results of a
noncompartmental analysis of cetuximab concentration-time data from patients treated at
different dose levels (81). In the cetuximab phase I study, a maintenance dose of around
200 mg/m2 was recommended based on an observed dose-dependent decrease of
cetuximab clearance over a range of 20-400 mg/m2, where saturation of the clearance
began to occur around the 200 mg/m2 dose level (81). The 600 mg dose level was also
selected, because at larger doses the two-compartment parallel linear and nonlinear
elimination model essentially collapses to a two-compartment linear model. At these
higher doses it would be difficult for any estimation method to detect the nonlinear PK.
This was indicated by the increasing bias in the population estimate for Km for the
NONMEM estimation methods as the dose levels increased under the uninformative
design (Tables 4-1, 4-3, C-1).
Under all study designs, the FO method generally produced larger bias and lower
precision for the model parameters compared to the other estimation methods evaluated.
This was expected since FO is generally considered to be a less accurate estimation
method compared to FOCE and LAP (13). All three methods in NONMEM (FO, FOCE,
LAP) linearize the nonlinear mixed effects model (e.g., population PK model) around the
between-subject random effects (112, 113). The FO method takes a first-order
approximation around the expected value of the between-subject random effects which is
0 (i.e., η = 0). On the other hand, FOCE takes a first-order approximation around the
conditional estimate of the between-subject random effects. The LAP method is similar
to FOCE, but takes a second-order approximation. Despite the more accurate
approximation of the nonlinear mixed effects model used by LAP, the estimation
performance of LAP and FOCE were very similar under the informative and
uninformative 600 mg study designs (Tables 4-1 through 4-4), although the LAP method
did show improvement over FOCE under the uninformative 600 mg study design for the
bias in Vmax and the between-subject variance for Vmax and V2. A detailed discussion of
the theory behind the approximate maximum likelihood methods in NONMEM (FO,
FOCE, LAP) and Bayesian MCMC methods, such as that used by WinBUGS, is not
within the scope of this text but are discussed elsewhere (112, 113, 115, 116, 150, 152).
Although, it is worth noting that Bayesian MCMC methods do not rely on analytical
approximations of the nonlinear mixed effects model like with FO, FOCE, and LAP, but
instead use Monte Carlo integration techniques to obtain parameter estimates for the
exact model (115, 116). The extent to which the theoretical differences in the methods in
NONMEM and WinBUGS translated into differences in their estimation performance is
unknown and was not evaluated per se in this study.
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There are a number of practical advantages and disadvantages with NONMEM
and WinBUGS. One advantage with Bayesian MCMC methods is the ability to include
prior information in the population PK analysis by using informative priors. This
advantage was demonstrated by the superior performance of Bayesian MCMC with
informative priors over the NONMEM estimation methods under the uninformative 600
mg design. Another advantage with Bayesian MCMC is that full posterior distributions
of the PK model parameters are provided from which inferences can made using the
entire distribution. Depending on the computing resources available, a potential
disadvantage with WinBUGS is prolonged run times. As observed in this study, run
times with WinBUGS were considerably longer compared to when the NONMEM
estimation methods were used. Average run times for FOCE-I and LAP-I under the
informative study design were 7 minutes and 30 minutes, respectively, while run times
for Bayesian MCMC with uninformative priors and informative priors averaged around
19 hours and 25 hours, respectively. Under the uninformative 600 mg study design,
average run times for FOCE-I, LAP-I, and Bayesian MCMC with informative priors were
8 minutes, 45 minutes, and 19 hours, respectively. In the past, another drawback to
Bayesian MCMC methods was the lack of accessibility to such methods and software
without having to do additional custom programming to implement the population PK
model and to input and manage data. However, accessibility to Bayesian MCMC
methods for population PK modeling is improving. For example, the
BUGSModelLibrary (157), a recently developed WinBUGS PK/PD model library, was
used in this study to implement the population PK model. In addition, a Bayesian
MCMC method was incorporated in the recent release of NONMEM version VII (164).
A benefit to using NONMEM is that it is the most widely used software for population
PK/PD modeling (151), and since it has been available for more than 30 years, there is a
wealth of studies and experience with using NONMEM in the literature. For
pharmacometricians that have primarily used NONMEM for population PK/PD
modeling, switching to WinBUGS may require additional training and education in
Bayesian analysis and MCMC methods.
The NONMEM user’s guide points out that the FO, FOCE, and LAP estimation
methods can be inaccurate when dealing with highly nonlinear models (112). However,
when evaluating the performance of any estimation method, one should always take into
consideration the nature of the data and study design under which the method was
evaluated. As shown in this study, the FOCE and LAP methods performed reasonably
well and on par with the Bayesian MCMC method under the conditions used for the
informative study design. FOCE and LAP also performed relatively well under the
uninformative 200 mg study design, as the bias and precision for many of the parameters
were comparable to those under the informative study design, although a noticeably
larger bias and/or lower precision was observed for some of the parameters (e.g., V2 and
weight effect on V2) under the uninformative 200 mg design (Tables 4-1, 4-2, C-1, C-2).
The estimation performance of FOCE-I and LAP-I decreased as the dose levels
used for the uninformative study design (200, 500, 600, and 800 mg) were increased
(Tables 4-3, 4-4, C-1, C-2). This decrease in performance was particularly evident for
the model parameters related to nonlinear elimination. This was not a surprise, since the
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larger doses resulted in concentrations well above the Km, thereby leading to saturation of
the nonlinear elimination pathway and making it more difficult to detect and characterize
the nonlinear PK. For this reason, I was interested in whether or not the nonlinearity
could be detected with FOCE-I and LAP-I at the dose levels used for the uninformative
design. In other words, would a two-compartment model with parallel nonlinear and
linear elimination be selected over a more parsimonious two-compartment model with
linear elimination at these dose levels? This question was investigated by fitting both PK
models to 50 replicate data sets simulated under the uninformative study design for the
200, 500, 600, and 800 mg dose levels. This was only done for the FOCE-I method,
since it was believed that similar results would be achieved using LAP-I. Model
selection was based on the likelihood ratio test. Since, the PK models are not strictly
hierarchical, a p value of 0.01 was used which corresponds to a change in the OFV of
13.28 at 4 degrees of freedom. In more than 70% of the runs under the 200, 500, and 600
mg dose levels, the two-compartment parallel elimination model would have been
selected over the two-compartment linear model. Under the 800 mg dose level, this
would have been the case in less than 30% of the runs. The significance of this finding is
that while FOCE-I in NONMEM was able to detect nonlinearity at the 600 mg dose level,
and that it is plausible that a two-compartment parallel elimination model would have
been selected over a simpler PK model, the results in Tables 4-3 and 4-4 show that
FOCE-I at the 600 mg dose level resulted in biased and imprecise estimates for many of
the model parameters. This scenario is also relevant, because it represents a situation
often encountered in population PK modeling where a more complex and
mechanistically-plausible PK model is not fully supported by available concentration data
due to study design limitations, and consideration must be given to using a more
parsimonious PK model.
The global sensitivity analysis produced some interesting findings. Under the
different study designs, the global sensitivity plots for the evaluated estimation methods
showed that for most of the model parameters the percent estimation errors were
insensitive to uncertainty in the values of the simulation parameters. However, FOCE-I,
LAP-I, and Bayesian MCMC with uninformative priors tended to be more robust to
uncertainty in the simulation values for select parameters (weight effect and the betweensubject variance for Vmax, CLL, and V2) compared to when informative Bayesian priors
were used. The global sensitivity analysis results are conditional on the degree of
uncertainty in the simulation parameter values employed in this study. Perhaps the
FOCE-I and LAP-I methods would have been less robust had broader simulation
uncertainty distributions been used for some of the parameters such as the betweensubject variances. However, the uncertainty distributions were defined so that the
sampled parameter values were realistic and representative of those reported in published
population PK analyses of therapeutic mAbs. Looking at the global sensitivity analysis
plots under the informative study design for the weight effect and the between-subject
variance for Vmax, CLL, and V2 (Figure 4-3), there were no trends in the estimation errors
when uninformative priors were used, but there were when informative priors were used.
This observation suggests that the formal inclusion of prior information influenced the
estimates for these parameters, and it also illustrates the importance of investigating the
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sensitivity of parameter estimates to different prior distributions when performing a
Bayesian analysis of population PK data.
The findings from this simulation study may be of value to pharmacometricians
performing population PK analyses of therapeutic mAbs. The acceptable performance of
the FOCE-I, LAP-I, and Bayesian MCMC estimation methods under the informative
study design suggests that if sufficient concentration-time data is available to adequately
characterize the nonlinear elimination of the mAb, then any one of these estimation
methods would be suitable for the population PK analysis. The choice then of one
estimation method over another would depend on other factors such as available
computing resources and familiarity with the methods. However, as often encountered in
drug development, concentration-time data may only be available from clinical studies
where limitations in the study design make it difficult to detect and characterize the
nonlinear elimination of the therapeutic mAb. As discussed in Chapter 1, these clinical
study design limitations are often due to the doses (concentrations) studied, because the
doses (which may be clinically relevant) result in concentrations that are high enough to
saturate the nonlinear target-mediated elimination of the therapeutic mAb. For example,
nonlinear elimination has been observed for efalizumab and trastuzumab and attributed to
saturable target-mediated elimination (33, 35, 79, 82), but population PK analyses of the
two mAbs were able to adequately describe their PK using a compartmental model with
linear elimination (33, 46). Based on PK data from dose escalation studies of efalizumab
(35) and trastuzumab (82), the doses of these mAbs investigated in the aforementioned
population PK analyses may have resulted in steady-state concentrations where targetmediated clearance was saturated, and thus the use of a PK model with linear elimination
was warranted. In this study, the estimation methods were evaluated under similar
conditions with the uninformative study designs where concentration data was only
available from a single dose level, and the dose levels selected resulted in concentrations
that were generally above the Km. Under a less-than-optimal study design, such as the
uninformative 600 mg dose design, consideration should first be given to what the
population PK model is to be used for. If the model is to be used for
describing/predicting concentrations at doses where the nonlinear elimination pathway is
at or near saturation, then using a PK model with linear elimination would be a
reasonable approach as the nonsaturable Fc-mediated elimination pathway becomes the
major determinant of the mAb clearance (Chapter 1, Figure 1-2B). In this case, the use
of the FOCE or LAP estimation methods in NONMEM would likely be sufficient.
However, if for example the population PK model is to be used to predict concentrations
at lower doses, then the findings under the uninformative 600 mg study design would
suggest that one may want to consider the use of a Bayesian MCMC method with
informative priors given its improved performance over the NONMEM estimation
methods. As shown in Figures 4-8 through 4-10, the analysis-derived predictions for
FOCE-I, LAP-I, and Bayesian MCMC with informative priors were quite similar to the
predictions based on the true model at the 600 mg dose level. However, at lower doses,
the analysis-derived predictions for FOCE-I and LAP-I deviated further from the true
model than the analysis-derived predictions for Bayesian MCMC with informative priors.
As discussed in Chapter 1 and implemented in this study, the findings from published
population PK analyses of therapeutic mAbs could be used as prior information given
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their similar population PK characteristics. Prior information on the PK of the
therapeutic mAb of interest could also be available and used in defining the priors.
The population PK analysis of cetuximab in Chapter 3 found that the PK of
cetuximab was best described using a two-compartment model with nonlinear
elimination. The final population PK model was able to adequately describe the
nonlinear PK of cetuximab at the clinically approved dosage regimen, and the PK
parameter estimates were in line with a previous population PK analysis of cetuximab
conducted for regulatory purposes which also used the same structural model as in my
study (109, 140). The population estimates for Vmax and Km were also in agreement with
findings from other PK analyses of cetuximab (123, 139). Concentration data from
multiple dose groups was available in the cetuximab population PK analysis conducted
for regulatory purposes (109, 140) and in the aforementioned cetuximab PK studies (123,
139). Various issues were encountered during the cetuximab analysis which were likely
the result of attempting to describe its nonlinear elimination. This difficulty was likely
due in part to limitations of the clinical study designs, which included the lack of dose
escalation concentration data and that the majority of patients provided only peak and
trough concentrations. Given the relative uninformativeness of the data that was
available for the cetuximab population PK analysis (particularly the single dose level
study designs), the results from the current study suggest that the inclusion of prior
information within the context of a full Bayesian analysis may have benefited the
cetuximab analysis. Prior information was available from a number of sources that could
have been used in the cetuximab population PK analysis. For example, the results from
the previously conducted population PK analysis of cetuximab could have been used
(109, 140), and parameter estimates for Vmax and/or Km had also been reported in other
PK studies of cetuximab (80, 123, 139). In addition, it would have been a reasonable
approach to have also used the published results from population PK analyses of other
therapeutic mAbs as prior information in the cetuximab analysis.
In summary, I conducted a simulation study to compare the parameter estimation
performance of the FO, FOCE-I, and LAP-I methods in NONMEM and a full Bayesian
MCMC method in WinBUGS when applied to population PK modeling of therapeutic
mAbs with nonlinear PK. The Bayesian MCMC method was evaluated with both
uninformative and informative priors. The estimation methods were evaluated under a
dose-ranging design and four different single dose level designs at different dose levels.
When sufficient data was available to characterize the nonlinear PK of the therapeutic
mAb, as in the case of the dose-ranging design, the estimation performance of the FOCEI, LAP-I, and Bayesian MCMC (with both sets of priors) methods were comparable and
demonstrated acceptable bias and precision of the parameter estimates. Under a lessthan-optimal study design, the formal inclusion of prior information with the Bayesian
MCMC method provided a clear performance advantage over the other methods.
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CHAPTER 5. SUMMARY OF DISSERTATION RESEARCH

Over the past two decades, there has been an increase in the research and
development and therapeutic application of mAbs. Currently, there are over 20 mAb
products (i.e. antibodies, antibody fragments, or antibody-conjugates) approved by the
FDA for therapeutic use in areas such as oncology, immunology, ophthalmology,
cardiovascular disease, and infectious disease. It is estimated that half of all current
projects in new drug development are biologics, with mAbs being the predominant class
of biologics under clinical study (1). In 2008, it was reported that there were over 200
mAbs undergoing clinical study (2). One likely reason for the continued success of the
clinical development of mAbs is the application and integration of PK and PD concepts
in all stages of pre-clinical and clinical drug development (3, 4). One application of
PK/PD concepts in drug development is population PK, which attempts to quantify the
typical disposition characteristics and sources of PK variability (such as between-subject,
within-subject, and inter-occasion variability) within study populations. Population PK
also attempts to identify and quantify the impact of covariates on systemic drug exposure,
and assess their potential implications for clinical dosing. The general theme of my
dissertation research was population PK modeling of therapeutic mAbs, which focused
on the population PK modeling of cetuximab (Chapter 3), and the evaluation of different
estimation methods for population PK modeling of therapeutic mAbs with nonlinear PK
characteristics (Chapter 4).
A large number of population PK analyses of therapeutic mAbs have been
published in the scientific literature. In Chapter 1, I summarized the findings from these
population PK studies and related the findings to the general PK and structural
characteristics of therapeutic mAbs. A two-compartment model was used in the majority
of the population analyses to describe the disposition of the mAb. Population estimates
for V1 and V2 were typically small with a median (range) of 3.1 L (2.4-5.5) and 2.8 L
(1.3-6.8), respectively. The estimated between-subject variability in V1 was usually
moderate with a median (range) of 28 %CV (12-84). Between-subject variability in other
distribution related parameters such as V2 and Q were often not estimated. Although the
most frequent PK models used in the population analyses were models with linear
elimination, other models with nonlinear or parallel linear and nonlinear elimination
pathways were also applied as many therapeutic mAbs are eliminated via saturable
target-mediated mechanisms. Population estimates of Vmax and Km, the parameters
characterizing Michaelis-Menten type saturable clearance pathways, varied considerably
among the different therapeutic mAbs. However, estimates for CLT in mAbs with linear
elimination characteristics and for CLL in mAbs with parallel linear and nonlinear
elimination were quite similar among the different mAbs, and typically ranged from
around 0.2-0.5 L/day, which is relatively close to the estimated CL of endogenous IgG of
0.21 L/day. The between-subject variability in Vmax, CLT, and CLL was moderate to
large with estimates ranging from 15-65 %CV. Measures of body size were the most
commonly identified covariates found to influence the PK of therapeutic mAbs. My
literature review found that many characteristics of the population PK of currently used
therapeutic mAbs are quite similar despite differences in their pharmacologic targets and
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studied patient populations. These similarities are likely in part due to general structural
features that are shared among most therapeutic mAbs as IgG molecules such as a
functional human Fc region. One could hypothesize that target-binding specific PK
parameters such as Vmax and Km are likely to be influenced by the interaction between a
given therapeutic mAb and its target, and thus show high variability among different
mAbs, while the differences among parameters such as CLL, V1, V2, and Q that are
thought to be largely affected by the general structural features of mAbs are minimal.
Given the similar population PK characteristics of therapeutic mAbs, I proposed in this
review that the results from the population PK analyses could serve a practical purpose
and be used to construct informative priors for a Bayesian data analysis or for
constructing parameter uncertainty distributions to simulate PK data for a prototypical
therapeutic mAb. These ideas were put into practice in Chapter 4 where the estimation
methods in NONMEM and WinBUGS were evaluated.
A therapeutic mAb that was of particular interest in my dissertation research was
cetuximab, which is directed against EGFR and is indicated in the treatment of SCCHN.
In Chapter 3, I performed a population PK analysis of cetuximab using nonlinear mixed
effects modeling and the software NONMEM (version V). I hypothesized that nonlinear
mixed effects modeling could be used to develop a population PK model that could
adequately predict the systemic exposure of cetuximab in patients with SCCHN.
Furthermore, I hypothesized that covariates could be identified that are significant
predictors for cetuximab systemic exposure. A total of 912 cetuximab concentrations
were available from 143 patients with recurrent and/or metastatic SCCHN enrolled in two
phase I/II studies. The PK of cetuximab was best described by a two-compartment model
with Michaelis-Menten type saturable elimination. Mean population estimates (betweensubject variability, %CV) of the PK parameters were: Vmax 4.38 mg/hr (15.4%), Km 74
μg/ml, V1 2.83 L (18.6%), V2 2.43 L (56.4%), and Q 0.103 L/hr (97.2%). Covariates that
were identified included IBW and WBC count as predictors of Vmax, and WGT as a
predictor of V1. The findings of the population PK analysis suggest that clinical dose
adjustments beyond the approved BSA-based dosing of cetuximab may be warranted in
patients with extreme deviations of their actual body weight from IBW. Agreement
between simulated and measured concentrations for up to 43 weeks of therapy indicated
that the final population PK model was able to adequately describe the nonlinear PK of
cetuximab in patients with SCCHN at the currently approved dosage regimen, and that
the cetuximab PK parameters remained constant during prolonged therapy.
During the cetuximab population PK analysis, a number of issues and challenges
were encountered which were likely the result of an attempt to describe the nonlinear
elimination of cetuximab. The difficulty characterizing the nonlinear PK of cetuximab
was likely due to limitations of the clinical study designs, which included the lack of dose
escalation data and the majority of patients provided only peak and trough
concentrations. However, the difficulty may also have been due to the use of the FOCE
estimation method throughout the analysis. It is known that FOCE, in addition to the FO
and LAP estimation methods in NONMEM, can be inaccurate when dealing with highly
nonlinear models such as the model with nonlinear elimination used to describe the PK of
cetuximab (112). Therefore, it was questioned whether or not the use of another
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population estimation method in the cetuximab analysis would have led to more accurate
parameter estimates and better characterization of the nonlinear PK of cetuximab. I was
particularly interested in how a full Bayesian analysis using MCMC methods such as that
implemented in the software WinBUGS would have performed. Unlike the
aforementioned estimation methods in NONMEM, Bayesian MCMC methods do not rely
on analytical approximations of the nonlinear mixed effects model, but instead use Monte
Carlo integration techniques to obtain parameter estimates for the exact model (115, 116).
Bayesian MCMC methods also allow one to include prior information about the model
parameters in the Bayesian hierarchical model by using informative priors.
The question of how well other population estimation methods would have
performed in evaluating the nonlinear elimination of cetuximab is also relevant for other
therapeutic mAbs. Nonlinear elimination is a common characteristic of the PK of
therapeutic mAbs (6, 8), and accordingly, PK models with nonlinear elimination were
used in almost half of the population PK analyses of therapeutic mAbs published in the
scientific literature (Chapter 1). In addition, similar difficulties encountered during the
cetuximab analysis were also reported in population PK analyses of other therapeutic
mAbs (Chapter 1). The challenge with detecting and characterizing nonlinear PK is not
only dependent on the study design, but also on the estimation method used for the
population PK analysis (163). However, little work has been done so far evaluating
population estimation methods using PK models that are representative of the typical
disposition characteristics of therapeutic mAbs, as most method comparison studies used
a one-compartment model with linear elimination for comparison (142-147).
I hypothesized that compared to the FO, FOCE-I, and LAP-I methods in
NONMEM, other parameter estimation methods that avoid linearization of the nonlinear
mixed effects model such as Bayesian MCMC, would lead to more accurate parameter
estimates and better characterization of the nonlinear PK encountered with therapeutic
mAbs such as cetuximab. I conducted a simulation study to compare the parameter
estimation performance of the FO, FOCE-I, and LAP-I methods in NONMEM and a
Bayesian MCMC method in WinBUGS when applied to population PK modeling of
therapeutic mAbs with nonlinear PK. The Bayesian MCMC method was evaluated with
uninformative and informative priors, which were obtained from the literature. To my
knowledge, this was the first study to have systematically evaluated the formal inclusion
of prior information with Bayesian MCMC methods when applied to population PK
modeling. The uncertainty distributions for the population PK model parameters were
also obtained from the literature in order to simulate concentration data for a prototypical
therapeutic mAb. The estimation methods were evaluated under a dose-ranging design
(informative study design) and four different single dose level designs at different dose
levels (uninformative study designs). In my analysis, I addressed the following three
subhypotheses: 1) under all study designs the FO method would be less accurate and
precise compared to the other estimation methods; 2) when sufficient data is available to
characterize the nonlinear PK of the therapeutic mAb, as in the case of the informative
design, the estimation performance of FOCE-I, LAP-I, and Bayesian MCMC (with both
sets of priors) would be adequate and comparable; and 3) under the less-than-optimal
(uninformative) study designs there would be a decline in the estimation performance of
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the FOCE-I and LAP-I methods, while the formal inclusion of prior information with the
Bayesian MCMC method would provide a clear performance advantage over the other
methods.
Under all study designs, the FO method generally produced larger bias and lower
precision for the model parameters compared to the other estimation methods.
Comparison of the estimation performance of the methods in NONMEM and WinBUGS
was limited to the informative and uninformative 600 mg dose level study designs due to
prolonged run times with WinBUGS. Under the informative study design, bias and
precision for all model parameters was less than ±25% and 52%, respectively, for FOCEI, LAP-I, and Bayesian MCMC with both sets of priors. Under the uninformative 600 mg
dose level study design, the estimation performance of FOCE-I and LAP-I decreased as
bias and precision for many of the model parameters, in particular those related to
nonlinear elimination, significantly increased to ±40-173% and 53-173%, respectively,
while Bayesian MCMC with informative priors produced results that were comparable to
those under the informative study design.
Given the relative uninformativeness of the data that was available for the
cetuximab population PK analysis, the results from the estimation method comparison
study suggested that the inclusion of prior information within the context of a full
Bayesian analysis may have benefited the cetuximab analysis. Prior information was
available from a number of sources that could have been used in the cetuximab
population PK analysis. For example, the results from a previously conducted population
PK analysis of cetuximab could have been used (109, 140), and parameter estimates for
Vmax and/or Km had also been reported in prior PK studies of cetuximab (80, 123, 139).
In addition, it would have been a reasonable approach to have also used the published
results from population PK analyses of other therapeutic mAbs as prior information given
their similar population PK characteristics.
To visualize the potential application of the results from the estimation method
comparison study, consider a population PK analysis of a prototypical therapeutic mAb
that exhibits nonlinear PK due to saturable target-mediated elimination mechanisms. If
sufficient concentration data is available to adequately characterize the nonlinear
elimination of the mAb, then the adequate performance of the FOCE-I, LAP-I, and
Bayesian MCMC estimation methods under the informative study design would suggest
that any one of these estimation methods would be suitable for the population PK
analysis. The choice then of one estimation method over another would depend on other
factors such as available computing resources and familiarity with the methods.
However, as frequently encountered in drug development, consider that concentration
data is only available from a less-than-optimal study design such as the uninformative
600 mg dose level design used in the method comparison study, where the dose results in
concentrations that are high enough to saturate the nonlinear target-mediated elimination
of the mAb. In this case, consideration should first be given to what the population PK
model is to be used for. If the model is to be used for describing/predicting
concentrations at doses where the nonlinear elimination pathway is at or near saturation,
then using a PK model with linear elimination would be a reasonable approach as the
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nonsaturable Fc-mediated elimination pathway becomes the major determinant of the
mAb clearance. In this case, the use of the FOCE or LAP estimation methods in
NONMEM would likely be sufficient. However, if for example, the population PK
model is to be used to predict concentrations at lower doses, then the findings under the
uninformative 600 mg study design would suggest that one may want to consider the use
of a Bayesian MCMC method with informative priors given the superior estimation
performance over the NONMEM estimation methods.
In summary, the general theme of my dissertation research was population PK
modeling of therapeutic mAbs. My research work began with a population PK analysis
of cetuximab in patients with SCCHN. The challenges and issues encountered during the
analysis led me to investigate the estimation performance of the FO, FOCE-I, and LAP-I
methods in NONMEM and a Bayesian MCMC method (with both uninformative and
informative priors) in WinBUGS when applied to population PK modeling of therapeutic
mAbs with nonlinear PK, and to delineate scenarios in which one estimation method may
be superior to the others. The findings from this work should be of value to
pharmacometricians who are involved in population PK modeling of therapeutic mAbs.
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A-1. NONMEM control stream for the final cetuximab population pharmacokinetic
model.

$PROBLEM **FINAL MODEL**
$INPUT C PTID=DROP ID DAT1=DROP TIME AMT RATE DV MDV VIS=DROP
WEEK=DROP STDY SITE=DROP SEX AGE=DROP ETHN=DROP HGT=DROP
WGT IBW BSA=DROP CBSA=DROP BUN=DROP SRCR=DROP CRCL=DROP
ADJC=DROP RENL=DROP TBIL=DROP ALB=DROP AST=DROP ALT=DROP
KSKY=DROP EF=DROP EFNA=DROP EGFR=DROP HACA=DROP FU=DROP
FUD=DROP PLTM=DROP PLTD=DROP CHEM=DROP WBC MONO=DROP
BUNM=DROP CRCM=DROP TBLM=DROP ALBM=DROP ALTM=DROP
WBCM=DROP
$DATA 8WK_LN_CTXDTB_medians.CSV IGNORE=C
$ABB COMRES=6
$SUBROUTINE ADVAN6 TRANS1 TOL=6 INFN=MYINFN.FOR
$MODEL NPAR=5 NCOMP=2 COMP=(CENTRAL DEFOBSERVATION DEFDOSE)
COMP=(PERIPH)
$PK
TVVMAX=THETA(1)*(1+THETA(6)*(IBW-64)+THETA(8)*(WBC-6.8))
VMAX=TVVMAX*EXP(ETA(1))
KM=THETA(2)
TVV1=THETA(3)*(1+THETA(7)*(WGT-60))
V1=TVV1*EXP(ETA(2))
TVV2=THETA(4)
V2=TVV2*EXP(ETA(3))
Q=THETA(5)*EXP(ETA(4))
S1=V1
$DES
C1=A(1)/V1
C2=A(2)/V2
DADT(1)=-VMAX*C1/(KM+C1)-(Q*C1)+(Q*C2)
DADT(2)=(Q*C1)-(Q*C2)
$ERROR
CALLFL=0
IF (F.LE.0) THEN
IPRED=-5
ELSE
IPRED=LOG(F)
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ENDIF
IRES=DV-IPRED
IWRES=IRES/IPRED
IF (STDY.EQ.8) THEN
Y=IPRED+ERR(1)
ELSE
Y=IPRED+ERR(2)
ENDIF
"LAST
"COM(1)=G(1,1)
"COM(2)=G(2,1)
"COM(3)=G(3,1)
"COM(4)=G(4,1)
"COM(5)=HH(1,1)
"COM(6)=HH(2,1)
$THETA
(1.5, 4.22, 7.5)
(35, 71.6, 150)
(1.3, 2.72, 5)
(1.1, 2.43, 5)
(0.001, 0.095, 0.15)
(0.001, 0.0115, 0.05)
(0.001, 0.0080, 0.05)
(0.001, 0.0240, 0.075)

;VMAX (mg/hr)
;KM (μg/mL)
;V1 (L)
;V2 (L)
;Q (L/hr)
;IBW(l)~Vmax
;WGT(l)~V1
;WBC(l)~Vmax

$OMEGA .025
$OMEGA .032
$OMEGA .29
$OMEGA .975

;VMAX
;V1
;V2
;Q

$SIGMA
0.030
0.050

;STUDY 08
;STUDY 16

$ESTIMATION NOABORT MAXEVAL=9999 PRINT=5 METHOD=1
$COVARIANCE PRINT=E
$TABLE ID TIME IPRED IWRES NOPRINT ONEHEADER FILE=sdtab1077
$TABLE ID VMAX KM V1 V2 Q NOPRINT ONEHEADER FILE=patab1077
$TABLE ID IBW WGT WBC NOPRINT ONEHEADER FILE=cotab1077
$TABLE ID SEX NOPRINT ONEHEADER FILE=catab1077
$TABLE ID COM(1)=G11 COM(2)=G21 COM(3)=G31 COM(4)=G41 COM(5)=H11
COM(6)=H21 IPRED MDV NOPRINT ONEHEADER FILE=cwtab1077
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A-2.

NONMEM run output for the final cetuximab population pharmacokinetic model.

1NONLINEAR MIXED EFFECTS MODEL PROGRAM (NONMEM)
DOUBLE PRECISION NONMEM VERSION V LEVEL 1.1
DEVELOPED AND PROGRAMMED BY STUART BEAL AND LEWIS SHEINER
PROBLEM NO.:
1
**FINAL MODEL**
0DATA CHECKOUT RUN:
NO
DATA SET LOCATED ON UNIT NO.:
2
THIS UNIT TO BE REWOUND:
NO
NO. OF DATA RECS IN DATA SET: 1849
NO. OF DATA ITEMS IN DATA SET:
13
ID DATA ITEM IS DATA ITEM NO.:
2
DEP VARIABLE IS DATA ITEM NO.:
6
MDV DATA ITEM IS DATA ITEM NO.: 7
0INDICES PASSED TO SUBROUTINE PRED:
13 3 4 5 0 0 0 0 0
0 0
0LABELS FOR DATA ITEMS:
C
ID TIME AMT RATE DV MDV STDY SEX
WGT IBW WBC EVID
0(NONBLANK) LABELS FOR PRED-DEFINED ITEMS:
G11 G21 G31
G41 H11 H21 VMAX KM V1
V2
Q IPRE IWRE
0FORMAT FOR DATA:
(E2.0,E4.0,E8.0,2E7.0,E12.0,E2.0,E3.0,E2.0,E6.0,E7.0,E5.0,1F2.0)
TOT. NO. OF OBS RECS:
912
TOT. NO. OF INDIVIDUALS: 143
0LENGTH OF THETA: 8
0OMEGA HAS SIMPLE DIAGONAL FORM WITH DIMENSION: 4
0SIGMA HAS SIMPLE DIAGONAL FORM WITH DIMENSION: 2
0INITIAL ESTIMATE OF THETA:
LOWER BOUND INITIAL EST UPPER BOUND
0.1500E+01 0.4220E+01 0.7500E+01
0.3500E+02 0.7160E+02 0.1500E+03
0.1300E+01 0.2720E+01 0.5000E+01
0.1100E+01 0.2430E+01 0.5000E+01
0.1000E-02 0.9500E-01 0.1500E+00
0.1000E-02 0.1150E-01 0.5000E-01
0.1000E-02 0.8000E-02 0.5000E-01
0.1000E-02 0.2400E-01 0.7500E-01
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0INITIAL ESTIMATE OF OMEGA:
0.2500E-01
0.0000E+00 0.3200E-01
0.0000E+00 0.0000E+00 0.2900E+00
0.0000E+00 0.0000E+00 0.0000E+00 0.9750E+00
0INITIAL ESTIMATE OF SIGMA:
0.3000E-01
0.0000E+00 0.5000E-01
0ESTIMATION STEP OMITTED:
NO
CONDITIONAL ESTIMATES USED:
YES
CENTERED ETA:
NO
EPS-ETA INTERACTION:
NO
LAPLACIAN OBJ. FUNC.:
NO
NO. OF FUNCT. EVALS. ALLOWED:
9999
NO. OF SIG. FIGURES REQUIRED:
3
INTERMEDIATE PRINTOUT:
YES
ESTIMATE OUTPUT TO MSF:
NO
ABORT WITH PRED EXIT CODE 1:
NO
0COVARIANCE STEP OMITTED: NO
EIGENVLS. PRINTED:
YES
SPECIAL COMPUTATION: NO
COMPRESSED FORMAT: NO
0TABLES STEP OMITTED:
NO
NO. OF TABLES:
5
0-- TABLE 1 -PRINTED:
NO
HEADERS:
ONE
FILE TO BE FORWARDED:
NO
0USER-CHOSEN ITEMS
IN THE ORDER THEY WILL APPEAR IN THE TABLE:
ID TIME IPRE IWRE
0-- TABLE 2 -PRINTED:
NO
HEADERS:
ONE
FILE TO BE FORWARDED:
NO
0USER-CHOSEN ITEMS
IN THE ORDER THEY WILL APPEAR IN THE TABLE:
ID VMAX KM V1 V2
Q
0-- TABLE 3 -PRINTED:
NO
HEADERS:
ONE
FILE TO BE FORWARDED:
NO
0USER-CHOSEN ITEMS
IN THE ORDER THEY WILL APPEAR IN THE TABLE:
ID IBW WGT WBC
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0-- TABLE 4 -PRINTED:
NO
HEADERS:
ONE
FILE TO BE FORWARDED:
NO
0USER-CHOSEN ITEMS
IN THE ORDER THEY WILL APPEAR IN THE TABLE:
ID SEX
0-- TABLE 5 -PRINTED:
NO
HEADERS:
ONE
FILE TO BE FORWARDED:
NO
0USER-CHOSEN ITEMS
IN THE ORDER THEY WILL APPEAR IN THE TABLE:
ID G11 G21 G31 G41 H11 H21 IPRE MDV
1DOUBLE PRECISION PREDPP VERSION IV LEVEL 1.1
GENERAL NONLINEAR KINETICS MODEL (ADVAN6)
0MODEL SUBROUTINE USER-SUPPLIED - ID NO. 9999
0MAXIMUM NO. OF BASIC PK PARAMETERS: 5
0COMPARTMENT ATTRIBUTES
COMPT. NO. FUNCTION INITIAL ON/OFF DOSE
DEFAULT DEFAULT
STATUS ALLOWED ALLOWED FOR DOSE FOR OBS.
1
CENTRAL ON
YES
YES
YES
YES
2
PERIPH
ON
YES
YES
NO
NO
3
OUTPUT
OFF
YES
NO
NO
NO
0NRD VALUE FROM SUBROUTINE TOL: 6
1
ADDITIONAL PK PARAMETERS - ASSIGNMENT OF ROWS IN GG
COMPT. NO.
INDICES
SCALE BIOAVAIL. ZERO-ORDER ZERO-ORDER ABSORB
FRACTION RATE
DURATION LAG
1
6
*
*
*
*
2
*
*
*
*
*
3
*
- PARAMETER IS NOT ALLOWED FOR THIS MODEL
* PARAMETER IS NOT SUPPLIED BY PK SUBROUTINE;
WILL DEFAULT TO ONE IF APPLICABLE
0DATA ITEM INDICES USED BY PRED ARE:
EVENT ID DATA ITEM IS DATA ITEM NO.:
13
TIME DATA ITEM IS DATA ITEM NO.:
3
DOSE AMOUNT DATA ITEM IS DATA ITEM NO.:
4
DOSE RATE DATA ITEM IS DATA ITEM NO.:
5
0PK SUBROUTINE CALLED WITH EVERY EVENT RECORD.
PK SUBROUTINE NOT CALLED AT NONEVENT (ADDITIONAL OR LAGGED)
DOSE TIMES.
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0DURING SIMULATION, ERROR SUBROUTINE CALLED WITH EVERY EVENT
RECORD.
OTHERWISE, ERROR SUBROUTINE CALLED ONLY WITH OBSERVATION
EVENTS.
0DES SUBROUTINE USES COMPACT STORAGE MODE
1
MONITORING OF SEARCH:
0ITERATION NO.: 0 OBJECTIVE VALUE: -0.1720E+04 NO. OF FUNC. EVALS.:12
CUMULATIVE NO. OF FUNC. EVALS.: 12
PARAMETER: 0.1000E+00 0.1000E+00 0.1000E+00 0.1000E+00 0.1000E+00
0.1000E+00 0.1000E+00 0.1000E+00 0.1000E+00 0.1000E+00
0.1000E+00 0.1000E+00 0.1000E+00 0.1000E+00
GRADIENT: -0.1987E+04 0.7020E+03 -0.1821E+04 -0.7369E+02 -0.1583E+03
0.1211E+03 -0.3783E+02 0.6401E+02 0.1225E+03 0.6147E+02
0.3547E+02 0.5211E+02 0.2233E+04 0.3586E+03
0ITERATION NO.: 5 OBJECTIVE VALUE: -0.1734E+04 NO. OF FUNC. EVALS.:16
CUMULATIVE NO. OF FUNC. EVALS.: 95
PARAMETER: 0.1022E+00 0.1018E+00 0.1111E+00 0.1004E+00 0.1054E+00
0.9592E-01 0.1017E+00 0.9341E-01 0.9685E-01 0.1023E+00
0.9986E-01 0.9828E-01 0.7662E-01 0.9383E-01
GRADIENT: -0.2774E+03 0.1573E+03 0.2254E+04 0.5423E+02 0.1088E+03 –
0.1481E+02 -0.5559E+01 0.2991E+02 -0.5791E+02 -0.2172E+03
-0.5601E+02 -0.2452E+02 -0.2079E+04 -0.1212E+03
0ITERATION NO.:10 OBJECTIVE VALUE: -0.1734E+04 NO. OF FUNC. EVALS.:28
CUMULATIVE NO. OF FUNC. EVALS.: 193
PARAMETER: 0.1023E+00 0.1018E+00 0.1107E+00 0.1021E+00 0.1135E+00
0.9619E-01 0.1030E+00 0.9554E-01 0.9668E-01 0.1037E+00
0.1026E+00 0.9905E-01 0.7667E-01 0.9333E-01
GRADIENT: -0.3024E+03 0.1401E+03 0.2190E+04 0.6069E+02 0.1494E+03 –
0.2381E+01 0.9320E+01 0.9397E+02 -0.5406E+02 -0.1898E+03
-0.4180E+02 -0.3083E+02 -0.2064E+04 -0.1451E+03
0ITERATION NO.: 15 OBJECTIVE VALUE: -0.1735E+04 NO. OF FUNC. EVALS.:24
CUMULATIVE NO. OF FUNC. EVALS.: 329
PARAMETER: 0.1107E+00 0.1230E+00 0.1108E+00 0.9981E-01 0.1108E+00
0.9788E-01 0.9636E-01 0.9667E-01 0.1018E+00 0.1054E+00
0.1069E+00 0.1026E+00 0.7697E-01 0.9319E-01
GRADIENT: -0.3194E+03 0.1718E+03 0.2123E+04 0.4061E+02 0.1482E+03
0.1371E+02 -0.6102E+02 0.9505E+02 -0.3377E+02 -0.1517E+03
-0.2690E+02 -0.1610E+02 -0.1952E+04 -0.1347E+03
0ITERATION NO.: 20 OBJECTIVE VALUE: -0.1749E+04 NO. OF FUNC. EVALS.:23
CUMULATIVE NO. OF FUNC. EVALS.: 445
PARAMETER: 0.1035E+00 0.1037E+00 0.1044E+00 0.1001E+00 0.1064E+00
0.9633E-01 0.1022E+00 0.9394E-01 0.9712E-01 0.1039E+00
0.1045E+00 0.9996E-01 0.8401E-01 0.9484E-01
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GRADIENT: -0.5994E+01 0.8684E+00 -0.1413E+02 0.7832E+00 -0.1302E+01 –
0.1207E+01 -0.7490E+00 -0.9671E-01 0.5682E+00 -0.2083E+01
-0.2933E+00 0.1312E+02 0.4625E+01 -0.1651E+01
0ITERATION NO.:25 OBJECTIVE VALUE: -0.1749E+04 NO. OF FUNC. EVALS.:23
CUMULATIVE NO. OF FUNC. EVALS.: 561
PARAMETER: 0.1035E+00 0.1038E+00 0.1045E+00 0.1002E+00 0.1063E+00
0.9638E-01 0.1023E+00 0.9393E-01 0.9711E-01 0.1040E+00
0.1046E+00 0.9842E-01 0.8402E-01 0.9488E-01
GRADIENT: -0.1407E+00 0.2594E+00 -0.1476E+00 0.5952E-01 0.1299E+00
0.9197E-01 0.1468E+00 -0.4645E-01 0.8486E-01 -0.3774E-01
-0.2707E-01 0.9374E-01 0.6367E-02 -0.1270E+00
0ITERATION NO.: 26 OBJECTIVE VALUE: -0.1749E+04 NO. OF FUNC. EVALS.: 0
CUMULATIVE NO. OF FUNC. EVALS.: 561
PARAMETER: 0.1035E+00 0.1038E+00 0.1045E+00 0.1002E+00 0.1063E+00
0.9638E-01 0.1023E+00 0.9393E-01 0.9711E-01 0.1040E+00
0.1046E+00 0.9842E-01 0.8402E-01 0.9488E-01
GRADIENT: -0.1407E+00 0.2594E+00 -0.1476E+00 0.5952E-01 0.1299E+00
0.9197E-01 0.1468E+00 -0.4645E-01 0.8486E-01 -0.3774E-01
-0.2707E-01 0.9374E-01 0.6367E-02 -0.1270E+00
0MINIMIZATION SUCCESSFUL
NO. OF FUNCTION EVALUATIONS USED: 561
NO. OF SIG. DIGITS IN FINAL EST.:
3.4
ETABAR IS THE ARITHMETIC MEAN OF THE ETA-ESTIMATES,
AND THE P-VALUE IS GIVEN FOR THE NULL HYPOTHESIS THAT THE TRUE
MEAN IS 0.
ETABAR: 0.13E-02

-0.11E-01

-0.29E-01

-0.95E-02

P VAL.: 0.90E+00
0.34E+00 0.22E+00
0.82E+00
0R MATRIX ALGORITHMICALLY NON-POSITIVE-SEMIDEFINITE
BUT NONSINGULAR
0COVARIANCE STEP ABORTED

************************************************************************
MINIMUM VALUE OF OBJECTIVE FUNCTION
************************************************************************
-1749.176
************************************************************************
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************************************************************************
FINAL PARAMETER ESTIMATE
************************************************************************
THETA - VECTOR OF FIXED EFFECTS PARAMETERS *********
TH 1

TH 2

TH 3

TH 4

TH 5

TH 6

TH 7

TH 8

4.38E+00 7.40E+01 2.83E+00 2.43E+00 1.03E-01 1.08E-02 8.30E-03 2.16E-02
OMEGA - COV MATRIX FOR RANDOM EFFECTS - ETAS ********
ETA1

ETA2

ETA3

ETA4

ETA1
+
2.36E-02
ETA2
+
0.00E+00 3.46E-02
ETA3
+
0.00E+00 0.00E+00 3.18E-01
ETA4
+
0.00E+00 0.00E+00 0.00E+00 9.44E-01
SIGMA - COV MATRIX FOR RANDOM EFFECTS - EPSILONS ****
EPS1

EPS2

EPS1
+
2.12E-02
EPS2
+
0.00E+00

4.50E-02
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APPENDIX B:
EXAMPLE COMPUTER CODES USED FOR THE SIMULATION AND
ESTIMATION STEPS IN CHAPTER 4

150

B-1. R script used to sample parameter values from their specified simulation prior
(uncertainty) distributions.

#Set seed for reproducibility
set.seed(48215)
rnorm(5)
#[1] 0.5228567 -2.2998926 0.6365216 -0.5349108 0.6051626
#Simulate Vmax (mg/hr) thetas from a lognormal distribution
vmax.theta.vct<-rlnorm(n=1000, meanlog=log(0.75), sdlog=0.1)
head(vmax.theta.vct)
#Convert vector of simulated Vmax thetas to dataframe; assign column name
vmax.theta<-data.frame(vmax.theta.vct)
dim(vmax.theta)
names(vmax.theta)<-"VMAX_TH"
head(vmax.theta)
#***#***#***#***#***#***#***#
#Simulate Km (mg/L) thetas from a lognormal distribution
km.theta.vct<-rlnorm(n=1000, meanlog=log(5.0), sdlog=0.1)
head(km.theta.vct)
#Convert vector of simulated Km thetas to dataframe; assign column name
km.theta<-data.frame(km.theta.vct)
dim(km.theta)
names(km.theta)<-"KM_TH"
head(km.theta)
#***#***#***#***#***#***#***#
#Read in Ln values of CLL, V1, V2, and Q thetas from 4 poppk studies
ln.cll.v1.v2.q.4mabs<-read.table("cll_v1_v2_q_ln theta_4 mabs.csv", header=T, sep=",",
as.is=T, skip=0)
ln.cll.v1.v2.q.4mabs
#Calculate correlation and covariance matrices for CLL, V1, V2, and Q
correlation<-cor(ln.cll.v1.v2.q.4mabs)
correlation
covariance<-cov(ln.cll.v1.v2.q.4mabs)
covariance
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#Export correlation and covariance matrices as .csv files
write.table(correlation, file="cll_v1_v2_q_correlation.csv", sep=",", col.names=T,
row.names=F)
write.table(covariance, file="cll_v1_v2_q_covariance.csv", sep=",", col.names=T,
row.names=F)
#Load MASS package for mvrnorm function
library(MASS)
#Create vector of means of Ln CLL, V1, V2, and Q thetas from 4 poppk studies
#Order is CLL, V1, V2, Q
mu<-c(-3.926715, 1.468283, 1.003866, -3.212994)
mu
#Simulate CLL (L/hr), V1 (L), V2 (L), and Q (L/hr) (Ln values) from multivariate
#normal distribution
multivariate.ln.vct<-mvrnorm(n=1000, mu=mu, Sigma=covariance)
head(multivariate.ln.vct)
#Convert vector of CLL, V1, V2, and Q (Ln values) thetas to dataframe;
#and assign column names
multivariate.ln<-data.frame(multivariate.ln.vct)
dim(multivariate.ln)
names(multivariate.ln)<-c("CLL_TH","V1_TH","V2_TH","Q_TH")
head(multivariate.ln)
#Convert CLL, V1, V2, and Q Ln values to normal scale
multivariate.theta<-exp(multivariate.ln)
head(multivariate.theta)
#***#***#***#***#***#***#***#
#Simulate thetas for body weight effect on Vmax, CLL, V1, and V2
#from uniform distributions; assign column names; and combine into
#one dataframe
wt.vmax.cll.vct<-runif(n=1000, min=0.4, max=1.0)
head(wt.vmax.cll.vct)
wt.vmax<-data.frame(wt.vmax.cll.vct)
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dim(wt.vmax)
names(wt.vmax)<-"WGT_VMAX"
head(wt.vmax)
wt.cll<-data.frame(wt.vmax.cll.vct)
dim(wt.cll)
names(wt.cll)<-"WGT_CLL"
head(wt.cll)
wt.v1.v2.vct<-runif(n=1000, min=0.4, max=1.0)
head(wt.v1.v2.vct)
wt.v1<-data.frame(wt.v1.v2.vct)
dim(wt.v1)
names(wt.v1)<-"WGT_V1"
head(wt.v1)
wt.v2<-data.frame(wt.v1.v2.vct)
dim(wt.v2)
names(wt.v2)<-"WGT_V2"
head(wt.v2)
wt.cov.theta<-cbind(wt.vmax, wt.cll, wt.v1, wt.v2)
dim(wt.cov.theta)
head(wt.cov.theta)
#***#***#***#***#***#***#***#
#Simulate population mean weights (kg) from lognormal distribution
wt.pop.vct<-rlnorm(n=1000, meanlog=log(72), sdlog=0.025)
head(wt.pop.vct)
#Convert vector of population mean weights to dataframe; assign column names
wt.pop.theta<-data.frame(wt.pop.vct)
dim(wt.pop.theta)
names(wt.pop.theta)<-"WT_POP"
head(wt.pop.theta)
#***#***#***#***#***#***#***#
#Simulate intersubject variances (omega^2) for Vmax and CLL from a uniform
#distribution; convert vector to dataframe and assign column names
vmax.om.vct<-runif(n=1000, min=0.0225, max=0.4225)
head(vmax.om.vct)
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vmax.om<-data.frame(vmax.om.vct)
dim(vmax.om)
names(vmax.om)<-"VMAX_OM"
head(vmax.om)
#***#***#***#***#***#***#***#
cll.om.vct<-runif(n=1000, min=0.0225, max=0.4225)
head(cll.om.vct)
cll.om<-data.frame(cll.om.vct)
dim(cll.om)
names(cll.om)<-"CLL_OM"
head(cll.om)
#***#***#***#***#***#***#***#
#Simulate intersubject variances (omega^2) for V1 and V2 from a lognormal
#distribution; convert vector to dataframe and assign column names
v1.om.vct<-rlnorm(n=1000, meanlog=log(0.0625), sdlog=0.4)
head(v1.om.vct)
v1.om<-data.frame(v1.om.vct)
dim(v1.om)
names(v1.om)<-"V1_OM"
head(v1.om)
#***#***#***#***#***#***#***#
v2.om.vct<-rlnorm(n=1000, meanlog=log(0.0625), sdlog=0.4)
head(v2.om.vct)
v2.om<-data.frame(v2.om.vct)
dim(v2.om)
names(v2.om)<-"V2_OM"
head(v2.om)
#***#***#***#***#***#***#***#
#Create vector of 1000 intersubject variances (omega^2) for weight; fix
#at a variance of 0.04, convert vector to dataframe and assign column name
wtpop.om.vct<-rep(0.04,1000)
head(wtpop.om.vct)
wtpop.om<-data.frame(wtpop.om.vct)
dim(wtpop.om)
names(wtpop.om)<-"WTPOP_OM"
head(wtpop.om)
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#***#***#***#***#***#***#***#
#Simulate residual error variance (sigma^2) from a lognormal distribution;
#convert vector to dataframe and assign column names
sigma.vct<-rlnorm(n=1000, meanlog=log(0.0225), sdlog=0.4)
head(sigma.vct)
sigma<-data.frame(sigma.vct)
dim(sigma)
names(sigma)<-"SIGMA"
head(sigma)
#***#***#***#***#***#***#***#
#Pull together dataframes into one large dataframe and export to .csv file
#Each row will contain one set of parameters to be used for each simulation
#of the data
ls()
sim<-cbind(wt.pop.theta, vmax.theta, km.theta, multivariate.theta,
wt.cov.theta, wtpop.om, vmax.om, cll.om, v1.om, v2.om, sigma)
dim(sim)
head(sim)
#Change number of sig digits in the output
simparam<-signif(sim, digits=4)
dim(simparam)
head(simparam)
write.table(simparam, file="simparam.csv", col.names=T, row.names=F, sep=",")
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B-2. Example R script (“trialsimulation.R”) used to automate creation of replicate
NONMEM control streams for simulation of the replicate data sets.

#Load MItools
library(MItools)
#setup control streams for simulation
DirName<-"/center/comp/home/nated/FOCE-I/sim/"
setwd(paste(DirName))
simparam<-read.table("simparam.csv", sep=",", header=T, skip=0, as.is=T)
dim(simparam)
head(simparam)
metaSub(
as.filename(paste(DirName,"simtemp2cnll.ctl",sep="")),
names=1:1000,
pattern=list("\\$PROBLEM[^$]*",
"\\$THETA[^$]*",
"\\$OMEGA[^$]*",
"\\$SIGMA[^$]*",
"\\$SIMULATION[^$]*",
"\\$TABLE.*"),
replacement=list(expression(paste("$PROBLEM RUN ",as.numeric(name),"
SIM","\n", sep="")),
expression(paste("$THETA
\n",paste(simparam[rownames(simparam)==name,c(1:11)],collapse="\n"),"\n",sep="")),
expression(paste("$OMEGA
\n",paste(simparam[rownames(simparam)==name,c(12:16)],collapse="\n"),"\n",sep="")),
expression(paste("$SIGMA
\n",paste(simparam[rownames(simparam)==name,17],collapse="\n"),"\n",sep="")),
expression(paste("$SIMULATION (",as.numeric(name)+12345,")
(",as.numeric(name)+6789," UNIFORM) ONLYSIMULATION","\n",sep="")),
expression(paste("$TABLE ID TIME AMT RATE DV EVID PKTR GRP WGTI
WGTP","\n","NOPRINT NOHEADER NOAPPEND
FILE=../trialdata.tmp/sim",(name),".TAB","\n",sep=""))
),
fixed=FALSE,
out=".",
suffix=".ctl"
)
#Perform Simulations
NONR(ProjectDir=DirName, NMcom="nm6amd64e.pl", b=c(1:1000),
checkrunno=F, diag=F, boot=1)

156

B-3. Example NONMEM control stream template (“simtemp2cnll.ctl”) used for
simulation of the replicate data sets. The R script in B-2 was executed using this control
stream.

$PROBLEM Control stream template for simulation of study replicates
;This will serve as the input for metaSUB, which will replace the
;thetas, omegas, sigmas, etc., with simulated parameter values.
;The substituted control stream will then be used to simulate data
;for one study (nrep=1)
$INPUT C ID TIME AMT RATE DV EVID PKTR GRP
$DATA ../studytemplate.csv IGNORE=C
$SUBROUTINE ADVAN6 TRANS1 TOL=8
$MODEL NPAR=11 NCOMP=2 COMP=(CENTRAL DEFOBSERVATION
DEFDOSE) COMP=(PERIPH)
$PK
WGTP=THETA(1)
WGTI=WGTP*EXP(ETA(1))
TVVMAX=THETA(2)*(WGTI/72)**THETA(8)
VMAX=TVVMAX*EXP(ETA(2))
KM=THETA(3)
TVCLL=THETA(4)*(WGTI/72)**THETA(9)
CLL=TVCLL*EXP(ETA(3))
TVV1=THETA(5)*(WGTI/72)**THETA(10)
V1=TVV1*EXP(ETA(4))
TVV2=THETA(6)*(WGTI/72)**THETA(11)
V2=TVV2*EXP(ETA(5))
Q=THETA(7)
S1=V1
$DES
C1=A(1)/V1
C2=A(2)/V2
DADT(1)=-VMAX*C1/(KM+C1)-(CLL*C1)-(Q*C1)+(Q*C2)
DADT(2)=(Q*C1)-(Q*C2)
$ERROR
Y=F*EXP(EPS(1))
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$THETA
72.0 ;WTPOP (KG)
0.75 ;VMAX (MG/HR)
5.0 ;KM (MG/L)
0.02 ;CLL (L/HR)
4.5 ;V1 (L)
3.0 ;V2 (L)
0.05 ;Q (L/HR)
0.7 ;WGT~VMAX
0.7 ;WGT~CLL
0.7 ;WGT~V1
0.7 ;WGT~V2
$OMEGA
0.04 ;WTPOP OM
0.04 ;VMAX OM
0.04 ;CLL OM
0.04 ;V1 OM
0.04 ;V2 OM
$SIGMA
0.04 ;EXPONENTIAL ERROR
$SIMULATION (12345) (6789 UNIFORM) ONLYSIMULATION
$TABLE ID TIME AMT RATE DV EVID PKTR GRP WGTI WGTP
NOPRINT NOHEADER NOAPPEND FILE=sim.TAB
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B-4. Example R script (“estctl_FOCEI_boot1.R”) for setting up and executing the
batch estimation runs with NONMEM.

#Load MItools
library(MItools)
#setup control streams for estimation
DirName<-"/center/comp/home/nated/FOCE-I/est/"
setwd(paste(DirName))
metaSub(
as.filename(paste(DirName,"esttemp2cnll_FOCEI_boot1.ctl",sep="")),
names=1:1000,
pattern=list("\\$PROBLEM[^$]*",
"\\$DATA[^$]*"),
replacement=list(expression(paste("$PROBLEM ESTIMATION RUN
",as.numeric(name),"\n", sep="")),
expression(paste("$DATA ../../sim/trialdata.tmp/sim", as.numeric(name), ".TAB",
"\n", sep=""))
),
fixed=FALSE,
out=".",
suffix=".ctl"
)
#Perform Estimations
NONR(ProjectDir=DirName, NMcom="nm6amd64e.pl", b=c(1:1000),
checkrunno=F, diag=F, boot=1)
rlog(b=c(1:1000), boot=1, ProjectDir=DirName, runlog=2)
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B-5. Example NONMEM control stream estimation template for the batch runs
(“esttemp2cnll_FOCEI_boot1.ctl”). The R script in B-4 was executed using this control
stream.

$PROBLEM Control stream template for estimation runs
$INPUT ID TIME AMT RATE DV EVID PKTR GRP WGTI WGTP
$DATA ../../sim/trialdata.tmp/sim#.TAB
$SUBROUTINE ADVAN6 TRANS1 TOL=8 INFN=../MItoolsboot.for
$MODEL NPAR=10 NCOMP=2 COMP=(CENTRAL DEFOBSERVATION
DEFDOSE) COMP=(PERIPH)
$PK
TVVMAX=THETA(1)*(WGTI/72)**THETA(7)
VMAX=TVVMAX*EXP(ETA(1))
KM=THETA(2)
TVCLL=THETA(3)*(WGTI/72)**THETA(8)
CLL=TVCLL*EXP(ETA(2))
TVV1=THETA(4)*(WGTI/72)**THETA(9)
V1=TVV1*EXP(ETA(3))
TVV2=THETA(5)*(WGTI/72)**THETA(10)
V2=TVV2*EXP(ETA(4))
Q=THETA(6)
S1=V1
$DES
C1=A(1)/V1
C2=A(2)/V2
DADT(1)=-VMAX*C1/(KM+C1)-(CLL*C1)-(Q*C1)+(Q*C2)
DADT(2)=(Q*C1)-(Q*C2)
$ERROR
Y=F*EXP(EPS(1))
$THETA
(0, 1.2) ;VMAX (MG/HR)
(0, 10) ;KM (MG/L)
(0, 0.03) ;CLL (L/HR)
(0, 3) ;V1 (L)
(0, 2) ;V2 (L)
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(0, 0.075) ;Q (L/HR)
0.8 ;WGT~VMAX
0.8 ;WGT~CLL
0.8 ;WGT~V1
0.8 ;WGT~V2
$OMEGA
0.16 ;VMAX OM
0.16 ;CLL OM
0.16 ;V1 OM
0.16 ;V2 OM
$SIGMA
0.16 ;EXPONENTIAL ERROR
$ESTIMATION METHOD=1 INTERACTION NOABORT MAXEVAL=9999
PRINT=5
NOTBT NOOBT NOSBT
$COVARIANCE
;END
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B-6. Section of the BUGSModelLibrary model file
(“TwoCptParallelModelRK45.odc”) specifying the differential equations for the twocompartment PK model with parallel nonlinear and linear elimination pathways.

MODULE PmetricsTwoCptParallelModelRK45;
IMPORT
PmetricsPKModels,
Math,
MathODE,
MathRungeKutta45,
Vec := LibVectors,
Solve := LibSolve;
TYPE
Equations = POINTER TO RECORD(MathODE.Equations) END;
ODEModel* = POINTER TO RECORD (PmetricsPKModels.PKModel)
END;
SSFun = POINTER TO RECORD (Solve.RouteFns)
m: PmetricsPKModels.PKModel;
p: PmetricsPKModels.ModelParameters;
amt, rate, tau: REAL;
cmt: INTEGER
END;
CONST tol = 1.0E-7;
numEq = 2;
VAR
equations: Equations;
solver: MathODE.Solver;
PROCEDURE UserDerivatives(IN theta, x: ARRAY OF REAL;
numEq: INTEGER; t: REAL; OUT dxdt: ARRAY OF REAL) ;
VAR
Vmax, Km, CLL, V1, V2, Q, C1, C2: REAL;
BEGIN
Vmax := theta[0];
CLL := theta[1];
V1 := theta[2];
V2 := theta[3];
Km := theta[4];
Q := theta[5];
ASSERT((Vmax > 0) & (Km > 0) & (CLL > 0) & (V1 > 0) & (V2 > 0) &
(Q > 0) , 20);
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C1 := x[0]/V1;
C2 := x[1]/V2;
(* Differential equations for the model excluding piecewise constant input
rates provided in the data set *)
dxdt[0] := -Vmax*C1/(Km+C1) - CLL*C1 - Q*C1 + Q*C2;
dxdt[1] := Q*C1 - Q*C2;
END UserDerivatives;
PROCEDURE (equations: Equations) Derivatives* (IN theta, x: ARRAY OF
REAL;
numEq: INTEGER; t: REAL; OUT dxdt: ARRAY OF REAL) ;
VAR
i, iRate: INTEGER;
BEGIN
UserDerivatives (theta, x, numEq, t, dxdt);
iRate := LEN(theta) - numEq;
FOR i := 0 TO numEq-1 DO
dxdt[i] := dxdt[i] + theta[iRate+i]
END;
END Derivatives;
PROCEDURE (equations: Equations) SecondDerivatives* (IN theta, x: ARRAY
OF REAL;
numEq: INTEGER; t: REAL; OUT d2xdt2: ARRAY OF REAL);
BEGIN
END SecondDerivatives;
PROCEDURE (equations: Equations) Jacobian* (IN theta, x: ARRAY OF REAL;
numEq: INTEGER; t: REAL; OUT jacob: ARRAY OF ARRAY OF REAL);
BEGIN
END Jacobian;
PROCEDURE (m: ODEModel) InitModel*;
BEGIN
m.nParameter := 10;
m.F1Index := 6;
m.tlag1Index := 8;
m.nCmt := 2;
MathRungeKutta45.Install;
solver := MathRungeKutta45.fact.New();
NEW(equations);
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solver.Init(equations, numEq);
END InitModel;
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B-7. Example R script (“1OSD_TwoCptParallelModelUP.R”) used in conjunction with
the Bayesian model with uninformative priors. This R script was used for data
management, launching WinBUGS, and analysis of the MCMC samples.

# WinBUGS PKPD Model Library: Two compartment PK model with nonlinear/linear
elimination pathways and infusion input
if(.Platform$OS.type == "windows") Sys.setenv(HOME = "c:")
#subdirectory containing the BUGS model file
#problemDir = file.path(Sys.getenv("HOME"),
"metrum/Institute/nateDirks/nate02032009")
problemDir = "C:/BUGSModelLibrary" #
toolsDir = problemDir
#toolsDir = file.path(Sys.getenv("HOME"), "bugsTools")
model.name = "TwoCptParallelModelUP_RK45" # root names of model file
bugsDir = "C:/Program Files (x86)/BlackBox Component Builder 1.5/"
#bugsDir = file.path(Sys.getenv("HOME"), "Program Files/BlackBoxWinBUGS/")
wineBin = "/usr/local/MacPorts/bin" # directory containing wine and winepath programs.
only relevant on unix or Mac OS X
setwd(problemDir)
#library(R2WinBUGS)
library(coda)
library(lattice)
source(file.path(toolsDir,"bugs.tools.R"))
source(file.path(toolsDir,"bgillespie.utilities.R"))
source(file.path(toolsDir,"myR2WinBUGS.R"))
set.seed(10271998) # not required but assures repeatable results
options(error = expression(NULL)) # prevents stopping for errors when running in batch
memory.limit(2048)
# get data files
datname = "1"
########################################################################
##############################
predata = read.table("C:/BUGSModelLibrary/OSD_Replicates/sim1.TAB", header=F,
as.is=T, skip=0) #####################
########################################################################
############################################
data = predata[ ,c(1:6,9)]
names(data) = c("subject","time","amt","rate","dv","evid","weight")
data$dv[data$evid==1] = "."
data$dv = as.numeric(data$dv)
data$addl = rep(0,nrow(data))
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data$ii = rep(0,nrow(data))
nobs = nrow(data)
start = (1:nobs)[!duplicated(data$subject)]
# create WinBUGS data set
bugsdata = list(
nobs = nobs,
nsub = length(unique(data$subject)),
start = start,
end = c(start[-1]-1,nobs),
subject = data$subject,
weight = data$weight,
time = data$time,
amt = data$amt,
rate = data$rate,
ii = data$ii,
evid = data$evid,
cmt = rep(1,nrow(data)),
addl = data$addl,
ss = rep(0,nobs),
logCobs = ifelse(data$dv <=0, NA, log(data$dv)))
# create initial estimates
bugsinit = list(
list(log.Vmax.Hat = log(1.2),
log.CLL.Hat = log(0.03),
log.V1.Hat = log(3),
log.V2.Hat = log(2),
log.Km.Hat = log(10),
log.Q.Hat = log(0.075),
WT.Vmax.Hat = 0.8,
WT.CLL.Hat = 0.8,
WT.V1.Hat = 0.8,
WT.V2.Hat = 0.8,
omega.Vmax = 0.40,
omega.CLL = 0.40,
omega.V1 = 0.40,
omega.V2 = 0.40,
sigmaC = 0.40),
list(log.Vmax.Hat = log(1.5),
log.CLL.Hat = log(0.0375),
log.V1.Hat = log(3.75),
log.V2.Hat = log(2.5),
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log.Km.Hat = log(12.5),
log.Q.Hat = log(0.094),
WT.Vmax.Hat = 1.0,
WT.CLL.Hat = 1.0,
WT.V1.Hat = 1.0,
WT.V2.Hat = 1.0,
omega.Vmax = 0.50,
omega.CLL = 0.50,
omega.V1 = 0.50,
omega.V2 = 0.50,
sigmaC = 0.50),
list(log.Vmax.Hat = log(0.9),
log.CLL.Hat = log(0.0225),
log.V1.Hat = log(2.25),
log.V2.Hat = log(1.5),
log.Km.Hat = log(7.5),
log.Q.Hat = log(0.0562),
WT.Vmax.Hat = 0.6,
WT.CLL.Hat = 0.6,
WT.V1.Hat = 0.6,
WT.V2.Hat = 0.6,
omega.Vmax = 0.30,
omega.CLL = 0.30,
omega.V1 = 0.30,
omega.V2 = 0.30,
sigmaC = 0.30)
)
# specify what variables to monitor
parameters = c("Vmax.Hat","CLL.Hat","V1.Hat","V2.Hat","Km.Hat","Q.Hat",
"WT.Vmax.Hat","WT.CLL.Hat","WT.V1.Hat","WT.V2.Hat","omega.Vmax","omega.C
LL",
"omega.V1","omega.V2","sigmaC")
# specify the variables for which you want history and density plots
parameters.to.plot = c("deviance","Vmax.Hat","CLL.Hat","V1.Hat","V2.Hat","Km.Hat",
"Q.Hat","WT.Vmax.Hat","WT.CLL.Hat","WT.V1.Hat","WT.V2.Hat",
"omega.Vmax","omega.CLL","omega.V1","omega.V2","sigmaC")
########################################################################
########################
# run WinBUGS
n.chains = 3
n.iter = 250000
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n.burnin = 25000
n.thin = 25
bugs.fit = my.bugs(data=bugsdata,inits=bugsinit,parameters.to.save=parameters,
model.file=file.path(getwd(),paste(model.name,".txt",sep="")),
n.chains=n.chains,n.iter=n.iter,n.burnin=n.burnin,n.thin=n.thin,clearWD=F,
bugs.directory = bugsDir, refresh = 1,
useWINE=(.Platform$OS.type == "unix"), WINE=file.path(wineBin,"wine"),
newWINE=(.Platform$OS.type == "unix"),
WINEPATH=file.path(wineBin,"winepath"))
# save scripts, data and results to a directory
#######################################################################
resultsdir = "C:/BUGSModelLibrary/OSD_UninformativePrior_Results"
#######################################################################
save.model(bugs.fit,paste(datname,"OSD","_",model.name,sep=""))
################################
#load(paste(model.name,"/",model.name,".fit.Rsave",sep=""))
# rename and reformat MCMC results to facilitate later calculations and plots
sims.array = bugs.fit$sims.array
posterior =
array(as.vector(sims.array),dim=c(prod(dim(sims.array)[1:2]),dim(sims.array)[3]),
dimnames=list(NULL,dimnames(sims.array)[[3]]))
########################################################################
########################
# posterior distributions of parameters
# open graphics device
pdf(file = paste(resultsdir,"/",datname,".plots.pdf",sep=""),width=6,height=6)
#################
# subset of sims.array containing selected variables
x1 = sims.array[,,unlist(sapply(c(paste("^",parameters.to.plot,"$",sep=""),
paste("^",parameters.to.plot,"\\[",sep="")),grep,x=dimnames(sims.array)[[3]]))]
# create history, density and Gelman-Rubin-Brooks plots, and a table of summary stats
ptable = parameter.plot.table(x1)
write.csv(signif(ptable,3),paste(resultsdir,"/",datname,".summary.csv",sep=""))
################
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########################################################################
########################
dev.off()
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B-8. BUGS language model for fitting the two-compartment parallel elimination PK
model using uninformative priors (“TwoCptParallelModelUP_RK45.txt”).

model
{
for(i in 1:nsub){
logtheta[i, 1] ~ dnorm(logthetaMean[i, 1], omega.inv.Vmax)
#Vmax eta
logtheta[i, 2] ~ dnorm(logthetaMean[i, 2], omega.inv.CLL)
#CLL eta
logtheta[i, 3] ~ dnorm(logthetaMean[i, 3], omega.inv.V1)
#V1 eta
logtheta[i, 4] ~ dnorm(logthetaMean[i, 4], omega.inv.V2)
#V2 eta
logtheta[i, 5] <- logthetaMean[i, 5]
#Km fixed
logtheta[i, 6] <- logthetaMean[i, 6]
#Q fixed
logthetaMean[i, 1] <log.Vmax.Hat + WT.Vmax.Hat*log(weight[start[i]]/72)

#Vmax TH

logthetaMean[i, 2] <log.CLL.Hat + WT.CLL.Hat*log(weight[start[i]]/72)

#CLL TH

logthetaMean[i, 3] <log.V1.Hat + WT.V1.Hat*log(weight[start[i]]/72)

#V1 TH

logthetaMean[i, 4] <log.V2.Hat + WT.V2.Hat*log(weight[start[i]]/72)

#V2 TH

logthetaMean[i, 5] <log.Km.Hat

#KM TH

logthetaMean[i, 6] <log.Q.Hat

#Q TH
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theta[i,7] <- 1 # F1
theta[i,8] <- 1 # F2
theta[i,9] <- 0 # tlag1
theta[i,10] <- 0 # tlag2
for(j in 1:6){
log(theta[i,j]) <- logtheta[i,j]
}
xhat[start[i]:end[i],1:2] <TwoCptParallelModelRK45(time[start[i]:end[i]], amt[start[i]:end[i]], rate[start[i]:end[i]],
ii[start[i]:end[i]], evid[start[i]:end[i]], cmt[start[i]:end[i]], addl[start[i]:end[i]],
ss[start[i]:end[i]], theta[i,])
}
for(i in 1:nobs){
logCobs[i] ~ dnorm(logCHat[i], tauC)
CHat[i] <- xhat[i,1]/theta[subject[i],3]
logCHat[i] <- log(CHat[i])
}
log.Vmax.Hat ~ dnorm(0.18, 0.0001)

#(mg/hr)

log.CLL.Hat ~ dnorm(-3.5, 0.0001)

#(L/hr)

log.V1.Hat ~ dnorm(1.1, 0.0001)

#(L)

log.V2.Hat ~ dnorm(0.69, 0.0001)

#(L)

log.Km.Hat ~ dnorm(2.3, 0.0001)

#(mg/L)

log.Q.Hat ~ dnorm(-2.6, 0.0001)

#(L/hr)

WT.Vmax.Hat ~ dunif(0, 5)
WT.CLL.Hat ~ dunif(0, 5)

171

WT.V1.Hat ~ dunif(0, 5)
WT.V2.Hat ~ dunif(0, 5)
log(Vmax.Hat) <- log.Vmax.Hat
log(CLL.Hat) <- log.CLL.Hat
log(V1.Hat) <- log.V1.Hat
log(V2.Hat) <- log.V2.Hat
log(Km.Hat) <- log.Km.Hat
log(Q.Hat) <- log.Q.Hat
tauC <- 1/(sigmaC*sigmaC)
sigmaC ~ dunif(1.0E-4,1.0E4)
omega.inv.Vmax <- 1/(omega.Vmax*omega.Vmax)
omega.Vmax ~ dunif(1.0E-4,1.0E4)
omega.inv.CLL <- 1/(omega.CLL*omega.CLL)
omega.CLL ~ dunif(1.0E-4,1.0E4)
omega.inv.V1 <- 1/(omega.V1*omega.V1)
omega.V1 ~ dunif(1.0E-4,1.0E4)
omega.inv.V2 <- 1/(omega.V2*omega.V2)
omega.V2 ~ dunif(1.0E-4,1.0E4)
}
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B-9. Example R script (“1OSD_TwoCptParallelModel_IP.R”) used in conjunction
with the Bayesian model with informative priors. This R script was used for data
management, launching WinBUGS, and analysis of the MCMC samples.

# WinBUGS PKPD Model Library: Two compartment PK model with nonlinear/linear
elimination pathways and infusion input
if(.Platform$OS.type == "windows") Sys.setenv(HOME = "c:")
#subdirectory containing the BUGS model file
#problemDir = file.path(Sys.getenv("HOME"),
"metrum/Institute/nateDirks/nate02032009")
problemDir = "C:/BUGSModelLibrary" #
toolsDir = problemDir
#toolsDir = file.path(Sys.getenv("HOME"), "bugsTools")
model.name = "TwoCptParallelModel_IP_RK45" # root names of model file
bugsDir = "C:/Program Files (x86)/BlackBox Component Builder 1.5/"
#bugsDir = file.path(Sys.getenv("HOME"), "Program Files/BlackBoxWinBUGS/")
wineBin = "/usr/local/MacPorts/bin" # directory containing wine and winepath programs.
only relevant on unix or Mac OS X
setwd(problemDir)
#library(R2WinBUGS)
library(coda)
library(lattice)
source(file.path(toolsDir,"bugs.tools.R"))
source(file.path(toolsDir,"bgillespie.utilities.R"))
source(file.path(toolsDir,"myR2WinBUGS.R"))
set.seed(10271998) # not required but assures repeatable results
options(error = expression(NULL)) # prevents stopping for errors when running in batch
memory.limit(2048)
# get data files
datname = "1"
########################################################################
##############################
predata = read.table("C:/BUGSModelLibrary/OSD_Replicates/sim1.TAB", header=F,
as.is=T, skip=0) #####################
########################################################################
############################################
data = predata[ ,c(1:6,9)]
names(data) = c("subject","time","amt","rate","dv","evid","weight")
data$dv[data$evid==1] = "."
data$dv = as.numeric(data$dv)
data$addl = rep(0,nrow(data))
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data$ii = rep(0,nrow(data))
nobs = nrow(data)
start = (1:nobs)[!duplicated(data$subject)]
#read in table with Ln values of CLL, V1, V2, and Q from literature
LNvalues <- read.table("LN_CLL_V1_V2_Q.csv", header=T, sep=",", skip=0, as.is=T)
#calculate covariance matrix for Ln CLL, V1, V2, and Q
covMatrix <- cov(LNvalues)
# create WinBUGS data set
bugsdata = list(
nobs = nobs,
nsub = length(unique(data$subject)),
start = start,
end = c(start[-1]-1,nobs),
subject = data$subject,
weight = data$weight,
time = data$time,
amt = data$amt,
rate = data$rate,
ii = data$ii,
evid = data$evid,
cmt = rep(1,nrow(data)),
addl = data$addl,
ss = rep(0,nobs),
logCobs = ifelse(data$dv <=0, NA, log(data$dv)),
logThetaHatPriorMean = c(-4.57, 1.29, 0.95, -3.40),
logThetaHatPriorPrecision = solve(covMatrix)
)
#logThetaHatPriorMean units: [L/hr, L, L, L/hr]
# create initial estimates
bugsinit = list(
list(log.CLint.Hat = log(0.1),
log.Km.Hat = log(10),
logThetaHat = log(c(0.01, 3.6, 2.6, 0.03)),
WT.Vmax.Hat = 0.8,
WT.CLL.Hat = 0.8,
WT.V1.Hat = 0.8,
WT.V2.Hat = 0.8,
log.omega.Vmax = log(0.35),
log.omega.CLL = log(0.35),
log.omega.V1 = log(0.25),
log.omega.V2 = log(0.25),
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log.sigmaC = log(0.2)),
list(log.CLint.Hat = log(0.125),
log.Km.Hat = log(12.5),
logThetaHat = log(c(0.0125, 4.5, 3.25, 0.0375)),
WT.Vmax.Hat = 1.0,
WT.CLL.Hat = 1.0,
WT.V1.Hat = 1.0,
WT.V2.Hat = 1.0,
log.omega.Vmax = log(0.4375),
log.omega.CLL = log(0.4375),
log.omega.V1 = log(0.3125),
log.omega.V2 = log(0.3125),
log.sigmaC = log(0.25)),
list(log.CLint.Hat = log(0.075),
log.Km.Hat = log(7.5),
logThetaHat = log(c(0.0075, 2.7, 1.95, 0.0225)),
WT.Vmax.Hat = 0.6,
WT.CLL.Hat = 0.6,
WT.V1.Hat = 0.6,
WT.V2.Hat = 0.6,
log.omega.Vmax = log(0.2625),
log.omega.CLL = log(0.2625),
log.omega.V1 = log(0.1875),
log.omega.V2 = log(0.1875),
log.sigmaC = log(0.15))
)
# specify what variables to monitor
parameters =
c("Vmax.Hat","CLL.Hat","CLint.Hat","V1.Hat","V2.Hat","Km.Hat","Q.Hat",
"WT.Vmax.Hat","WT.CLL.Hat","WT.V1.Hat","WT.V2.Hat","omega.Vmax","omega.C
LL",
"omega.V1","omega.V2","sigmaC")
# specify the variables for which you want history and density plots
parameters.to.plot =
c("deviance","Vmax.Hat","CLL.Hat","CLint.Hat","V1.Hat","V2.Hat","Km.Hat",
"Q.Hat","WT.Vmax.Hat","WT.CLL.Hat","WT.V1.Hat","WT.V2.Hat",
"omega.Vmax","omega.CLL","omega.V1","omega.V2","sigmaC")
########################################################################
########################
# run WinBUGS
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n.chains = 3
n.iter = 250000
n.burnin = 25000
n.thin = 25
bugs.fit = my.bugs(data=bugsdata,inits=bugsinit,parameters.to.save=parameters,
model.file=file.path(getwd(),paste(model.name,".txt",sep="")),
n.chains=n.chains,n.iter=n.iter,n.burnin=n.burnin,n.thin=n.thin,clearWD=F,
bugs.directory = bugsDir, refresh = 1,
useWINE=(.Platform$OS.type == "unix"), WINE=file.path(wineBin,"wine"),
newWINE=(.Platform$OS.type == "unix"),
WINEPATH=file.path(wineBin,"winepath"))
# save scripts, data and results to a directory
#######################################################################
resultsdir = "C:/BUGSModelLibrary/OSD_InformativePrior_Results"
#######################################################################
save.model(bugs.fit,paste(datname,"OSD","_",model.name,sep=""))
################################
#load(paste(model.name,"/",model.name,".fit.Rsave",sep=""))
# rename and reformat MCMC results to facilitate later calculations and plots
sims.array = bugs.fit$sims.array
posterior =
array(as.vector(sims.array),dim=c(prod(dim(sims.array)[1:2]),dim(sims.array)[3]),
dimnames=list(NULL,dimnames(sims.array)[[3]]))
########################################################################
########################
# posterior distributions of parameters
# open graphics device
pdf(file = paste(resultsdir,"/",datname,".plots.pdf",sep=""),width=6,height=6)
#################
# subset of sims.array containing selected variables
x1 = sims.array[,,unlist(sapply(c(paste("^",parameters.to.plot,"$",sep=""),
paste("^",parameters.to.plot,"\\[",sep="")),grep,x=dimnames(sims.array)[[3]]))]
# create history, density and Gelman-Rubin-Brooks plots, and a table of summary stats
ptable = parameter.plot.table(x1)
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write.csv(signif(ptable,3),paste(resultsdir,"/",datname,".summary.csv",sep=""))
################
########################################################################
########################
dev.off()
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B-10. BUGS language model for fitting the two-compartment parallel elimination PK
model using informative priors (“TwoCptParallelModel_IP_RK45.txt”).

model
{
for(i in 1:nsub){
logtheta[i, 1] ~ dnorm(logthetaMean[i, 1], omega.inv.Vmax)
#Vmax eta
logtheta[i, 2] ~ dnorm(logthetaMean[i, 2], omega.inv.CLL)
#CLL eta
logtheta[i, 3] ~ dnorm(logthetaMean[i, 3], omega.inv.V1)
#V1 eta
logtheta[i, 4] ~ dnorm(logthetaMean[i, 4], omega.inv.V2)
#V2 eta
logtheta[i, 5] <- logthetaMean[i, 5]
#Km fixed
logtheta[i, 6] <- logthetaMean[i, 6]
#Q fixed
logthetaMean[i, 1] <log.Vmax.Hat + WT.Vmax.Hat*log(weight[start[i]]/72)

#Vmax TH

logthetaMean[i, 2] <logThetaHat[1] + WT.CLL.Hat*log(weight[start[i]]/72)

#CLL TH

logthetaMean[i, 3] <logThetaHat[2] + WT.V1.Hat*log(weight[start[i]]/72)

#V1 TH

logthetaMean[i, 4] <logThetaHat[3] + WT.V2.Hat*log(weight[start[i]]/72)

#V2 TH

logthetaMean[i, 5] <log.Km.Hat

#KM TH

logthetaMean[i, 6] <logThetaHat[4]

#Q TH
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theta[i,7] <- 1 # F1
theta[i,8] <- 1 # F2
theta[i,9] <- 0 # tlag1
theta[i,10] <- 0 # tlag2
for(j in 1:6){
log(theta[i,j]) <- logtheta[i,j]
}
xhat[start[i]:end[i],1:2] <TwoCptParallelModelRK45(time[start[i]:end[i]], amt[start[i]:end[i]], rate[start[i]:end[i]],
ii[start[i]:end[i]], evid[start[i]:end[i]], cmt[start[i]:end[i]], addl[start[i]:end[i]],
ss[start[i]:end[i]], theta[i,])
}
for(i in 1:nobs){
logCobs[i] ~ dnorm(logCHat[i], tauC)
CHat[i] <- xhat[i,1]/theta[subject[i],3]
logCHat[i] <- log(CHat[i])
}
logThetaHat[1:4] ~
dmnorm(logThetaHatPriorMean[], logThetaHatPriorPrecision[,])
log.CLint.Hat ~ dnorm(-2.30, 4.0)

#(L/hr)

log.Km.Hat ~ dnorm(2.30, 0.725)

#(mg/L)

WT.Vmax.Hat ~ dunif(0.25, 1.25)
WT.CLL.Hat ~ dunif(0.25, 1.25)
WT.V1.Hat ~ dunif(0.25, 1.25)
WT.V2.Hat ~ dunif(0.25, 1.25)
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log(CLint.Hat) <- log.CLint.Hat
log(CLL.Hat) <- logThetaHat[1]
log(V1.Hat) <- logThetaHat[2]
log(V2.Hat) <- logThetaHat[3]
log(Km.Hat) <- log.Km.Hat
log(Q.Hat) <- logThetaHat[4]
Vmax.Hat <- Km.Hat*CLint.Hat
log.Vmax.Hat <- log(Vmax.Hat)
tauC <- 1/(sigmaC*sigmaC)
log(sigmaC) <- log.sigmaC
log.sigmaC ~ dnorm(-1.61, 6.25)
omega.inv.Vmax <- 1/(omega.Vmax*omega.Vmax)
log(omega.Vmax) <- log.omega.Vmax
log.omega.Vmax ~ dnorm(-1.05, 6.25)
omega.inv.CLL <- 1/(omega.CLL*omega.CLL)
log(omega.CLL) <- log.omega.CLL
log.omega.CLL ~ dnorm(-1.05, 6.25)
omega.inv.V1 <- 1/(omega.V1*omega.V1)
log(omega.V1) <- log.omega.V1
log.omega.V1 ~ dnorm(-1.39, 6.25)
omega.inv.V2 <- 1/(omega.V2*omega.V2)
log(omega.V2) <- log.omega.V2
log.omega.V2 ~ dnorm(-1.39, 6.25)
}
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Table C-1. Bias (median percent estimation error) in the population pharmacokinetic model parameters under the uninformative
200, 500, and 800 mg dose level study designs.

Parameter
Vmax
Km
CLL
V1
V2
Q
WGT~Vmax
WGT~CLL
WGT~V1
WGT~V2
Vmax BSV (ω2)
CLL BSV (ω2)
V1 BSV (ω2)
V2 BSV (ω2)
Residual variance (σ2)

FO
10
48
-16
-3.2
31
21
-26
11
-2.6
42
-57
33
-4.2
240
11

200 mg dose level
FOCE-I
LAP-I
7.4
5.5
5.0
6.5
-3.0
-4.3
-1.1
-1.6
-1.3
-4.1
-0.10
1.3
-4.8
4.2
-6.1
-9.7
-0.70
-0.57
5.5
5.5
-13
-14
-7.6
1.8
-6.6
-5.0
-98
-83
-2.6
-2.3

FO
59
268
-20
-3.8
25
20
-21
-13
-2.0
47
-74
2.4
-5.5
94
7.3

BSV = between-subject variance; WGT = weight.
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500 mg dose level
FOCE-I
LAP-I
32
12
63
86
-9.8
-6.4
-1.3
-1.5
0.33
-2.3
1.9
2.5
2.9
3.7
-17
-17
-0.33
-0.71
16
18
-29
-7.7
-1.4
-2.3
-6.9
-6.2
-100
-94
-2.5
-2.5

FO
121
1028
-23
-4.1
24
21
-13
-17
-2.1
36
-89
-2.8
-6.4
16
6.6

800 mg dose level
FOCE-I
LAP-I
67
-2.8
340
317
-12
-4.8
-1.5
-1.4
-1.3
-1.9
2.7
2.2
8.8
-6.7
-18
-4.2
-0.25
-1.0
16
18
-61
61
1.4
-6.9
-7.2
-5.9
-100
2.17
-2.7
-2.3

Table C-2. Precision (median absolute percent estimation error) in the population pharmacokinetic model parameters under the
uninformative 200, 500, and 800 mg dose level study designs.

Parameter
Vmax
Km
CLL
V1
V2
Q
WGT~Vmax
WGT~CLL
WGT~V1
WGT~V2
Vmax BSV (ω2)
CLL BSV (ω2)
V1 BSV (ω2)
V2 BSV (ω2)
Residual variance (σ2)

FO
44
77
37
4.1
33
26
94
136
27
136
73
100
21
240
12

200 mg dose level
FOCE-I
LAP-I
19
20
27
30
19
21
3.0
3.3
10
12
13
14
60
61
77
82
22
23
68
73
33
33
41
39
18
19
100
100
5.3
5.7

FO
87
268
26
4.4
30
23
107
102
27
126
100
61
21
100
8.6

BSV = between-subject variance; WGT = weight.
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500 mg dose level
FOCE-I
LAP-I
42
39
97
100
16
15
3.2
3.3
15
17
15
17
89
90
79
73
24
24
98
101
68
64
32
30
19
20
100
100
5.2
5.6

FO
121
1028
25
4.6
29
25
125
105
28
115
100
61
22
100
8.1

800 mg dose level
FOCE-I
LAP-I
78
58
340
317
17
14
3.2
3.2
17
19
17
17
121
108
81
70
23
24
105
113
100
100
31
27
20
20
100
100
5.3
5.5

Figure C-1. Markov Chain Monte Carlo chain histories (first set of plots), probability
densities of the posterior distributions (second set of plots), and Gelman-Rubin-Brooks
plots (third set of plots) for a representative estimation run using Bayesian informative
priors under the informative study design.
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Figure C-1 continued.
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Figure C-1 continued.
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Figure C-1 continued.
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Figure C-1 continued.
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Figure C-1 continued.
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Figure C-2. Markov Chain Monte Carlo chain histories (first set of plots), probability
densities of the posterior distributions (second set of plots), and Gelman-Rubin-Brooks
plots (third set of plots) for a representative estimation run using Bayesian uninformative
priors under the informative study design.

191

192

Figure C-2 continued.
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Figure C-2 continued.
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Figure C-2 continued.

195

Figure C-2 continued.
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Figure C-2 continued.
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Figure C-3. Markov Chain Monte Carlo chain histories (first set of plots), probability
densities of the posterior distributions (second set of plots), and Gelman-Rubin-Brooks
plots (third set of plots) for a representative estimation run using Bayesian informative
priors under the uninformative 600 mg study design.
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Figure C-3 continued.
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Figure C-3 continued.
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Figure C-3 continued.
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Figure C-3 continued.
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Figure C-3 continued.
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